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iS U M M A R Y
A radioimmunoassay was developed and validated for human C-peptide in 
unextracted plasma, using a synthetic 31 amino acid human C-peptide for 
immunogen, standard and tracer. The sensitivity of the assay (10 pg/tube) enabled 
the measurement of both fasting and stimulated circulating C-peptide levels. 
Normal Tanges were established in lean healthy volunteers after (a) fasting (b) 
stimulation of insulin secretion using oral and intravenous stimuli (c) suppression of 
endogenous insulin secretion using exogenous insulin. Human C-peptide 
measurements were used to investigate patients presenting with hypoglycaemia due 
to a number of clinical conditions and were found to be of especial use in the 
differencial diagnosis of the factitious hypoglyca’emia of insulin abuse.
A rat C-peptide radioimmunoassay was developed and validated to investigate the 
possibility that C-peptide, as well as insulin, inhibits fat stimulated GIP release. 
Both exogenous and endogenous C-peptide were shown to inhibit fa t stimulated GIP 
release in rat fed normal laboratory food. However, neither insulin or C-peptide 
were effective in inhibiting fat stimulated GIP release in rats maintained on short­
term high fat diets. Studies were, therefore, extended to investigate the feed-back 
inhibition of exogenous insulin on GIP release in humans maintained on low and high 
fa t dietary regimens. Exogenous insulin was found to be ineffective in inhibiting 
fa t stimulated GIP secretion in subjects maintained on a high fat diet. The control 
of GIP secretion with its consequent effect on insulin secretion via the 
enteroinsular axis therefore appears to be affected by dietary fat intake.
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CHAPTER I
INTRODUCTION
1:1 General Introduction
The hormone insulin is synthesised in the B cells of the pancreatic islets from the 
prohormone proinsulin. Enzymatic cleavage of proinsulin results in the formation 
of equimolar amounts of insulin and C-peptide (See Figure 1:1). The role of 
C-peptide was initially thought to be only a structural one during their synthesis 
of holding the A and B chains of insulin in the correct conformation, but recent 
evidence has pointed to a possible physiological role for the peptide.
1:2 Morphology of the pancreatic islet cells
In man, the islets of Langerhans are composed of several distinct cell types
which secrete different peptides. The cells all have a direct access to the 
vascular supply and are well innervated. The major islet cell types are the 
insulin (B cells), glucagon (A cells), somatostatin (D cells) and the pancreatic 
polypeptide (F cells) producing cells (Munger, 1981). Other cells have been 
identified but they have not as yet been completely elucidated. These islet cells 
appear in anastomosing cords, are cuboidal or columnar and the nucleus is 
present in the base of the cell. The endocrine cells are found in definite areas 
within the islets. In a cross-section of a human pancreatic islet the B cells 
occupy the central position with the A, D and F cells being mostly in the 
periphery (Orci and Unger, 1975, Orci et al. 1976, Fig 1:2). This peripheral area 
has been shown not to be homologous, since marked regional differences have 
been reported in the distribution of the A and F cells. In the mammalian 
pancreas the F cells are concentrated in small regions of the lower dorsal part of 
the head whilst areas rich in A cells are found in the body and tail (Orci et al. 
1976). This difference in the distribution of the A and F cells could stem from
the genesis of the pancreas which is formed by the fusion of two distinct
pancreases, the so called dorsal and ventral pancreas (Pictet and Rutter, 1972).
3Fig. 1:1 Schematic diagram o f che biosynthesis o f human in s u lin  and
C-peptide from prepro insu lin
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Fig. 1:2 Schematic representation o f an is le t  o f Langerhans
shown d is tr ib u t io n  o f glucagon, somatostatin, pancreatic 
polypeptide, and in s u lin  containing c e lls .  Is le t - c e l l  
types fo r  which no pos itive  func tion  has ye t been 
established are omitted.
( Modified from functiona l subdivis ion o f is le ts  o f Langerhans and 
possible ro le  o f D c e lls  by Orci and Unger, 1975).
Junctions have been demonstrated between A and B cells as well as between 
individual B cells (Orci, 1974, 1975). These junctions are thought to enable the 
transfer of ions and small molecules between the cells and have been shown to be 
modulated according to the functional activity of the cells (Meda et al. 1978, 
Orci, 1976).
1:3 Evolutionary development of pancreatic islets
Studies using immunocytochemical techniques have enabled some information to 
be obtained on the evolution of pancreatic cells. As far as possible, information 
obtained using this technique, has been supplemented by radioimmunoassays of 
acid ethanolic extracts of the same tissues.
In the invertebrates there is neither islet organs or any exocrine pancreatic 
gland. Insulin-like immunoreactivity has been located in the cells of the 
gastrointestinal mucosa of invertebrates such as mussels and amphioxus (Falkmer 
et al. 1973, Fig 1:3). Somatostatin, glucagon and gastrin-like immunoreactivities 
have also been located in the gut cells of amphioxus.
A separate islet organ developed from the bile duct, but with no exocrine 
pancreas, appears for the first time in primitive vertebrates such as the lamprey 
and hag fish. Somatostatin and insulin occur in the bile duct mucosa and the 
islet parenchyma, the insulin producing cells being the most abundant in the islet 
organ. No glucagon producing cells occur in either location, they still remain 
exclusively in the gut mucosa (Falkmer and Osberg, 1977).
The first evidence of a discrete pancreas is observed in holocephalan fish e.g. 
the ratfish. It is intimately associated with the spleen and widely separated 
from the alimentary tract. A long slender duct connects the pancreas to the gut 
lumen. The islets contain insulin, somatostatin and glucagon cells. Pancreatic 
polypeptide cells are present in the gut mucosa and pancreatic duct epithelium.
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At the next evolutionary level, that of the cartilaginous fish e.g. sharks and rays, 
the pancreas is close to the alimentary canal. All four islet hormone secreting 
cells are present in the islets of Langerhans. Somatostatin, pancreatic 
polypeptide and glucagon secreting cells are also found in the mucosa of the 
alimentary canal (Falkmer and Stefan, 1978). This pattern is similar to that 
found in higher vertebrates.
1:4 The B cells (beta cells)
As long ago as 1890 Von Mering and Minkowski demonstrated in dogs that 
diabetes could be caused by pancreatectomy. Later Banting and Best (1922) 
successfully extracted insulin from dog and beef pancreases. They demonstrated 
that insulin caused a rapid amelioration in the diabetic state of the animals. The 
chemical nature of insulin was a more elusive problem and not until 1951 was the 
amino acid sequence determined (Sanger and Tuppy, 1951). Ryle et al. (1955) 
established its two-chain structure. Lacy (1959) using electron microscopy and 
fluorescent antibody techniques demonstrated that insulin was stored and 
synthesised in the B cell. In 1967 Steiner and Oyer isolated a single polypeptide 
chain precursor of insulin which could be converted to insulin and C-peptide. 
They named the peptide proinsulin.
1:4:1 Biosynthesis of Insulin and C-peptide
Preproinsulin has since been identified as the initial insulin precursor which is 
processed to proinsulin and finally to insulin (Figure 1:1, Chan and Steiner, 1977, 
Patzelt et al. 1978). The 'pre'region on this protein varies in length between 20- 
30 amino acid residues depending on the species. A high proportion of these amino 
acids are hydrophobic. In humans, rats and chickens, this region consists of 24 
amino acids. Conservation of the initial 14 residues of this region is observed in 
mammals and birds. Milstein et al.(1972) and Blobel and Doberstein (1975) 
proposed that the 'pre'region assists in the formation of the ribosome membrane 
junction leading to the release and segregation of the polypeptide and because of 
this, the secondary structure of the region is thought to be important for its 
function (Schecter et al. 1979, Fig 1:4).
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Proinsulin is generated from preproinsulin by proteolytic elimination of the 
preregion. Proinsulin was discovered by Steiner and his colleagues (Steiner and 
Oyer, 1967, Steiner et al. 1969) using pancreatic islet cell tumour slices and 
radioactively labelled amino acids. It was initially isolated from crystalline pork 
insulin (Steiner and Oyer 1967) and the amino acid sequence determined by Nolan 
and Margoliash (1969).
Proinsulin is transported from the ribosomal site of biosynthesis on the rough 
endoplasmic reticulum to the golgi region. This energy dependent process takes 
approximately 15-20 minutes. Once the proinsulin has reached the golgi 
apparatus it is packaged into secretory granules where it undergoes proteolytic 
cleavage (Fig 1:5). This process has been reported as having a half-tim e of about 
one hour (Steiner, 1967). The protease enzymes responsible for the cleavage of 
proinsulin causes the release of arginine and lysine in the ratio 3:1. The arginine 
molecules originate from positions 31, 32 and 65 and the lysine from position 64 
on the human proinsulin (Fig 1:1). The major products of this reaction are insulin 
and C-peptide. A small proportion, approximately 5 percent, remains as 
pro insulin. Insulin then undergoes crystallization with the zinc ions that are 
present in the granules. An additional cleavage of proinsulin has been reported 
to occur in rats due to chymotrypsin-like enzyme (Tager et al. 1973). It would 
appear unlikely that this chymotrypsin-like cleavage occurs in all animals due to 
the large variation in the primary sequence of C-peptide. The products of 
proteolysis are secreted by emiocytosis. This involves the migration of the 
granules to the B cell membrane, dissolution of the membrane at the points of 
contact and extrusion of the granule contents. This release process is modified 
by a number of factors such as oxygen and calcium ion concentration (Curry et 
al. 1968, Rubenstein, 1979). Oxygen consumption rises as insulin secretion is 
stimulated by exposing islets to high glucose concentration and ATP turnover is 
simultaneously increased. Studies have shown that calcium ions accumulate in 
the islets after stimulation with glucose (Malaisse et al. 1978) although the 
precise nature of its action remains to be elucidated.
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1:4:2 The primary sequence of insulin and C-peptide
The amino acid sequence of insulin in a number of species has been determined. 
In man, insulin is made-up of a 30 amino acid B chain which is joined by two 
disulphide bridges to the A chain which contains 21 amino acids. The structure 
of the A and B chain is highly conserved in mammals and birds except in the 
rodent group which contains guinea pigs and coypus. The A chain has a small 
cone of amino acids in the middle of the chain which are divergent.
The primary structure of C-peptide is extremely diverse. It contains no 
aromatic residues and consequently does not absorb light at a wavelength of 
276nm (Tager and Steiner, 1972). The majority of amino acids in the human 
C-peptide chain are neutral. Human C-peptides contain no basic residues and 
only 17 percent of the residues are acidic. The primary structure of C-peptide 
not only differs between species in the amino acid composition but also in the 
number of amino acids present. It has, however, maintained a length of between 
26 and 35 residues throughout an evolutionary span of approximately 500 million 
years (Steiner e t a ! . . 1975, S te in e r ,1978)
1:4:3 Biological function of C-peptide
During the biosynthesis of insulin the connecting peptide fulfills an important 
biological role by facilitating the formation of the correct secondary and 
tertiary structure of the hormone (Steiner et al. 1968). The peptide functions by 
aiding the folding of proinsulin so that the A and B chains are able to form the 
correct sulphydryl bridges in proinsulin. Studies on the folding of proinsulin have 
shown that a smaller peptide was sufficient to allow the formation of insulin in 
as much as the gap spanned by the connecting segment in the fully folded 
proinsulin is only 8-10 /?ngstfbms (Blundell et al. 1972). Further studies 
supporting this conclusion came from the work of Blundell et al.(1978) who 
investigate insulin growth factors I and II (IGF I and II) which have an 11 amino 
acid region homologous to the proinsulin connecting segment. They showed that 
this 11 amino acid region was sufficient to span the gap between the ends of the
region corresponding to the insulin A and B chains. This would 
suggest that C-peptide, although required for the formation of insulin, may serve 
some other function unrelated to this structure-making role. Snell and Smyth 
(1975) have suggested that C-peptide covers and protects the biologically active 
site of proinsulin thus accounting for its low biological activity. A further 
suggestion has been proposed by Patzelt et al. (1978) that C-peptide functions as 
a spacer which makes the proinsulin molecule long enough to span the ribosome 
membrane junction.
Several other physiological roles have also been suggested. Wojcikowski et al. 
(1977) demonstrated that C-peptide had some inhibitory effect on glucose 
stimulated insulin release and Dryburgh et al. (1980) demonstrated that fat 
stimulated GIP release was inhibited by exogenous Gpeptide in the rat. These 
studies are described more fully in Chapter V where further work undertaken to 
elucidate the role of endogenous C-peptide on fa t stimulated GIP release is 
described.
1:4:4 Insulin secretion
The most important stimulus to insulin secretion in man is glucose. Certain 
amino acids, e.g. leucine and arginine, also stimulate insulin release under 
physiological conditions independent of changes in blood glucose levels (Fajans 
and Floyd, 1972). Medium chain triglycerides and ketone bodies have been shown 
to stimulate insulin release in both man and animals. The pattern of insulin 
release from the B cell following glucose stimulation is biphasic (Grodsky et al. 
1967), the first phase starting after 1 minute and lasting approximately 5 to 10 
minutes. This is then followed by a sustained and more prolonged increase in 
insulin secretion over the next 30 to 60 minutes. A higher rise in plasma insulin 
occurs after oral than after intravenous adminstration of glucose. An incretin 
factor released bythe gastrointestinal tract plays a major role in enhancing 
glucose-induced insulin secretion (McIntyre et al. 1964).
A number of hormones have been shown to stimulate insulin release. Excess 
circulating growth hormone and corticoids such as are present in acromegaly or 
Cushing’s syndrome markedly enhance insulin secretion. Placental lactogen, 
progesterone and estrogen all play a role in enhancing insulin secretion in the 
latter half of pregnancy. Whether these hormones act indirectly by inducing a 
state of insulin resistance, or directly remains to be elucidated. Insulin release 
has been demonstrated by Samols et al. (1965) after an injection of glucagon. 
Substances which react at the receptor level have been shown to affect insulin 
release. Adrenaline inhibits insulin release by acting on the alpha cell receptor 
(Porte, 1967). Adrenaline is both an alpha and beta adrenergic stimulator. When 
the adrengenic action is blocked with phenotolamine the beta adrengenic 
stimulating action persists. Isoprenaline enhances insulin release by acting on 
the beta cell receptor.
1:4:5 Metabolism
Insulin is found not only in plasma but also in bile, lymph and urine in low 
concentrations. The half time disappearance of exogenous porcine insulin is 3 to 
5 minutes in man (Samols and Marks, 1966, Orskotfand Christensen,1.966 , Turner 
et al. 1971). The metabolic clearance rate of bovine insulin in the rat has been 
calculated at 16.4+0.4 ml/min (Katz and Rubenstein, 1973). Many tissues 
accumulate insulin in small amounts but the major site of uptake and degradation 
is the liver (Samols and Ryder, 1961, Kanazawa et al. 1966) and kidney 
(Rubenstein et al. 1975). The liver removes approximately 20 to 50 percent of 
the insulin after a single transhepatic passage. This hepatic uptake mechanism 
for the extraction of insulin can be saturated (Rubenstein et al. 1972). In the 
kidney, insulin is filtered through the glomerulus and reabsorbed by the proximal 
tubular cell. The kidney also extracts insulin from the peritubular circulation 
(Rabkin et al. 1978). Of all the insulin removed by the kidney only five percent 
is excreted in the urine and the remainder is degraded by specific enzymes. Two
enzyme systems have been implicated in insulin degradation. Burgen et al. 
(1972) found an insulin specific protease in the cytosol of many tissues 
particularly in the liver, pancreas and kidney. A second enzyme, a glutathione- 
insulin transhydrogenase, catalyses the reductive cleavage of the insulin 
disulphide bonds by glutathione with the liberation of the intact A and B chain 
(Varandani, 1972). These chains are then rapidly degraded to small peptides. 
Proinsulin comprises only a small proportion of the secretory product of the B 
cell in normal subjects. No evidence has been found of the conversion of 
proinsulin to insulin and C-peptide in plasma. Starr and Rubenstein (1974) 
demonstrated in man that following the removal of an insulin producing adenoma 
proinsulin had a half-life of 17.2 minutes. Proinsulin is removed from the 
circulation by the kidney, hepatic extraction being almost negligible. (Katz and 
Rubenstein, 1973). The fractional urinary clearance of this peptide is 0.6 
percent indicating that more than 99 percent of the amount filtered is 
sequestered and degraded in the kidney.
Many workers have investigated the disappearance of C-peptide from the 
circulation both in man and rodents. The major site of removal of C-peptide 
from the body is the kidney (Katz and Rubenstein, 1973). The liver removes only 
a very minor amount (Canivet and Krebs, 1980). As with insulin and proinsulin, 
C-peptide is avidly absorbed from the lumen by the kidney cells where it is 
degraded (Katz and Rubenstein, 1973). The half-life of endogenous and 
exogenous C-peptide in man has been reported by a number of workers and 
values range from 11 to 33 minutes (Horwitz et al. 1973, Munemura et al. 
1974, Kutuza and Maksuda, 1976, Krause, 1977, Faber et al. 1978). The wide 
range of values for the immunological half-life  of C-peptide in plasma reported 
may be due to the different experimental conditions under which they were 
determined. Most C-peptide radioimmunoassays crossreact with proinsulin in 
varying degrees. Extraction of proin&ulin from the serum prior to the
measurement of C-peptide would shorten the apparent half-life found when 
measuring disappearance rate using a C-peptide assay and should, therefore, be a 
more reliable estimate of actual circulating half-life. Additional studies in man 
with natural or biosynthetic human C-peptides are needed to resolve this 
problem. Studies in animals are of limited value for extrapolation to the human 
situation since many species of C-peptide are still unavailable in adequate 
amounts.
The urinary excretion of C-peptide is 5% of the total quantity secreted
from the pancreas as compared with a value of 0.1% for insulin. The increased 
urinary clearance had been made use of by several workers to measure C-peptide 
levels in urine as an indicator of B cell activity over prolonged periods (Kuzuya 
et al. 1976, Horwitz et al. 1977, Meistas et al. 1981).
1:5 The A cells (alpha cells)
Glucagon, secreted by the pancreatic A cells, was not isolated until 1955 (Staub 
et al. 1955). Glucagon is a 29 amino acid peptide stored in the islets in an alpha 
helix form and like insulin it has been shown to be synthesised from a 
prohormone. This prohormone, glicentin, is believed to consist of 69 amino acids 
in pigs (Thim and Moody, 1981). Proglucagon has C and N terminal extensions 
which undergoes enzymic cleavage, similar to proinsulin, at sites with two basic 
amino acid residues (Tager and Markese, 1979). There is a remarkable degree of 
conservation of the amino acid sequence of this hormone in mammals and birds. 
Evidence of heterogenicity of circulating immunoreactive glucagon has been 
reported (Valverde et al. 1974, Weir et al. 1975). The biologically active 
hormone has a molecular weight of 3500 daltons. Other peptides with glucagon­
like immunoreactivity have been identified in gut extracts with molecular weight 
ranging from 2000-160,000 daltons.
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1:6 The D cells
The D cells of the pancreas secrete somatostatin. Somatostatin was initially 
isolated from ovine hypothalami (Burgus et al. 1973); Mammalian somatostatin 
contains 14 amino acids with a molecular weight of approximately 1642. It has 
been identified in various regions of the central nervous system, the 
gastrointestinal mucosa, several endocrine organs and the blood (Parsons et al. 
1976). Prosomatostatin has been isolated from angler fish islets and consist of 
approximately 100 amino acids (Shield, 1980). As with the other prohormones 
prosomatostatin has areas which contain amino acids which are sensitive to 
enzyme cleavage.
1:7 The F cells (PP cells)
The F cells of the pancreas secrete pancreatic polypeptide. These cells are 
located at the periphery of the islets and are also present in the exocrine areas 
of the pancreas (Gersell et al. 1979). Mammalian pancreatic polypeptide is a 36 
amino acid structure with an approximate molecular weight of 4200. It is also 
synthesised initially as a larger prohormone. The primary structure of various 
pancreatic polypeptides show very little  homology with other pancreatic and 
gastrointestinal hormones.
1:8 Gastric inhibitory polypeptide (GIP)
A much greater insulin release is observed in response to oral as opposed to 
intravenous glucose (McIntyre et al. 1964). Unger and Eisentraut (1969) proposed 
the term enteroinsular axis to describe a regulatory system in which insulin 
secretion from the pancreatic islets was modified to some extent by 
gastrointestinal hormones. The gastrointestinal hormone, GIP, appears to be one 
of the factors involved in this regulatory system.
The pancreatic islet cells probably all originated in the gut mucosa and migrated 
to the pancreas in the course of evolution. The GIP cells present in the gut 
mucosa have also been identified in a number of early vertebrates. The absence 
of GIP cells in the sea squirt which has insulin and somatostatin cells (Falkmer et
nl. 1977) har, lead to the hypothesis that HIP cells did not appear until there was 
a structural basis for an enteroinsular axis. Although failure of the sea squirt 
cells to crossreact with a GIP antiserum raised against porcine GIP could explain 
this data.
GIP is an acronym for gastric inhibitory polypeptide initially named because of
its ability to inhibit gastric acid secretion. However. GIP has subsequently been
shown to stimulate insulin secretion (Brown et al. 1975). GIP appears to fulfil all
the criteria for a physiological endocrine stimulator of insulin secretion, the so-
called incretin effect. Creutzfeldt (1979) proposed several criteria that a
substance had to meet before it could be called an incretin. It had to be an
endocrine hormone, released in response to ingestion of nutrients in particular
carbohydrates and stimulate insulin secretion in the hyperglycaemic state. The
major physiological role of GIP appears to be that of stimulating insulin
secretion.G IP leve ls  are increased a f te r  ingestion o f carbohydrate, fa t  and 
acids but in su lin  leve ls  are increased only a f te r  carbohydrate and some ami
acids. This would suggest that some other factor or factors are controlling the 
release of insulin by GIP. Primary among these factors that may determine the 
insulin secretory responsiveness of the B cell to GIP is the plasma glucose 
concentrations (Pederson et al. 1975, Andersen et al. 1978, Verdonk et al. 1980). 
Studies in man and rats have shown that the plasma glucose concentration must 
be above 5.5 mM before GIP is able to exert any insulinotropic activity.
The release of GIP in response to nutrients has been shown to be affected by 
several factors. Nutrient absorption has been shown to be essential for the 
release of GIP. Studies with non-dietary fibres such as guar, which slows down 
the rate of nutrient absorption, have been shown to affect the GIP response to a 
meal (Morgan et al. 1979. Jenkins. 1980). The molecular configuration of sugars 
appears to affect GIP release (Sykes et al. 1980). Reiser et al.(1980) 
demonstrated that dietary adaptation affects GIP release. They maintained 
subjects on diets containing 30 percent starch or sucrose. An increased GIP
response to a sucrose load was observed in those subjects maintained on the 
sucrose diet. They suggested that this was due to induction of a specific 
intestinal enzyme e.g. suer ase and a consequent increase rate of absorption of 
glucose and fructose.
1:9 Estimation of C-peptide levels
The development of the C-peptide radioimmunoassay has enabled the 
measurement of this peptide to be made in a variety of biological fluids. The 
ability to measure circulating C-peptide levels has been extremely useful in the in  
vivo investigation of B cell function. However, difficulties have been 
encountered in the development and validation of C-peptide radioimmunoassays 
and these are discussed below.
1:9:1 Methodology
Radioimmunoassays are based on the principle of competitive inhibition whereby 
unlabelled hormone competes with a radiolabelled hormone for binding to a 
specific antibody (Yalow and Berson, 1959, Fig. 1:6). The amount of labelled 
hormone which is bound to the antibody is dependent on the concentration of 
unlabelled hormone. The higher the concentration of unlabelled hormone the less 
labelled hormone is bound to the antibody. The concentration of hormone in an 
unknown plasma or serum sample is determined from the degree of binding of 
labelled hormone observed in the sample by comparison with that observed in 
standard solutions, containing known concentration of the hormones. Many 
procedures are necessary in the validation of a radioimmunoassay. One of the 
esssential procedures is the demonstration that the endogenous and standard 
hormone react with the antiserum identically under the conditions of the assay, 
and this has been a particular problem in the C-peptide radioimmunoassay.
1:9:2 The problems associated with measuring human C-peptide by 
radioimmunoassay
In 1970 Melani et al. described a double antibody radioimmunoassay for human 
C-peptide. However, several major problems have subsequently been
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encountered specific to the radioimmunoassay of C-peptide.
The large degree of species variation in the primary structure of C-peptide has 
prevented the use of C-peptide obtained from other species for the development 
of human C-peptide radioimmunoassays. Human C-peptide has to be obtained 
either from natural sources or synthesised in order to develop the assays. Melani 
et al.(1970) and later Heding (1975) described assays using natural C-peptide 
extracted from human pancreases. However, Markussen et al.(1971) found that 
the amount of human C-peptide isolated from pancreases was extremely small 
and not practicable for any large scale production of the peptide. Human 
C-peptide, therefore, had to be synthesised chemically before it could become 
more readily available (Naithani, 1973, Yanaihara et al. 1974, 1978b, Igano et al. 
1981). However, different forms of C-peptide of varying chain length have been 
synthesised. Several assays using antisera raised against synthetic human 
C-peptide have been reported in the literature (Kaneko et al. 1974, Beischer et 
al. 1976, Faber et al. 1976, Kuzuya et al. 1976). Although natural C-peptide has 
only 31 amino acids some peptides have been synthesised containing extra amino 
acids and functional groups (Naithani, 1973, Yanaihara et al. 1974). Crude 
human proinsulin components have also been used to develop a C-peptide 
radioimmunoassay (Heding et al. 1974).
The wide variation in fasting levels of C-peptide may, in part, be due to the 
different sources and varying purity of the peptides. Values of 0.9-3.5yg/L itre  
have been reported in normal non-obese subjects (Block et al. 1972, Kaneko et al. 
1974, Heding and Rasmussen, 1975, Heding, 1975). The development of an 
international standard should help reduce this variability. The first international 
standard,'a formyl lysine 34 amino acid C-peptide, was unfortunately found to 
run non parallel in most C-peptide assays (Caygill et al. 1980). These workers 
highlighted the need for an international standard by reporting the wide variety 
of C-peptide standards used by the participants in the study.
Difficulties have been encountered in raising an antiserum against C-peptide.
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Human C-peptide has a molecular weight of 3025 and has to be coupled to a
larger protein such as albumin in order to be immunogenic. Even when coupled
to a carrier protein its immunogenicity is poor. Markussen (1971) suggested that
the poor immunogenicity of C-peptide is due, in part, to its random coil
conformation.
125 I used for radiolabelling is incorporated into the tyrosine or histidine residues 
of a peptide using conventional iodination techniques. A further problem 
encountered with C-peptide radioimmunoassays is that human C-peptide 
possesses neither tyrosine or histidine residues and it is necessary to use a 
synthetic C-peptide into which a tyrosine residue has been incorporated. 
Proinsulin is the major known crossreactant in the C-peptide assay because it 
contains the complete C-peptide molecule within its amino acid sequence. The 
cross-reactivity varies between 15-66 percent in C-peptide assays reported in 
the literature (Melani et al. 1970, Kaneko et al. 1974, Caygill et al. 1980). High 
proinsulin levels in plasma would affect the C-peptide result depending on the 
antiserum used in the assay. Basal proinsulin levels have been reported to range 
from undetectable to approximately 300 ng/Litre in normal non-obese subjects 
(Heding, 1977, Rainbow et al. 1979). Proinsulin levels are, therefore, normally 
less than 5 to 10 percent of those of C-peptide. However, because of differences 
in their half lives after oral glucose proinsulin levels rise slowly and peak later 
than insulin (Rubenstein et al. 1977). A fter 50g oral glucose load proinsulin 
levels increase by 8 fold from the fasting levels (Rainbow et al. 1979). Obese 
subjects with hyperinsulinaemia have raised fasting levels of proinsulin and a 
greater absolute increase after glucose compared with normal weight subjects 
(Melani et al. 1970). However, the proinsulin and insulin levels occur in 
relatively the same proportion in obese subjects as in normal volunteers (Gordon 
and Roth, 1969). High proinsulin levels have been reported in patients with 
insulin producing tumours (Sherman et al. 1972, Rubenstein et al. 1974, Rainbow 
et al. 1979). In this situation the proportion of insulin to proinsulin has been
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shown to be extremely’ variable. However, by no means do all patients with 
insulin producing tumours have elevated percentages of proinsulin.
Proinsulin extraction and subsequent measurement of C-peptide levels in serum 
samples has been reported (Melani et al. 1970, Heding, 1975). Initially proinsulin 
was separated from C-peptide in sera by column chromatography (Melani et al.
1970). This technique is time consuming and unsuitable for handling large 
numbers of samples. Removal of proinsulin has also been accomplished by 
incubating patients' sera with sepharose-coupled insulin antibodies. These bound 
both insulin and proinsulin enabling C-peptide to be determined directly in the 
supernatant (Heding, 1975).
The heterogenicity of C-peptide in plasma has been investigated by a number of 
groups (Kuzuya et al. 1977, 1978; K ak ita , 1980) Several workers have reported 
that different antisera used in the same assay system react to different degrees 
with the same plasma sample (Heding, 1975, Kuzuya et al. 1978). Variable cross- 
reactivities to various molecular forms of C-peptide has been suggested as a 
possible explanation of these differences. Kuzuya et al.(1977) reported the 
detection of a low molecular weight form of C-peptide which increased during 
storage of the samples. Recently Kakita 1980 detected a large molecular 
weight form of C-peptide which had the same immunoreactivity, in their assay, 
as the 3025 molecular weight C-peptide. Beck et al.(1981) suggested the 
existence of C-peptide in plasma which is bound to protein. This occurrence is 
relatively common and has been reported for insulin (Vallaume et al. 1981)* 
Difficulties have been encountered when measuring residual B cell activity in 
insulin treated diabetics. Insulin antibodies usually present in the sera from 
insulin treated diabetics bind not only insulin but proinsulin (Block et al. 1972). 
The half-life of proinsulin is increased when it is complexed with antibodies.
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Finke et al. (1974,) have reported that the proinsulin levels may accumulate in 
such diabetics far in excess of circulating C-peptide levels. The C-peptide levels 
measured in these diabetics, although indicating B cell activity, cannot therefore 
be compared with values obtained from normal subjects. Kuzuya et al.(1977a) 
precipitated the insulin antibodies in diabetic sera with polyethylene glycol and 
measured C-peptide levels in the supernatant. This method removed all the 
proinsulin bound to the antibodies but circulating unbound proinsulin remained. 
C-peptide levels ranged from 2.1-28.7 yg/Litre in the insulin treated diabetics, 
after polyethylene glycol, levels ranged from 0.5-4.3 yg/Litre.
1:9:3 C-peptide levels in normal non-obese subjects
Reported fasting C-peptide levels in healthy subjects range between 0.9 and 3.5 
yg/Litre (Block et al. 1972, Kaneko et al, 1974, Heding, 1975, Heding and 
Rasmussen, 1975, Beischer et al. 1976, Beyer et al. 1977). Beyer et al.(1977) 
reported that C-peptide levels, like insulin, were dependent upon body weight. 
The larger the increase in body weight over ideal weight the higher the 
C-peptide levels.
Stimulation of the B cell results in a slower rise in circulating C-peptide levels in 
the peripheral circulation compared to insulin. Peak C-peptide levels occur one 
hour after oral glucose (Kuzuya et al. 1976) and peak levels are approximately 5 
to 7 times the fasting values after a lOOg glucose load (Block et al. 1972). C - 
peptide remains elevated for considerably longer than insulin because of its 
longer half-life.
Several workers have investigated the measurement of C-peptide in urine 
( Kuzuya e t al .1976, Horwitz e ta l.1977 , Meistas et al. 1981). Values for the 
twenty-four hour excretion of C-peptide vary between 36-81 yg(( Kuzaya e t a l .  
1976, Horwitz e t  a l . 1977,Meistas et al. 1981). This variability could be 
attributed at least, in part, to intrinsic differences in the assay systems 
including the preparation of the standard C-peptide or antiserum. The urinary 
clearance of C-peptide is much higher than that of insulin. The 24 h urinary
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clearance of C-peptide has been calculated to be between 4 and 20 percent 
(Kuzuya e t  a l . 19765 Horwitz e t a l.1977,^  Meistas et al. 1981). Except for
patients with renal failure, urine C-peptide excretion reflects the daily B cell 
secretory activity fairly well. Weisinger et al.(1977)iave investigated patients 
with varying degrees of renal function. They demonstrated a strong correlation 
between kidney function and the C-peptide excreted when the kidney function 
was less than 50 percent of a healthy kidney. They suggested that renal function 
should be assessed if the C-peptide levels in the circulation or urine were going 
to be used diagnostically.
C-peptide insulin ratios have been recently us*ed as an indicator of hepatic 
extraction of insulin. Sando et al. (1980) found that hepatic insulin extraction 
was decreased in both obese and non-obese diabetics compared with normals. 
This ratio was also altered in subjects with moderate degrees of glucose 
tolerance (Malmquist et al. 1981).
1:9:4 The clinical importance of C-peptide measurements
Measurements of C-peptide levels have been useful in the evaluation of several 
clinical states.
Residual B cells activity has been assessed in diabetics by measuring C-peptide 
levels. In newly diagnosed insulin-requiring diabetics the highest C-peptide 
levels were associated with the lowest requirement for exogenous insulin (Faber 
and Binder, 1977). However, in long-term diabetics this relationship is not so 
clear and may partly be due to the presence of circulating insulin antibodies. 
Absence of measurable levels of C-peptide have been reported in some diabetics 
with good metabolic control (Rubenstein et al. 1981). The importance of good 
control in diabetics has been studied using the artific ia l pancreas and monitoring 
C-peptide levels. Mirouze et al. (1978) found that C-peptide levels increased and 
insulin doses were reduced compared with a control diabetic group.
Many clinical situations besides diabetes have made use of the measurement of 
C-peptide levels. An important use has been in the diagnosis of various
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hypoglycaemic states notably the measurement of C-peptide levels with insulin 
producing tumours. Turner and Heding (1977) and Sefvice et al.(1977) 
demonstrated impaired suppression of the B cell by monitoring C-peptide levels 
during hypoglycaemia induced by exogenous insulin in patients with insulinomas. 
The evaluation of results obtained during an insulin stress test is extremely 
important in determining whether a patient has an insulin producing tumour
(Marks., H  981 h
The clinical problem of factitious hypoglycaemia due to administration of insulin 
can be clearly diagnosed with the measurement of low C-peptide and high insulin 
levels. In the past the presence of insulin antibodies was diagnostic of insulin 
administration. However, antibodies will only be present after repeated insulin 
injections and also several cases of insulin auto antibodies have been reported 
(Hirata et al. 1972, 1974) without previous insulin injections.
After removal of the pancreas due to nesidioblastosis or certain carcinomas, 
C-peptide measurement has been useful to indicate the presence of any residual 
pancreatic tissue. If an insulin producing tumour has been removed from the 
pancreas long term C-peptide monitoring can be of use in detecting the 
recurrence of the tumour or the presence of functioning metastases.
1:10 Project
A human C-peptide radioimmunoassay was developed using a synthetic thirty-one 
amino acid C-peptide. Several problems were encountered when initially  
developing the assay such as difficulties in producing an antiserum and a high 
specific activity tracer. The lack of an international human C-peptide standard 
made it essential to establish fasting and stimulated C-peptide values in normal 
non-obese subjects in the assay system in order to assess clinical samples. The 
diagnostic value of human C-peptide estimations has been evaluated in certain 
clinical conditions.
Recent studies using exogenous C-peptide (Dryburgh et al. 1980) suggested that 
C-peptide may have a physiological role and this was, therefore, investigated in
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the rat. Due to the species variability in the primary sequence of C-peptide a 
specific rat C-peptide radioimmunoassay had to be developed. Endogenous C - 
peptide stimulated by glucose and tolbutamide was found to inhibit fat 
stimulated GIP release using the gut perfusion technique. However, this 
technique involves extensive handling of the gut which could have affected the 
results. The technique of orally dosing rats with fat was, therefore, 
investigated. Rats were orally dosed with fat for four days prior to investigation 
(pretreated) in order to increase their GIP response to fat. Endogenous C- 
peptide was found not to inhibit fat stimulated GIP release in these animals. A 
shortage of insulin antiserum prevented further investigation using this 
method in rats maintained on normal laboratory food (untreated). Studies 
using a known inhibitor of fat stimulated GIP release, insulin, in pretreated and 
untreated rats was therefore carried out. Fat pretreatment prevented exogenous 
insulin from inhibiting fat stimulated GIP release in the rat. Studies in man 
maintained on high and low fat dietary regimens also demonstrated that fat 
stimulated GIP release was inhibited by exogenous insulin only when the subjects 
were on a low fat diet.
CHAPTER II
A RADIOIMMUNOASSAY FOR THE MEASUREMENT OF IMMUNOREACTIVE
HUMAN C-PEPTIDE
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2:1 Introduction
Since the introduction of radioimmunoassay (RIA) in 1959 (Yalow and Berson, 
1959) this analytical method has found a wide application in the quantitative 
determination of low concentrations of proteins in biological fluids (Hunter, 
1973, Skelley et al. 1973). Two major advantages of radioimmunoassay over 
bioassay are sensitivity and specificity. However, in order to achieve this it is 
necessary to possess antibodies which have a high avidity and specificity. The 
production of antisera is determined by a number of factors. These include 
conjugation of the hapten to a carrier protein, the use of adjuvants, the choice of 
species and route of administration.
The immunogenicity of a substance is extremely important in the production of 
antisera. Immunogenicity is related to molecular weight and rigidity of 
structure of a substance. Low molecular weight substances, below 5000 daltons, 
have to be conjugated to large molecules before they will elic it an immune 
response. A variety of chemical procedures are available for the covalent 
linkage of such substances to large molecules (Nisonoff, 1967). Care must be 
taken when conjugating a large carrier protein not to distort or mask the smaller 
molecules or haptens, since the antibody produced will reflect this structure. 
The carrier protein itself does not have to be immunogenic. Immunogenic or 
non-immunogenic carrier proteins may be used with an equal expectation of 
success (Hum and Landon, 1971).
The use of an adjuvant, such as mineral oil, has been shown to increase the 
chances of an antibody response. The adjuvant is also mixed with an immunogen 
to form a stable emulsion. Adjuvants are believed to work by releasing 
immunogens slowly, thereby, preventing rapid uptake into the circulation and 
degradation of the immunogen by proteolytic enzymes. The adjuvant causes 
stimulation of the reticuloendothelial system by facilitating phagocytosis and 
causing formation of a local granulomatous lesion. This may act as a focus for 
antibody production. The use of adjuvants has allowed the
sustained release of antigens over a period of some weeks and careful monitoring 
of antibody production is. therefore, required to determine when to reimmunise 
an animal.
The immune response of an animal to a particular compound is genetically 
determined. Unless one is aware of a particular strain of animal which responds 
well to a particular immunogen it is probably best to choose randomly bred 
animals.
The route of administration is important. Evidence has indicated that routes 
affecting the lymph nodes may increase the effectiveness of immunisation (Hum 
and Landon, 1971).
The sensitivity of a radioimmunoassay depends on a number of factors, the two 
most important being the avidity of the antibody and the specific activity of the 
tracer. The avidity of an antiserum can be regarded as synonymous with its 
sensitivity in the assay system. Construction of standard curves is an essential 
step in determining the suitability of an antiserum. Provided the specificity of 
the antiserum is suitable the best antiserum is usually that which provides the 
greatest sensitivity. Sensitivity in general terms can be determined as the least 
amount of unlabelled antigen that can be detected with confidence. The 
inherent sensitivity of any given antiserum is dependent on its equilibrium 
constant, K. The equilibrium constant characterises the reaction of the antigen 
with the predominant order of antibody binding sites, the higher the K values the 
more sensitive is the assay. Having obtained an antiserum with suitable 
characteristics it is then necessary to employ a tracer. This is a labelled antigen 
that does not lim it the sensitivity of the assay by its undesirable 
immunochemical properties or by its inappropriately high concentration (low 
specific activity).
The production of a high specific activity tracer is, therefore, also required if a
radioimmunoassay is to have the ability to measure picogram quantities. Thus 
125 iodine is generally used in peptide RIA because of its relatively long half-life  
(60 days) compared with '^ io d in e  (half-life 8 days).
The iodination reaction consists of a substitution of iodine, produced by oxidation
of iodide, into an ionized tyrosine or histidine residue in the protein. The most
125common methods of oxidising the Na I involve using chloramine T (Hunter and 
Greenwood, 1962) as the oxidising agent or the enzyme lactoperoxidase (Thorell 
and Johansson, 1971). The enzymatic method does not directly expose the 
peptide to large amounts of oxidising agent and is, therefore, less likely to cause 
damage to the protein.
Many methods are available which separate the iodinated protein from the
unreacted iodide and degradation products, the most commonly used being gel
filtration and ion exchange systems. It is important to obtain a tracer free from
all radioactive degradation products since this results in a higher specific
activity. The shelf life of the tracer depends on three factors. Firstly, the
125radioactive decay of I: secondly, whether the peptide contains two or more 
iodinated tyrosine residues and finally, the slow loss of immunoreactivity which 
occurs during storage (Hunter, 1971).
To enable groups of workers measuring levels of a certain peptide to make 
quantitative comparisons between published results, it is useful to have a 
common standard. Unfortunately many such standards are not available and 
many laboratories have to use their own "in house" standard. One disadvantage 
of these standards is that usually their purity and homogenicity has not been 
investigated. The use of a common international standard is important. 
Production of such a standard takes a considerable time, firstly in obtaining 
sufficient supply of a suitable material and secondly in establishing its purity and 
stability. In addition, it is essential to ensure that in the radioimmunoassay 
system it reacts identically to the peptide in endogenous serum samples.
The widespread use of human C-peptide radioimmunoassay has been prevented by 
the scarcity of human C-peptide for standard and immunogen. Human C-peptide 
cannot be substituted by animal C-peptides because C-peptides are highly 
species specific in their primary structure. Human C-peptide, therefore, has to
be used for standard, iodinated tracer and as antigen for the production of 
antiserum. Natural human C-peptide can only be obtained from normal pancreas 
and because of the difficulty involved in obtaining this, human C-peptide has 
been synthesised by a number of workers (Yanaihara et al. 1974,1978b,Igano e t a l . 
1981). Human C-peptide has a low molecular weight (3025 daltons) and lacks a 
rigid secondary and tertiary structure (Frank and Veros, 1968; Markussen et al.
1971). These factors may explain its poor immunogenicity.
The production of antiserum to human C-peptide and its use in measuring 
circulating C-peptide concentrations was first described by Melani et al. (1970).
They raised their antisera in guinea pigs by immunization with C-peptide 
extracted from human pancreases and measured C-peptide in extracted plasma 
samples. Block et al. (1972) then developed an assay that could measure C- 
peptide in unextracted plasma samples. Since then many workers ( Faber e t  a l .
1976# Heding et al. 1974, Kaneko et al. 1974, Yanaihara et al. 1974, Heding,
1975, Horwitz et al. 1975, Beischer et al. 1976) have developed their own 
radioimmunoassays using natural or synthetic C-peptide.
Natural human C-peptide has 31 amino acids (Kemmler and Steiner, 1970) but 
with the synthesis of C-peptide, it has been possible to synthesise the connecting 
peptide which contains the additional 4 basic amino acid residues which are split 
off during the conversion of proinsulin to C-peptide (Figure 2:1). A 
radioimmunoassay using a 35 amino acid connecting peptide for standard and 
hapten for immunization was developed by Kaneko et al. (1974). They showed 
that the natural C-peptide and synthetic connecting peptide gave similar 
crossreactivity with their antiserum. Workers have chosen a variety of animals 
including rabbits, goats and guinea pigs in which to raise their antisera (Kaneko 
et al. 1974, Heding, 1975, Beischer et al. 1976). Even though a number of 
different species and immunization protocols have been used, a high titre  
antiserum has not consistently resulted.
I ' inure 2 : 1 Human_ pro insu l  in cova lent s t ru c tu re  and
cTeavaqe To i nsuTi’ri ancf C-pepTide
B-Chain
A-Chain
C -P e p tid e
64 65
Lys Arg
31 32
Arg Arg
P ro te o ly t ic  degradation
C-peptide In s u l in
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Human proinsulin is the only substance, so far, shown to crossreact in a human 
C-peptide radioimmunoassay. Proinsulin plasma concentrations are much lower 
than those of C-peptide in normal subjects the contribution of proinsulin to 
serum C-peptide immunoreactivity is, therefore, usually very small. However, in 
patients with islet cell tumours, hypokalaemia or chronic renal failure, the 
plasma proinsulin levels are increased. To overcome this interference Melani et 
al. (1970) used an extraction procedure followed by gel filtration for measuring 
C-peptide levels in serum. The use of sepharose coupled insulin antibodies 
(Heding, 1975) has also enabled proinsulin to be removed from serum leaving 
behind the C-peptide.
The iodination of human C-peptide is complicated by the absence of tyrosine or
125histidine residues in the molecules in which to incorporate the iodine. Human 
C-peptide has one free amino group, namely that of the n-terminal glutamic acid 
to which it is possible to attach one molecule of tyrosine by a peptide bond.
The preparation of a suitable standard for the human C-peptide assay has 
depended upon the availability of materials. Workers developing human C- 
peptide radioimmunoassays have either used natural or synthetic C-peptides 
(Melani et al. 1970, Heding et al. 1974, Kaneko et al. 1974, Yanaihara et al. 
1974, Heding, 1975, Horwitz et al. 1975, Beischer et al. 1976). Both natural and 
synthetic C-peptide may undergo some chemical changes during isolation and 
storage. Contaminants may be present in human C-peptides obtained from both 
sources. Increased purity can be achieved by use of high pressure liquid 
chromatography. No international reference standard is, as yet, available for 
use in the radioimmunoassay.
A radioimmunoassay for human C-peptide has been developed using a synthetic 
human C-peptide (31 amino acid) as standard and hapten. A detailed description 
of the development, validation and problems encountered are reported. This 
study resulted in a radioimmunoassay for human C-peptide which is capable of 
measuring C-peptide levels in unextracted plasma.
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2:2 Materials and Methods 
2:2:1: Antiserum Production
Human C-peptide antiserum was prepared using a synthetic human C-peptide 
(Dr.Geiger, Farbwerke, Hoechst A.G., Frankfurt, West Germany) (Fig. 2:2) as 
hapten.
(a) Preparation of Immunogen
A solution was made containing 2 mg of egg albumin and 1 mg of synthetic 
human C-peptide dissolved in sterile distilled water. To this was added 200 pi of 
0.25M gluteraldehyde solution. The resulting conjugate was immediately mixed 
with two equal volumes of complete Freund's adjuvant (Freund, 1951), to give a 
final C-peptide concentration of 333 pg/ml. The solution was mixed vigorously 
until a stable emulsion formed.
(b) Immunisation Procedure
Attempts to produce antiserum in rabbits proved unsuccessful with this 
immunogen. Two Soay sheep were immunised with 500 pg of the synthetic C- 
peptide. They were immunised intradermally along the neck and back at fifteen  
separate injection sites and intramuscularly at four sites in the upper legs 
according to the method of Beischer et al. (1976). Both animals were 
reimmunised (boosted) at six week intervals with 250 pg of synthetic C-peptide 
until antiserum of sufficiently high titre was obtained. The antiserum currently 
used in the assay was obtained from one of these two sheep nine days after the 
first boost (batch no. MF/S/743-IB).
(c) Antibody Specificity
To determine antibody specificity the crossreactivity of the antiserum with 
human insulin (Wellcome Foundation Ltd., Beckenham), porcine insulin (Novo 
Research Institute, Denmark), porcine proinsulin (Novo Research Institute, 
Denmark), glucagon (WHO First International Standard 69/194), GIP (Dr.J.Brown, 
University of British Columbia, Canada) and human biosynthetic proinsulin (Eli 
Lilly and Company Ltd., Basingstoke, Hants) was assessed.
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Figure 
2:2
A number of synthetic fragments of human C-peptide donated by Professor 
N.Yanaihara, were tested in an attempt to determine the antigenic determinants 
of the antiserum. The fragments were:
1) Batch No. NY-TN-8-62 - Fragments 20-31
2) Batch No. NY-TN-8-90 - Fragments 14-31
3) Batch No. NY-TN-8-94 - Fragments 10-31
4) Batch No. NY-TN-8-98 - Fragment 7-31
Synthetic C-peptides obtained from various sources were also investigated to 
determine their crossreactivity with antiserum batch no. MF/S/743-IB. The 
synthetic C-peptides were:
1) A 31 amino acid synthetic Human C-peptide - IRE-UK Ltd., High Wycombe
2) A 31 amino acid synthetic Human C-peptide - Novo Research Institute 
Denmark
3) A 31 amino acid synthetic Human C-peptide (batch no. NY.TN.8.102) 
Professor N.Yanaihara, Japan.
4) A 35 amino acid synthetic Human "C-peptide" - (batch no. NY.TN.8.86) 
Professor N.Yanaihara, Japan.
5) A 35 amino acid synthetic Human "C-peptide" - NIBSC Standard 76/561 which 
has a formyl lysine residue in position 34.
6) NIBSC standard 76/321 batch no. NY.TN.10.52. This C-peptide is synthetic, 
no other information is available.
2:2:2: Standard
(a) Preparation of Standard
The standard used in the C-peptide radioimmunoassay was the same 31 amino 
acid, synthetic human C-peptide (Hoechst Ltd., Germany) employed as antigen. 
The standard was weighed out on a Kahn balance, dissolved in a small quantity of 
1M acetic acid and then diluted in 0.05M sodium phosphate buffer pH7.4 
containing 0.1% human serum albumin. This was then aliquoted (20 ng/vial), 
freeze dried and stored at -20°C.
(b) Investigation of standard purity using High Pressure Liquid Chromatography
(HPLC)
High pressure liquid chromatography was used to investigate the purity of the 
Hoechst and N Y .TN .10.52 C-peptide standard. Chromatography was carried out 
at constant pressure using an Altex high pressure liquid chromatography machine 
equipped with a variable wavelength spectro photometer.
Organic solvents used were HPLC grade. Buffer and salt solutions were made up 
with Analar or Aristar reagents using double glass distilled water.
Compounds for chromatography were freshly dissolved in 0.05M sodium 
phosphate buffer pH7.4. A 135 x 5 mm ID column was used with a guard column 
packed with Nucleoside 5-C8 and operated at ambient temperature. A 20 y l  (20 
yg) aliquot of standard was injected on to the column. Buffer A was 0.1 % 
trifluoroacetic acid (TFA) and Buffer B was 60 % acetonitrile with 40 % 
Buffer A. A linear gradient was supplied from 29 % -60 % acetonitrile at a
wavelength of 220 nm. The chart speed was 200 mm hr"^. 1 ml aliquots of 
elution buffer were collected using an automatic fraction collector. To each 
aliquot was added 1 mg bovine serum albumin (dry) and each was frozen. These 
aliquots were lyophilized and resuspended in 0.05M sodium phosphate buffer pH 
7.4 containing 0.1% HSA. The concentration of human C-peptide in these 
aliquots was measured by radioimmunoassay.
Hoechst C-peptide (batch no. Op 25/26) was investigated further using an 
isocratic system. The compound for chromatography was freshly dissolved in 
0.05M sodium phosphate buffer pH7.4. The HPLC column used was 150 x 4.6mm 
ID plus a guard column packed with Hypersil-ODS and operated at ambient 
temperature. A 10 yl (10 yg) aliquot of sample was injected into the column. 
The buffer was 27 % acetonitrile/75 % 0.1 % TFA. Absorbance was 
monitored at a wavelength of 215 nm. The flow rate was 1 ml/min and the chart 
speed was 200 mm/hr. 250 yl aliquots of the elution buffer were collected using 
a fraction collector. The samples were lyophilized with BSA, as before, and
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resuspended in 0.05M sodium phosphate buffer pH7.4 containing 0.1% H5A. The 
concentration of human C-peptide in these samples was determined by 
radioimmunoassay.
2:2:3: Iodination of Tyrosylated human C-peptide
Since human C-peptide contains no tyrosine or histidine residues it is necessary 
to use a tyrosylated analogue for iodination. Three iodination and purification 
methods were investigated to obtain a stable iodinated product.
(a) Purification of tyrosylated human C-peptide
High pressure liquid chromatography was used to investigate the purity of the 
tyrosylated C-peptide (Dr.Geiger, Farbwerke, Hoechst, A.G., Frankfurt, West 
Germany). The machine and method were identical to that previously described 
for HPLC of human C-peptide standard.
(b) Iodination methods
(i) Chloramine T iodination
The method used was a modification of the Hunter and Greenwood (1963) 
method. Tyrosylated C-peptide was weighed out on a Kahn balance and dissolved 
in a small quantity of 1M acetic acid. The C-peptide was then diluted in a 0.05M  
sodium phosphate buffer pH7.4 to a concentration of 200 yg/ml. This solution 
was then aliquoted into plastic autoanalyzer cups. These cups contained 5yg of 
tyrosylated C-peptide and were stored at -20°C  until required. Iodination 
procedure was as follows:- the reagents were added in the following order to a 
plastic autoanalyzer cup.
1) 5 yg tyrosylated C-peptide dissolved in 25 yl of 0.05M sodium phosphate 
buffer pH7.4
2) 25 yl of 0.5M sodium phosphate buffer
3) 18.5MBq (0.5 mCi) in a 5yl aliquot of N a ^ ^ I
4) 2 yg chloramine T dissolved in 10 yl of 0.05M sodium phosphate buffer pH7.4 
15 seconds
5) 48 yg sodium metabisulphite dissolved in 200 yl of 0.05M sodium phosphate 
buffer pH7 4
10 seconds
6) 500 yg potassium iodide dissolved in 5 yl of 0.05M sodium phosphate buffer 
pH7.4.
The reactants were mixed throughout this process with a small magnetic flea. 
The reactants were then loaded on to the purification column.
(ii) Lactoperoxidase Iodination
The method used was a modification of the Thorell and Johansson (1971) method. 
All reactions were carried out in a plastic autoanalyzer cup at ambient 
temperature. The reactants were mixed with a small magnetic flea. Iodination 
procedure was as follows:- the reagents were added in the following order to a 
plastic autoanalyzer cup.
1) 5 yg tyrosylated C-peptide dissolved in 50 yl of 0.04M sodium acetate buffer 
pH5.6
2) 50 yl 0.4M sodium acetate buffer pH5.6
3) 18.5 MBq (0.5mCi) in a 5 yl aliquot of N a ^ ^ I
4) 10 yl - 0.003% solution of hydrogen peroxide (100 vol) dissolved in 0.04M  
sodium acetate buffer pH5.6
5) 10 yl - containing 500 ng of lactoperoxidase dissolved in 0.04M sodium 
acetate buffer pH5.6
15 seconds
6) 240 yg sodium metabisulphite dissolved in 200 yl of 0.04M sodium acetate 
buffer pH5.6
The reactants were then loaded on to the purification column.
(iii) Iodoqen iodination
The method used was a modification of the method of Salacinski et al. (1979). 
20yg of Iodogen (1, 3, 4, 6 Tetrachloro 3a 6a diphenylglyco uril) was dissolved in 
Analar dichloromethane in the bottom of a small polypropylene tube and allowed 
to dry. Iodination procedure was as follows:
1) 20 yg of Iodogen contained in a polypropylene tube.
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2) 18.5 MBq (0.5 mCi) in a 5 yl aliquot of N a ^ ^ I
3) 5 yg tyrosylated human C-peptide dissolved in 0.1M sodium phosphate buffer 
pH7.4
The reactants were mixed by gentle shaking of the tube for 10 minutes.
4) 240 yg sodium metabisulphite dissolved in 200 yl of 0.05M sodium phosphate 
buffer pH7.4
The reactants were then loaded on to the purification column.
(c) Purification of Iodinated C-peptide
(i) Purification on Sephadex G25
The purification on Sephadex G25 was used for all three methods of iodination. 
A 25 x 1.1cm column of Sephadex G25 was equilibrated with 0.05M sodium 
phosphate buffer pH7.4 containing 0.1% HSA. The iodination mixture was 
applied to the column and the iodinated C-peptide was eluted from the column 
with 0.05M sodium phosphate buffer pH7.4 containing 0.1% HSA. The unreacted 
iodide peak was eluted after the protein peak. The purified tracer was aliquoted 
and stored at -20°C .
(ii) Purification on Sephadex QAE A25
This method of purification has been used only for the lactoperoxidase iodination 
products. A 10 x 1.1 cm column of Sephadex QAE A25 was equilibrated with 
0.1M histidine/0.05M HCL pH6.1. The iodination mixture was applied to the 
column. Iodinated lactoperoxidase followed by unreacted iodide were eluted 
with 0.1M histidine/0.05M HCL pH6.1. The iodinated tracer was eluted with 
0.02M HCL containing 1% HSA. This tracer was then aliquoted and stored at - 
20°C.
(iii) Purification on Octadecasilyl (OPS) silica
This is a modification of the method of Bennett et al. (1977). A 1 x 0.5 cm 
column of Spherisord (10 micron ODS silica) was washed with 80 v/v methanol in 
1 v/v TFA (Trifluroacetic acid). A fter equilibration with 1% TFA in water the 
iodination mixture was loaded onto the column and washed with increasing
125concentrations of methanol containing 1% TFA to elute the I Tyr-C peptide. 
This purified tracer was stored at -20°C in 0.05M phosphate buffer pH7.4 in 20 
yl aliquots.
2:2:4:Assay procedure
(a) Human C-peptide assay (Table 2:1)
The diluent buffer used in the assay was 0.05M sodium phosphate buffer pH7.4 
containing lg  HSA per litre.
Standard curves were constructed using human C-peptide in the range
0.125-8 yg/Litre diluted in charcoal stripped serum (see section 2:2:4:(b)).
To a series of polystyrene LP3 tubes were added either 100 yl of C-peptide
standard or 100 yl of plasma sample and 100 yl antiserum diluted in assay buffer
to a final dilution 1:4500. Standards and samples were set up in duplicate. A set
of tubes were set up without antiserum to measure non-specific binding of the
samples and standard curve. The counts in these tubes were subtracted from the 
125total I C-peptide bound when calculating the amount of immunologically
active C-peptide in unknown samples. All tubes were mixed on a vortex mixer
and incubated at 4°C for 48 hours. Tracer was diluted to give approximately
6000 cpm/100 yl (8550 dpm/100 yl). Tubes were then mixed on a Vortex mixture
125and incubated for a further 24 hours at 4°C . Separation of bound from free I
Tyr -  C-peptide was carried out by double antibody precipitation. The antisheep
Y globulin (Batch no. HP/D/43-IC)was used at a final dilution of 1:200. Double
antibody precipitation time can be reduced by the addition of polyethylene glycol
6000 to the tubes. Polyethylene glycol, at a final concentration of 2%, was
added to all tubes except totals, mixed on a vortex mixture and incubated at 4°C
for 2 hours. The tubes were then spun in a refrigerated centrifuge for 25
minutes at 2000g. The supernatant was then aspirated. The protein precipitate
125which contained the antibody bound I C-peptide was counted in an automatic 
gamma counter. The amount of immunologically active C-peptide in unknowns 
and standards was determined by subtracting the number of counts in the non­
specific tubes. These corrected values were used in the construction of a 
standard curve and in calculating results.
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(b) Preparation of charcoal stripped serum
Pooled serum was obtained from volunteers after an overnight fast. The serum 
was mixed with activated charcoal 20 g per 100 ml serum overnight at 4°C . The 
plasma was then centrifuged at 2000 g for 15 min and the supernatant filtered  
through a Zeitz filter Grade HP/EKS. The serum obtained was then aliquoted 
and stored at -20°C  until required.
(c) Collection of samples
Venous blood was collected into lithium heparin tubes. The blood wasI
centrifuged within 15 minutes of collection and the plasma was frozen 
immediately and stored at -20°C.
(d) Storage of samples
The effect on C-peptide levels of storing samples at three different 
temperatures (4°C, -20°C  and -80°C) was investigated.
(e) Validation of C-peptide assay
(i) Recoveries
625, 1250, 2500 and 5000 pg of human C-peptide standard were each added to 
one ml of serum. The serum was obtained from a normal volunteer after an 
overnight fast.
(ii) Parallelism of standard curve with circulating endogenous C-peptide
A plasma sample, which had a high endogenous C-peptide level, was serially 
diluted with charcoal stripped plasma.
2:2:5: Correlation of plasma levels using two Human C-peptide antisera 
Goat human C-peptide antiserum was received from Dr.E.F.Pfeiffer, Germany. 
This antiserum was prepared using a synthetic human C-peptide supplied by 
Hoechst. The antiserum was produced using a carbodiimide method of 
conjugating C-peptide to rabbit albumin. Immunoreactive C-peptide levels in 45 
samples were assessed using the C-peptide assay previously described. Samples 
were measured using both the Pfeiffer and MF/S/743-IB C-peptide antiserum. 
The correlation between the two values of the samples was ascertained.
2:3:Results
2:3:l:Antibody Specificity
The antiserum showed no crossreactivity with human insulin, porcine insulin, 
porcine proinsulin, glucagon and GIP over the concentration range tested (Figure 
2:3). The antiserum had a 10% crossreactivity with biosynthetic human 
proinsulin (Figure 2:4).
Crossreactivity with the C-peptide fragments (Figures 2:3) showed slight 
displacement with those fragments 7-31 and 10-31. The crossreactivity of C- 
peptide antiserum (MF/S/743-IB) with 1-35 and 1-31 synthetic C-peptide 
obtained from Professor N.Yanaihara /was 4.1% and 33% respectively. The 
NIBSC standard 76/561 has a 35 amino acid chain with a formyl lysine on residue 
34. This only crossreacted 15% in the assay.
Standard curves with Hoechst, Novo, NIBSC standard 76/321,and IRE synthetic 
C-peptide were obtained (Figure 2:6) The NIBSC standard 76/321 (NY.TN.10. 
52) is a synthetic C-peptide of unknown chain length. All the other synthetic C- 
peptide standards have 31 amino acids.
2:3:2:Purity of Standard
The purity of Hoechst (Figure 2:7) and NIBSC 76/321 (Figure 2:8) C-peptide 
standard were investigated using HPLC. The Hoechst synthetic C-peptide 
contains two compounds which can be separated on an' isocratic HPLC system 
(Figure 2:9). Each peak can then be measured by radioimmunoassay. Fractions 
collected from HPLC runs were measured in the C-peptide radioimmunoassay 
(Figures 2:7, 2:8, 2:9).
2:3:3:Assay Conditions
(a) Assay Conditions
The effect of increasing the preincubation time on human C-peptide standard 
curves (Figure 2:10) demonstrated that the greatest displacement was obtained 
after 48 hours.
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F ig .2 :7
Hnechst \ y n t h c l i c  human C-peptick- HPLC t ra c e  and immunon-ac L i v i ty 
of f r a c t i o n s  on a g ra d ie n t  system.
Human C-peptide batch no. Op 25/26
HPLC gradient
(A) 0 .1 "  TFA
(B) 60 CH^ CN Injected sample (20 ug)
Fractions collected at 0.1 min 
in tervals  
Chart speed 200 nm hr" 1
Wavelength 220 nm
Human C-peptide immunoreactivity of HPLC fractions
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Fig. 2 : 8  Human C-peptide batch no. NY-TN-10-52 HPLC trace and 
immunoreactivity of fractions on a gradient system.
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Figure 2 : 9 Hoechst human C-peptide HPLC trace and immunoreactivity of 
fraction  of an Isocr^ tic  system. ~
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Figure 2:10
Optimisation of Human C-peptide standard curves
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(b) Standard curve
Under the conditions described for the C-peptide radioimmunoassays increasing
125quantities of unlabelled C-peptide displaced I tyrosylated C-peptide in the 
range 0.11 - 8yg/Litre (Figure 2:11). The non-specific binding varied with the 
age of the tracer but was always less than 10%.
(c) Sensitivity
The lim it of sensitivity of the assay defined as two standard deviations from the 
zero standard (Feldman and Rodbard 1971) was 10 pg.
(d) Scatchard Plot
The binding affinity and equilibrium constant were determined by Scatchard 
(1949) analysis (Figure 2:12). The method of Walker (1977) was used to calculate 
the amount of tracer added to each assay tube. The binding affin ity of the 
antiserum was calculated to be 7.75 x 10 Litre/mole.
2:3:4:Iodination
(a) Purity of Tyrosylated Human C-peptide
Figure 2:13 shows the HPLC trace of tyrosylated C-peptide which appears as two 
peaks.
(b) Assessment of iodination methods
Chloramine T iodination resulted in a tracer which maximally bound only 54% of 
C-peptide tracer under conditions of antibody excess. The binding of the tracer 
to the antiserum deteriorated rapidly on storage. Figure 2:14 shows the antibody 
dilution curves produced with the iodogen and lactoperoxidase produced tracer. 
The iodogen tracer was separated on G25 Sephadex while the lactoperoxidase 
tracer was purified on Sephadex QAE A25. The highest affinity tracer was 
produced when tyrosylated C-peptide was iodinated with iodogen. However, 
attempts to obtain a standard curve using this tracer resulted in a hooked shaped 
curve. This effect disappeared after the tracer had been stored for two weeks 
(Figure 2:15) but the tracer also showed a considerable loss of binding after  
storage for 1 month.
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Figure 2:11
Human C-peptide standard curve showing the intra-assay precision  
fo r each point on the standard curve.
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Figure 2:13 HPLC trace of Hoechst tyrosylated C-peptide
HPLC gradient (A) 0.1% TFA
(B) 60% CH.CN 
40% A J
Chart speed 200 mm hr
Flow Rate 1 ml min 
Wavelength 200 nm
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Figure 2:15 Comparison o f Human C-peptide standard curves using tracers  
produced by lactoperoxidase and iodogen methods.
Final concentration of antiserum 1:4500
100 o Lactoperoxidase method 
•  Iodogen Method
Human C-peptide (p g /L itre )
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(c) Purification of tracer
Figure 2:16 shows the result of separating lactoperoxidase iodinated tyr-C - 
peptide on a Sephadex QAE A25 column using a two buffer system. The tracer 
obtained was aliquoted and stored at -20°C. The tracer remained stable for up 
to eight to ten weeks. This tracer was far more stable when separated using 
Sephadex QAE A25 than when using G25 Sephadex as a separation method.
The elution profile obtained from separating iodinated tyr-C-peptide using an 
ODS silica system is shown in Figure 2:17. The antibody dilution curves and 
standard curves produced with this tracer and the QAE A25 Sephadex tracer 
(Figure 2:18 and 2:19) were almost identical. However, the ODS silica separated 
tracer was less stable and could be used for only four weeks before loss of 
antigen binding occurred.
Specific activity could not be calculated using the QAE A25 Sephadex separation 
method, as a large amount of free iodide remained on the column. However, the 
specific activity was calculated to be 172 mCi/mg by determining the amount of 
tracer added to each tube (Walker, 1977).
2:3:5: Validation of Human C-peptide assay
(a) Precision
The intraassay coefficient of variation at a mean plasma level of 1.3 yg/Litre  
was 8.6% (n = 7) and at 6.2 yg/Litre was 10.7% (n = 7).
The calculated interassay coefficient of variation of four serum samples is shown 
in Table 2:1.
(b) Recovery
The mean recovery of exogenous human C-peptide when added to fasted serum 
was 97% (Table 2:2).
(c) Parallelism
Plasma samples containing a high concentration of endogenous C-peptide serially 
diluted in charcoal extracted plasma were superimposable upon the human C- 
peptide standard curve (Fig. 2:20).
Fi
gu
re
 
2:1
6 
P
ro
fil
e 
of 
la
ct
op
er
ox
id
as
e 
io
di
na
te
d 
Ty
r-C
-p
ep
tid
e 
se
pa
ra
te
d 
on 
QA
E 
A2
5 
Se
ph
ad
ex
 
(P
ea
k 
A 
- 
io
di
na
te
d 
1a
ct
op
er
ox
id
as
e 
pe
ak
 
B 
- 
un
re
ac
te
d 
io
di
de
 
Pe
ak
 
C 
- 
io
di
na
te
d 
C-
pe
pt
id
e 
(a
pp
ro
x.
80%
 
ma
xim
um
 
bi
nd
in
g)
 
el
ut
ed
 
w
ith
60
S-
QJ
XJ
E13C
<c
CO
o
CMO
Li_■O
CO
O
LO
CO
^  o
CMO
O
CO
o
CM
CD
O
00 O
puooas uad s^unog
Fi
gu
re
 
2:
17
 
P
ro
fil
e 
of 
1 a
ct
op
er
ox
id
as
e 
io
d
in
at
ion
 
Ty
r-
C
-p
ep
tid
e 
s&
pa
ra
t.e
d.
on 
OD
S 
s
ili
c
a
61
c_> -o
o
o
o
o
o
o
^  I p u o jd s  J0 d sgunog
o
oooo
Fr
ac
tio
n 
nu
m
be
r
%B
ou
nd
 
I1
25 
C-
pe
pt
id
e 
of 
To
ta
l
62
Figure 2 : 18 Comparison .of ai
Jactoperoxidase iodinated tra ce r p u r if ie d  on 
Sephadex QAE A25 and ODS s i l ic a
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Figure 2:19 Comparison of Human C-peptide standard curves using lactoper- 
oxidase iodinated tracer p u rifie d  in Sephadex 
QAE A25 and ODS s il ic a
100,
a Sephadex QAEA25 p u rified  tracer  
*  ODS s il ic a  p urified  tracer
80.
60-
C-popt ide ( n n / L i t r e )
tab le  2:1 In te r  assay precision o f plasma samples containing a
range o f endogenous C-peptide le v e ls -
Mean C-peptide Value (y g /L itre ) 
0.44
No. o f Observations 
14
SD C o-eff. o f V aria tion  
(%)
0.11 24.5
1.7 8 0.0976 5.7
3.7 13 0.35 9.0
6.17 7 0.39 6.3
Table 2:2 Recovery data - add ition  o f varving amounts o f C-Deotide
standard to  normal fasted serum (mean o f duplicate  estim ation)
Exogenous C-peptide added 
pg/tube
C-peptide measured 
pg/tube
% Recovery
0 95 -
25 115 96
50 135 93
100 185 95
250 325 94
375 495 105
% 
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Human C-peptide standard d iluted  in charcoal -  
extracted serum
- Serum samples d ilu ted  in charcoal-extracted serum
30.
Human C- pe pt id e ( t i g/ Li  t r e ) ,
(d) Stability of C-peptide samples
The stability of endogenous C-peptide was only affected when stored at 4°C . 
Levels remained similar at both -20°C  and -80°C  (Figure 2:21). No deterioration 
in the endogenous C-peptide was apparent after seven months.
(e) Normal Range of human C-peptide levels
Twenty blood samples were taken from non-obese healthy volunteers after an 
overnight fast. The mean C-peptide level was 1.38 yg/Litre -  0.61 (x -  SD), the 
observed range being from undetectable to 2.43 yg/Litre.
(f) Correlation of plasma levels using two human C-peptide antisera
Blood samples were taken and measured in the assay system described using two 
different antisera. The correlation of values obtained from both assays was 0.97 
(Fig. 2:22).
2:4: Discussion
A radioimmunoassay for the detection of immunoreactive human C-peptide has 
been developed. All previously published C-peptide radioimmunoassays have 
used antisera either raised by using crude 8 insulin component or conjugated C- 
peptide using the carbodiimide method. Carbodiimide reagent reacts with many 
functional groups and it is difficult to forecast where conjugation has taken 
place. In this study, antiserum was raised by conjugating C-peptide to egg 
albumin using the gluteraldehyde method. This method is quick, simple and the 
place of conjugation is less variable. Gluteraldehyde is thought to react with the 
epsilon amino group of lysine (Quiocho and Richards, 1966) and possibly the 
amino group at the N-terminal end of the protein. Human C-peptide, which has 
31 amino acids, has no lysine residues therefore the conjugation was presumed to 
have occurred on the N-terminal glutamic acid.
Antiserum to human C-peptide has been produced in a variety of animal species. 
Rabbits, goats and guinea pigs have all been used by other workers (Melani et al. 
1970; Kaneko et al. 1974; Heding, 1975; Beischer et al. 1976.Faber e t a l.  
1976.) Initial attempts to produce antiserum in rabbits resulted in only one
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Fig. 2:22
C orrelat ion o f plasma leve ls using two Human C-peptide antiserum
0.968
v
( yg /L itre )C -peptide  Guildford
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animal responding. This animal produced an antiserum which had a low titre and 
avidity. The immunogenicity of compounds varies according to the species of 
animals used. A primitive breed of sheep was therefore immunized with the 
conjugated human C-peptide. These animals responded and a usable antiserum 
was obtained after the first re immunisation.
The crossreactivity of the antiserum was assessed with synthetic C-peptide 
fragments. Only slight displacement was shown with fragments 10-31 and 7-31. 
No fragments were available containing the amino acid sequence at the amino 
end of the molecule. It is possible that the antigenic determinants of the human 
C-peptide are at the amino end of the molecule for this antiserum. It cannot be 
established from the data available whether or not there is more than one 
determinant. It is known that in the case of peptide hormones each antigenic 
determinant consists of a sequence of some 2-8 amino acids, having a diameter 
of less than 13 angstrom units. It has been shown that these amino acids have a 
unique three dimensional configuration. A difference of only one amino acid is 
sufficient to distort this arrangement and impair the binding to specific 
antibodies.
Studies with various synthetic standards showed varying degrees of displacement 
compared with the Hoechst standard. The need, therefore, for an International 
standard which could be used by all laboratories measuring C-peptide is required. 
Unfortunately the NIBSC C-peptide standard 75/361 only crossreacted 15% in 
the assay. Another sample of synthetic standard (NY-TN-10-8) from NIBSC 
crossreacted 52.4% in the assay. High pressure liquid chromatography of this 
standard showed more than one component. This could explain the low 
crossreactivity in the assay. The chain length is also important in recognition of 
a standard, since the 1-35 C-peptide crossreacted by 4.1% while the 1-31 C- 
peptide crossreacted by 33%. Synthetic C-peptide standards obtained from Novo 
and IRE-UK Ltd. produced similar standard curves in the assay when compared 
with the Hoechst standard. Both these standards are synthetic and have 31 
amino acids.
7 0
The high pressure liquid chromatography trace of the Hoechst C-peptide showed 
that it contains two components. When these components were separated using 
an isocratic HPLC method, each component displaced tracer in the assay. The 
antiserum used in the assay was raised against a previous batch of synthetic C- 
peptide. Previous batches may also have contained two components. It can be 
postulated that of these two components, one has the correct C-peptide 
sequence while the other component is an analogue, varying by one or more 
amino acids. It would appear that because of the close elution of these two 
components that they vary in only one or two amino acids. Investigating the 
amino acid sequence of this second component would take considerable time, but 
it is possible to conjecture that the amino acids which differ are the glutamine 
residues as these residues can be easily hydrolysed to glutamic acid.
Tyrosylated C-peptide eluted in two peaks from the HPLC column. The minor 
component could be human synthetic C-peptide without the tyrosine moiety. 
Iodination of human C-peptide proved to be extremely difficult despite following 
previously published methods for C-peptide iodinations (Melani et al. 1970, 
Heding. 1975, Beischer et al. 1976). In itia l iodinations using the chloramine T 
method produced a tracer which only maximally bound 40% under condition of 
antibody excess. This method of iodination is fairly harsh since it directly 
exposes the peptide to the oxidizing agent. The lactoperoxidase method was, 
therefore, investigated. Previous workers (Beischer et al. 1976) have used this 
method and left the reaction mixture for twenty minutes before terminating the 
reaction. After varying the reaction time it was found that terminating the 
reaction after only 15 seconds produced a high specific activity tracer. The 
tracer produced by iodination using the iodogen method gave a higher maximum 
binding than with the lactoperoxidase trace in the assay. However, it was 
observed that an anomalous rise occurred in the percentage binding of the 
labelled antigen to the antibody upon the addition of low concentration of the 
unlabelled antigen. This observation has been described in the literature a
number of times (Cresto, 1974; Beischer et al. 1976). Although this effect 
disappeared after the tracer had been stored for two to three weeks iodination of 
C-peptide using iodogen was not considered suitable for routine assay without a 
considerable amount of further investigation into this effect and the alternative  
lactoperoxidase method was therefore used.
The shelf life of the tracer can be increased by some four weeks by selecting the 
optimum purification procedure using an ion-exchange chromatography method, 
first described by Heding et al. (1974). A lactoperoxidase tracer was obtained 
which remained stable for up to 8-10 weeks after the iodination. This improved 
separation of iodinated from non-iodinated C-peptide and iodinated 
lactoperoxidase resulted in a highly purified tracer of consequently high specific 
activity being added to the assay system. The sensitivity and reliability of the 
assay was greatly improved by this method of purification of the tracer.
The stability of the human C-peptide in plasma samples was investigated. 
Samples stored at -20°C and -80°C had similar values when measured in a 
radioimmunoassay after 20 weeks' storage. If stored at 4°C, however, there was 
a 24 % decrease of immunoreactivity after only 22 days. These results do not 
substantiate those reported by Garcia-Webb et al. (1979). They reported that 
there was a marked reduction of C-peptide in samples stored at -18°C for longer 
than three weeks but found that no change occurred in samples stored at - 70°C  
for up to 16 weeks.
The values obtained in the assay system for fasting C-peptide levels in normal 
subjects, compared closely with other published ranges (Block et al. 1972; 
Beischer et al. 1976). Heding et al. (1974) reported levels which were lower than 
the values reported in this chapter. Their assay, however, involved the 
extraction of proinsulin and proinsulin-like components before measurement of 
C-peptide.
The human C-peptide assay developed crossreacted 10% with human biosynthetic 
proinsulin. This compares favourably with other workers who have reported
crossreactivity with proinsulin in their C-peptide assays ranging from 15-66% 
(Melani et al. 1970; Ca ygill et al. 1980). C-peptide values obtained in 
unextracted plasma by this assay method are the sum of crossreactivity of C- 
peptide, proinsulin and proinsulin-like components. The levels of proinsulin and 
proinsulin-like components have been reported to be very low in normal subjects 
(Heding, 1977, Rainbow et al. 1979) but raised in certain clinical situations e.g. 
insulin producing tumours.
The sensitivity of an assay is determined by a number of factors. It is related to 
the slope of the dose response curve and is affected by the precision with which 
the percent bound can be measured in replicate tubes containing 'O' standard. 
The sensitivity of the assay may be affected by physiological fluids. Plasma and 
serum samples have been shown to cause both incubation damage and 
interference in the separation system. It has been shown that charcoal stripped 
serum from different individuals has lower binding and a greater variation than 
that of the 'O' standard in diluent. This effect is defined by Hunter (1971) as 
'noise' and it has been suggested that the sensitivity of an assay could be defined 
as the minimum amount of hormone that w ill produce a fall, in percent bound, 
significantly below that arising from noise. The sensitivity of the C-peptide 
assay described was 10 pg, sensitivity being defined as two standard deviations 
from zero. No account has been taken in the calculation of the effect of plasma 
and serum in the assay.
Other workers have shown variations in the level of circulating C-peptide 
immunoreactivity measured in human subjects depending on the antiserum used. 
In particular Heding (1975) has shown that there was considerable variation in 
displacement of the tracer from different antisera by serum from long-term  
insulin treated diabetics. The correlation of C-peptide immunoreactivity in 
samples measured using two different antiserum was extremely close. However, 
the majority of the samples assessed were obtained from normal subjects and 
this may explain why no differences were apparent.
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CHAPTER III
HUMAN C-PEPTIDE LEVELS IN NORMAL NON-OBESE SUBECTS 
IN THE FASTED AND STIMULATED STATES
3:1 Introduction
Radioimmunoassays for the measurement of human C-peptide have been developed 
by a number of workers (Melani et al. 1970,^Kaneko e t al.1974, Hedingl975 
Faber e t al.1976 > Beischer et al. 1976). There are many clinical conditions in 
which C-peptide measurement is useful in diagnosis. Its greatest use has been in 
the diagnosis of various hypoglycaemic disorders. The establishment of a normal 
range of C-peptide values in normal non-obese subjects in the fasted and fed states 
is important. Since there is no international standard available each laboratory has 
to use its own standard which may vary in amino acid chain length and amount of 
impurities (see Chapter II). Fasting C-peptide levels in healthy subjects vary 
depending on the assay (Block et al. 1972,Kaneko e t a l.  1974, Heding,1975',
Heding,and-.Rasmussen, 1975, Beischer et al.1976, Beyer e t a l.1976.) 
Evidence to date regarding diurnal rhythms observed in blood levels of insulin and 
glucose are not well understood. It is not certain whether truly endogenous 
circadian rhythms exist or whether the phenoma are secondary to feeding and 
activity patterns.
A variety of observations have been made on the effect of fasting on plasma 
glucose levels. Fairman and Moorhouse (1967), reported that a diurnal rhythm in 
blood glucose levels was observed in maturity onset diabetics during three days of 
starvation. They could not, however, demonstrate a rhythm in normal non-obese 
volunteers. Merimee and Tyson (1974), reported lower fasting blood glucose levels 
| women than in men. The difference is noticed after twenty four hours fasting 
and is striking after thirty six hours. The variation in the blood glucose levels in 
men and women may be due to differences in muscle mass, the effect of sex 
hormones on the uptake of glucose into the tissues or ketosis which may inhibit the 
release of precursors of gluconeogenesis.
A circadian rhythm in plasma insulin levels has been shown in fasted rats and mice 
(Bellinger et al. 1973, Ressacq et al. 1976) but evidence in man is less convincing. 
Fairman and Moorhouse (1967), have reported no significant change in fasting
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insulin levels in normal non-obese subjects either within one day or from day to 
day. Freinkel et al. (1968), however, have shown that in a group of normal non- 
obese volunteers, fasted for three days, consistently lower plasma insulin levels 
were recorded in the afternoon (1500-1600h) than in the early morning (0700- 
0800h). This lower plasma insulin level in the afternoon was not associated with 
any changes in blood glucose. A diurnal change in plasma insulin and glucagon 
levels has been reported in a patient with a malignant insulinoma (Ohneda et al. 
1979). The glucagon level peaked between 0600-0730h while the insulin level 
peaked at approximately 0730h.
Insulin estimations in the fasted state are very near the detection lim it of the 
conventional insulin radioimmunoassay. When measuring these low insulin levels, 
the coefficient of variation of the assay is large and may mask any small changes 
which occur in insulin concentration. C-peptide is present in much higher 
concentrations than insulin in the peripheral circulation and fasting levels in 
most subjects are therefore well above the detection lim it of the assay in most 
subjects and can be measured with greater precision. However, the long half life  
of C-peptide would prevent short term changes in B cell activity being detected. 
Evidence for a diurnal rhythm in post-prandial plasma insulin and glucose levels 
is conflicting (SchlieTf and Raetzer, 1972, Hautecouvature et al. 1974, Ahmed et 
al. 1976). SchlietT and Raetzer (1972), reported a study carried out in normal 
non-obese young subjects in which either six small meals or three large meals 
were given on two separate occasions to each volunteer. The same total energy 
intake was maintained on both regimens. These workers found improved glucose 
tolerance during the mdrning and high blood glucose values in the afternoon. The 
integrated insulin areas for 24 h were identical after both regimens. Cohn et al. 
(1968) reported that the size of the insulin response was a function of the energy 
load. Ahmed et al. (1976) using a three meal schedule found a diurnal rhythm in 
plasma glucose responses but only in women. The integrated glucose area 
increased significantly through the day, although integrated insulin area did not
change. Haute'couvature et al. (1974) using a two-meal schedule, showed no 
difference in glucose response between sexes, but a significantly higher insulin 
response in the morning compared with the afternoon. Obviously it is difficult to 
compare findings when different meal times and groups of subjects are used. 
Diumal variation in glucose tolerance in man, with reduced tolerance to both 
intravenous and oral glucose in the afternoon has been reported by a number of 
workers (Roberts 1964, 1967, Bowen &Reevesl 967Jarrett and Keen, 1969, 1970). 
Carroll and Nest&l (1973) found that after an evening oral glucose tolerance 
test the insulin response was delayed and the insulin response to an intravenous 
glucose load was diminished in the evening compared with the morning. These 
workers suggested that this reduced glucose tolerance in the evening may be due 
to the impairment of the early response. Other workers (Gibson and Jarrett, 
1972, Gagliardino et al. 1976) have suggested that the diumal difference in 
glucose tolerance might be attributed to a diurnal variation in sensitivity to 
endogenous insulin. Gibson and Jarrett (1972) showed that exogenous insulin was 
less effective in the afternoon than in the morning. Schulz et al. (1980) showed 
that normal subjects who were infused with a constant amount of glucose 
required varying amounts of exogenous insulin to maintain normoglycaemia at 
different times during the day. Human C-peptide levels were monitored to show 
any changes in endogenous insulin activity. The highest insulin requirement 
occurred between 1400-1800h and lowest between 0200-0600h.
Small seasonal variations in fasting blood glucose levels and good glucose 
tolerance with a low insulin secretion during the summer months have also been 
observed in a group of men suffering from myocardial infaction (Fahlen et al. 
1971). It is not known whether normal subjects have a seasonal variation in 
insulin and glucose levels.
The disposal of a glucose load is progressively impaired in subjects over the age 
of 60 years (McKendry, 1980, Davidson, 1979). The reason for this impairment 
remains unclear but poor diet, lower physical activity, decrease in lean body
77
mass in which to store the carbohydrate load, decreased insulin secretion and 
insulin antagonism may all be contributory factors. Care must, therefore, be 
taken to age match subjects as much as possible when investigating changes in 
glucose tolerance.
Studies have been carried out in order to obtain a fasting range of C-peptide 
levels in normal, non-obese volunteers. Human C-peptide levels have been 
studied in fasting subjects and in response to oral and intravenous stimulation in 
normal volunteers. These investigations provide background information in 
which to assess C-peptide levels found in hypoglycaemic subjects. These are 
discussed in a later chapter.
3:2 Materials and Methods 
3:2:1 Study 1
Twenty four hour profiles of C-peptide, insulin and glucose levels in normal 
subjects following a meal and subsequent fasting
Ten normal healthy volunteers, four men and six women, aged between 20-39 
years (27.1 -1.78 (x — SEM)) and within 20% of their ideal body weight 
(Metropolitan Life Insurance Company Tables) took part in the study. Relevant 
physical characteristics are summarised in Tables 3:1. During the study the 
volunteers were confined to the hospital unit. A test meal (Table 3:2) was eaten 
between 0710-0730 h after an overnight fast. Two jam doughnuts and tea or 
coffee were taken at 0943 h. A 10 ml blood sample was taken at hourly intervals 
for 24 h starting at 1000 h by means of an indwelling catheter inserted into an 
antecubital vein, kept patent with 0.12M sodium citrate. After each sample a 
100 yl aliquot of whole blood was deproteinised for glucose analysis. The 
remaining blood was collected into a lithium heparin tube mixed and centrifuged. 
Plasma was aliquoted and stored frozen at -20°C  until assayed.
3:2:2 Study 2
C-peptide, insulin and glucose levels after intravenous glucose and a test meal at 
two different times within twenty four hours
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Table 3:1
Physical Characteristics of subjects in 24 hour study
Subject
(code)
Sex Age
(yr)
Height(cm) 
in shoes
Weight
(Kg)
A M 25 165 52.5
B M 24 173 79
C M 24 180 55.5
D F 29 173 58.5
F F 29 170 50.0
G F 39 175 79.0
H F 33 170 74.0
I M 26 183 77.5
3 F 20 170 66.5
K F 22 168 59.5
Table 3:3
Physical Characteristics of subjects in two meal study
L F 24 175 70
M M 28 165 53
N M 27 180 69
P M 23 188 77
S M 25 185 73
Table 3:4
Physical Characterists of subject in intravenous glucose study
T M 24 173 77
V F 33 170 72
W M 22 168 37
X F 29 173 58
Z F 29 170 50
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Table 3:2
TEST MEAL
WT(g) Protein(g) FAT(g) CHO(g) Kcals
Cornflakes 17 1.5 0.3 14.5 63
Milk 200 6.6 7.6 9.4 130
Sugar 10 - - 10 40
Bread 20 1.8 0.5 8.4 43
Butter 11.3 - 9.3 - 84
*  Doughnuts 120 7.2 19.5 8.6 419
Total 17.1 36.7 100.9 779
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(a) A study on the effect of intravenous glucose administration at two 
different times during twenty four hours
Five normal healthy volunteers, two men and three women, aged between 22-33 
years (27.4 -  1.96) and within 20% of their ideal body weight (Metropolitan Life 
Insurance Company Tables) were studied. The physical charcteristics of the 
subjects are shown in Table 3:4. During the study the volunteers were confined 
to the hospital unit. All subjects fasted overnight for 13 hours prior to the start 
of the study. The basal blood samples were taken by means of an indwelling 
catheter inserted into an antecubital vein, kept patent with 0.12M sodium 
citrate. At 1030 h the volunteers were intravenously given 25g of glucose, made 
up in 30 ml sterile saline, by means of an indwelling catheter inserted into the 
antecubital vein in the other arm. Samples were taken at 5, 10, 15, 30, 45, 60, 
90, 120, 150 and 180 minutes after the intravenous administration of the glucose. 
The volunteers were then allowed to carry on with their normal activities and 
were allowed to drink water if they wished. A second 25g intravenous glucose 
load was given at 0130 h, 15 h after the first load. Blood samples were taken at 
the same time points as before. A fter each blood sample 100 yl aliquots of 
whole blood were deproteinised for glucose analysis. The remaining 10 ml of 
blood was mixed in a lithium heparin tube. The tube was spun and plasma 
aliquoted, stored and frozen at -20°C until assayed.
The rate of disappearance of glucose (K value) was calculated, according to the 
formula of Conard (1955), from the regression time of the blood glucose levels 
against time between 15 and 60 minutes after glucose injection.
(b) A study on the effect of a test meal eaten at two different times in 
twenty-four hours on glucose, insulin and C-peptide levels
Five normal healthy volunteers, four men and one woman, aged 23-28 years (27.4 
— 1.96) were studied. Their weights did not exceed ideal body weight by more 
than 10% (Metropolitan Life Insurance Company Tables). The physical 
characteristics of the subjects are shown in Table 3:3. During the study the
81
volunteers were confined to the hospital unit. All subjects fasted overnight for 
15 hours prior to the start of the experiment. Blood samples were taken by 
means of an indwelling catheter inserted into an antecubital vein, kept patent 
with 0.12M sodium citrate. At 1030 h, after a basal blood sample had been 
taken, the volunteers were given a test meal (see Table 2). Blood samples were 
taken at hourly intervals for 24 h starting at 1045 h. An identical test meal (see 
Table 2) was given 15h after the first test meal. Subjects were allowed to drink 
water as and when they wished. After each blood sample a lOOyl aliquot of 
whole blood was deproteinised for glucose analysis. The remaining blood was 
collected into lithium heparin tubes, mixed and centrifuged. Plasma was 
aliquoted and stored at -20°C until assayed.
3:2:3 Study 3
Diumal rhythms in C-peptide, insulin and glucose levels in response to a
test meal given at different times over twenty four hours 
Six normal healthy volunteers, three men and three women, aged between 23-33 
years (27.8 -  1.47) and within 20% of their ideal body weight (Metropolitan Life 
Insurance Company Tables) were studied. The physical characteristics of the 
volunteers are shown in Table 3:5 All subjects fasted for 10-12 hours before the 
start of each experiment. Test meals (see Table 3:2) were eaten at the following 
times, 0200, 0600. 1000, 1400, 1800, 2200 h on six separate occasions. At least a 
week elapsed between each experiment. The volunteers were divided into two 
groups. Each group were given a test meal at a different time on the same day. 
Two basal blood samples were taken by means of an indwelling catheter inserted 
into an antecubital vein, kept patent with 0.12M sodium citrate. The test meal 
was eaten within 30 minutes of the start of the experiment. Blood samples were 
taken 30, 60, 90, 120, 180, 240, 300 and 360 minutes after the meal. During the 
sampling the volunteers were confined to the hospital unit. Blood samples were 
collected into lithium heparin tubes, mixed and centrifuged. Plasma was 
aliquoted and stored frozen at -20°C until assayed.
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Table 3:5
Physical Characteristics of subjects on diu rnal rhythms study.
Subject Sex Age(y) Weight (Kg) Height
(cm)
A F 29 57 173
B F 30 60 175
C M 25 80 173
D M 27 75 180
E M 23 61 183
F F 23 72 170
Table 3:6
K values obtained after intravenous glucose study
K value = per cent removal of glucose per minute between 15 and 60 minutes 
Subject K values after 1st infusion K values after 2nd Infusion
T 3.46 1.6
W 2.8 0.87
X 2.04 1.1
Y 1.1 0.61
Z 1.7 1.46
t = 3.15 p < 0.025
3:3 Assays
3:3:1 Glucose analysis
Blood glucose was determined in duplicate by a glucose oxidase method (Trinder, 
1969) in Study 1 and 2. Plasma glucose determination in Study 3 involved the use 
of hexokinase enzyme in an automatic glucose analyser.
3:3:2 Insulin Radioimmunoassay
Plasma immunoreactive insulin was measured by a double antibody
radioimmunoassay developed at St.Luke's Hospital, using guinea-pig antiserum.
123The standard used was human insulin standard and the I insulin tracer was 
obtained from the Radiochemical Centre, Amersham. The detection lim it of the 
assay was 2.5 m U/Litre. The interassay coefficient of variation was 15% at 65 
m U/Litre and 7.4% at 46 m U/Litre.
3:3:3 C-peptide Radioimmunoassay
Plasma immunoreactive C-peptide levels were measured in duplicate by the 
method described in Chapter I I .  The assay has a detection lim it of 10 pg/tube 
(100 ng/Litre). The interassay coefficient of variation was 24.5% at 0.44 
yg/Litre and 9% at 3.7 yg/Litre.
3:3:4: Statistical analyses
Statistical analyses of the results were carried out using a student 't' test for 
paired data. Correlation coefficients were determined by simple linear 
regression. Integrated areas were calculated by plotting the graph, cutting out 
and weighing the paper representing the area under the curve.
3:4 Results
3:4:1 Normal Range of Human C-peptide levels
Blood samples were taken from healthy non-obese volunteers after an overnight 
fast. Fasting immunoreactive C-peptide levels correlated with fasting 
immunoreactive insulin levels in seventeen subjects (correlation 0.78) (Fig.3:1). 
When all twenty subjects were included the correlation was reduced to 0.387. 
The three subjects who were excluded from the initial correlation had fasting
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Figure 3:1
Co rre la t io n  o f basal in su lin  with C-peptide levels in 
healthy volunteers.
Slope 3.609 
in te rcep t 1.6
Corr Coeff 0.78
2.5
2
1.5
1
0.5
0 ^ Insulin^mU/Litre ^ 122 10
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immunoreactive insulin levels of 4, 5, 6 m U/Litre yet fasting immunoreactive 
C-peptide values of 2.55, 2.45, 2.4 yg/L itre. One of these subjects had a renal 
function test in order to determine creatinine clearance. The value obtained was 
80 ml/min, the normal range being 95-105 ml/min. The renal function of the 
other two subjects was not investigated.
Fasting immunoreactive C-peptide values were found to correlate significantly 
with body weight (correlation 0.89) and body mass index (correlation 0.78) (Fig. 
3:2 and 3:3). The weight and height of the healthy volunteers ranged from 50-79 
kg (63 ±2 .4 ) and 165-188 cm (174.7 ±  1.87).
3:4:2 Twenty four hour profiles of immunoreactive C-peptide. insulin and blood 
glucose in normal volunteers following a meal and subsequent fasting.
The mean blood glucose levels throughout the sampling period are shown in 
Figure 3.4. The mean blood glucose levels showed very little  variation throughout 
the 24 h sampling period. There was no significant difference between males and 
females when plotted separately.
The mean plasma immunoreactive insulin levels throughout the study are shown 
in Figure 3:5. Plasma immunoreactive insulin peaked one hour after ingestion of 
the meal (40.1 + 5.51 m U/Litre (x -  SEM)) and returned to fasting levels after  
approximately 5 hours. The mean fasting levels defined as 6 hours after the 
start of sampling until the end of the study was 5.27 -  1.7 m U/Litre.
The profile of mean plasma immunoreactive C-peptide levels in the study are 
shown in Fig. 3:6. Plasma immunoreactive C-peptide levels peaked after one 
hour at 5.86 — 0.76 yg/Litre and returned to basal levels after 11 hours. The 
initial fall in immunoreactive C-peptide levels was sharp, from 5.86 yg/L itre to 
2.4 yg/Litre, in three hours. The mean fasting immunoreactive C-peptide, 
defined as 12 hours after the start of sampling until the end of the study was 1.7 
± 0.2 yg/Litre.
The peak values of the blood glucose and hormones in the study would not 
necessarily reflect the actual peak values obtained in view of the sampling
C-
oe
pt
id
e 
ug
/L
itr
e 
C-
pe
pt
id
e 
pg
/L
itr
e
86
Fig. 3:2
Correlation o f fas t ing  C-peptide levels and body weight 
healthy volunteers^
N = 15 In tercept 4.14
Correlation 0.89 Degree o f Freedom 13
Slope 16.06 p < 0.001
3
1008020 40 60
Body Weight (kg)
Figure 3:3
Correlation o f fas t ing  C-peptide levels and Body mass index (BMI)
N = 15 In tercept 15.8
Correlation 0.78 Degree o f Freedom 13
Slope 3.56 p < 0.001
•  •
3010 20
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Figure 3:4
Twenty four hour p ro f i le  of blood glucose, in su lin  and 
C-peptide in normal non-obese volunteers fo llow ing a 
meal and subsequent fas t ing . j QfrM
Blood Glucose mmol/Litre
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Figure 3:5
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times. In order to obtain an accurate value more frequent sampling would 
initially be necessary because of the rapid post-prandial rise.
3:4:3 Study 2
Immunoreactive C-peptide, insulin and blood glucose levels after intravenous 
glucose and test meals at two different times in twenty four hours.
(a) Intravenous glucose tolerance tests
The mean blood glucose levels throughout the sampling period are shown in 
Fig. 3:7. Blood glucose levels peaked 3 minutes after the start of the infusion 
and similar levels were reached after both infusions. Blood glucose levels after 
the 1000 h intravenous infusion took 90 minutes to fall to fasting levels. A fter 
the 0200 h infusion blood glucose levels reached basal values 150 minutes after 
the glucose had been infused. Statistical analysis of the area under the curves 
showed a significant difference (p < 0.0125) using student paired 't' test. 
Estimation of the k values, the rate of disappearance of glucose against time 
(15-60 minutes) showed that all volunteers had smaller values after the second 
infusion (Table 3:8).
The mean plasma immunoreactive insulin levels throughout the study are shown 
in Fig. 3:8. The mean fasting immunoreactive insulin level at the start of the 
study were 63 -  0.73 m U/Litre ,. The levels increased sharply reaching a peak 5 
minutes after the glucose load and similar levels were reached after each 
infusion. Plasma insulin levels took longer to return to basal levels after the 
second infusion. Calculation of the area under the curve of individuals followed 
by statistical analysis by paired ft f test showed no significant difference between 
the two responses. Significantly higher mean insulin levels were reached 90, 120 
and 180 minutes after the second infusion compared with the first infusion.
The mean level of immunoreactive C-peptide in the two intravenous glucose 
tolerance tests are shown in Fig. 3:9. In this study mean fasting immunoreactive 
C-peptide levels were 1.22 -  0.11 yg/L itre. Levels increased sharply after the 
glucose load, reaching a peak 5 minutes after the start of both infusions. The
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Blood glucose leve ls  a f te r  intravenous glucose in fusion a t two 
d iffe re n t times in 24 hours in healthy volunteers.
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Figure 3:8
Plasma i nsulin  leve ls  a f te r  an intravenous glucose in fu s io n a t  
two d iffe re n t  times in 24 hours in healthy
 1 ± SEM
o 0200h * p < 0.0125
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Figure 3:9
Plasma C-peptide levels a f te r  an intravenous glucose in fusion at 
two d i f fe re n t  times in 24 hours in healthy volunteers.
I  ± SEM * p < 0.05
0200h **  P < 0.025
1000h ***p < 0.0025
■r ■" ...   i ■■ I l---------- 1---------- 1---------------------- 1---------------------- 1-----------------------1 l
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Time (min)
peak levels after the first and second infusion were 4.06 -  0.87 yg/Litre and 
4.44 -  1.2 yg/Litre respectively. Immunoreactive C-peptide levels returned to 
basal values 180 minutes after the first infusion. After the second infusion 
immunoreactive C-peptide levels had not returned to basal levels by the end of 
the experiment. Calculation of the area under the curve of individuals, followed 
by statistical analysis by paired 't' test showed a significant difference (p < 0.01) 
between the two responses.
The molar ratio of immunoreactive C-peptide to immunoreactive insulin in the 
fasted samples was 9.75 -  1.42. ‘ This level decreased to 3.17 — 0.56
5 minutes after the 1000 h glucose infusion (Fig.3:10).
(b) A study on the effect of a test meal at two different times in twenty four 
hours on immunoreactive C-peptide, insulin and blood glucose levels 
The mean*blood glucose levels throughout the sampling period are shown in Fig. 
3:11..Blood glucose levels peaked at 5.12 -  0.4 mmol/Litre approximately 3.5 
hours after food ingestion. The peak response in blood glucose levels was 9.56 
-  1.2 mmol/Litre which occurred 30 minutes after the second test meal was 
ingested. Blood glucose levels took approximately 5.5 hours to return to basal 
levels.
The plasma immunoreactive insulin levels after the two test meals are shown in 
Fig. 3:12. The peak level was 48.2 -  4.7 m U/Litre and fasting levels were 
regained 4.5 hours after ingestion of the morning meal. The second meal peak 
levels were 63 -  5.1 m U/Litre and levels were still elevated at the end of the 
study. Statistical analysis showed that the area under the curve was 
significantly larger after the second test meal (p <0.01) (Table 3:7).
The plasma immunoreactive C-peptide levels after the two meals are shown in 
Fig. 3:13. The maximum plasma C-peptide response was 5.95 -1 .2  yg/L itre  
following the first meal. Fasting levels were 1.44 -  0.23 yg/Litre. Levels did 
not return to fasting values until 5.5 hours after food ingestion. A fter the 
second meal levels peaked at 7.92 -  1.5 yg/Litre and had not returned to basal
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Table 3:7 Statistical analysis of insulin results obtained during two meal study
Units m U/Litre.h
Subject Area under curve 1st meal Area under curve 2nd meal
L 133 163
M 96 213
N 73 169
P 101 218
S 133 197
Mean 107.2 192
SD 23.8 25.1
SEM 11.5 11.2
t value 5.05 p < 0.005
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the curve was significantly greater after the second meal (p < 0.0005) (Table 
3:8). The peak value of blood glucose and hormones measured in this study would 
not necessarily reflect the true peak values because of the infrequent sampling 
times.
3:4:4' Study 3
Diurnal rhythms in response to test meals given at different times over twenty 
four hours
The mean plasma glucose levels at all six time points in the study are shown in 
Fig.3:14. Peak plasma glucose levels varied with the time the meal was ingested. 
The maximum mean peak level reached was 9.03 -  0.26 mmol/Litre after the 
0200 h meal. The minimum mean response occurred after the 1800 h meal. The 
glucose levels returned to fasting levels 1.5 hours after the 1000 h test' meal. 
After all other meals the levels took considerably longer to return to fasting 
levels. After the 0200 h meal levels took approximately 4.5 hours to return to 
basal values. Statistical analysis of the area under the curves showed that the 
glucose response was less at 1000 h compared with all other time, the maximum 
response being at 2200 h (Fig. 3:15).
The mean immunoreactive plasma insulin levels for ail six meals are shown in 
Fig. 3:16. The mean peak level was 106.4 — m U/Litre which was reached 90 
minutes after the 2200 h meal. The mean nadir plasma insulin level occurred 60 
minutes after ingestion of the 0600 h meal. The integrated response to food 
ingestion, defined as the period from 0 minutes until the levels returned to basal 
values, showed a significant increase at 2200 h compared with 1000 h (p <0.025) 
(Fig. 3:15). It is interesting to note that the shape of the mean insulin response
curve was altered considerably depending on the time the meal was eaten.
The mean immunoreactive plasma C-peptide levels fo r  a l l  s ix  meals are 
shown in F ige3 : l7 .  
Calculation o f the integrated ra t io  o f immunoreactive C-peptide to 
in su lin  a f te r  each meal showed no s ta t is t ic a l  d ifference between the 
responses. 
Integrated plasma immunoreactive GIP (gas tr ic  in h ib i to ry  polypeptide) 
responses showed a s ig n if ic a n t increase a f te r  1400h compared w ith 2200h 
(Fig. 3:15).
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Table 3:8
Statistical analysis of immunoreactive C-peptide results obtained after the meal study 
Units ng/Litre.h
Subject Area under curve 1st meal Area under curve 2nd meal
L 147 295
M 112 198
N 97 221
P 138 269
S 79 197
Mean 115 236
SD 28.2 44
SEM 12.6 19.7
t = 11.93 p <0.0005
Varia tion  in  plasma glucose response to a te s t meal given a t 6 
d if fe re n t times over a 24 hour period.
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3:5 Discussion
Very little  variation in fasting blood glucose, immunoreactive insulin and 
immunoreactive C-peptide levels occurred in the twenty four hour study. 
Fairman and Moorhouse (1967) reported no diurnal cycle in blood glucose and 
insulin levels in normal non-obese subjects. Their study involved blood sampling 
every four hours over a three day period of starvation. Other workers (Merimee 
and Tyson, 1974) have shown that women had lower blood glucose levels after 
fasting for twenty four hours. The volunteers in Merimee and Tyson's study 
(1974) were only sampled once in the morning and again in the afternoon. In the 
24 hour study no significant difference was found when treating data from men 
and women separately.
Oscillations in blood glucose and B cell activity have been reported by a number 
of workers (Hansen and Johansen 1970, Ohneda et al. 1979, Lang et al. 1979). 
Lang et al. (1979) working with normal non-obese volunteers sampled every 
minute and found that basal insulin levels oscillated regularly at 15 minute 
intervals. Goodner et al. (1977) showed that, in monkeys, insulin and C-peptide 
levels oscillate in phase within a period of nine minutes. They demonstrated that 
these oscillations occurred spontaneously and disappeared with prolonged fasting. 
Since this oscillation is due to cyclical secretion of insulin rather than an 
oscillating pattern of hormone metabolism any oscillation occurring in B cell 
activity would, therefore, not have been detected in the twenty four hour study 
due to the interval between samples. The measurement of fasting insulin levels 
in normal non-obese subjects is very near the detection lim it of most insulin 
radioimmunoassays. In the present study the C-peptide levels are well above the 
detection lim it of the radioimmunoassay. One disadvantage, however, in 
measuring C-peptide is that short and rapid changes in B cell activity cannot be 
detected since the long circulating half life of C-peptide tends to mask such 
changes.
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Fasting immunoreactive C-peptide values compare very closely with fasting 
C-peptide values obtained by other workers (Block et al. 1972, Kaneko et al. 
1974, Heding, 1975, Beischer et al. 1976).
Obesity in man and animals is often associated with glucose intolerance (Smith 
and Levine, 1964) and the degree of intolerance is exaggerated by weight gain 
(Sims et al. 1968) and ameliorated by weight reduction (Olefsky, Reaven and 
Farquhar, 1974). This intolerance is almost invariably accompanied by 
hyperinsulinaemia (Karam, Grodsky and Forsham, 1963). Other workers 
(Bagdade, Bierman and Porte, 1967) reported a correlation between the degree of 
obesity and basal insulin levels. In the twenty four hour study fasting C-peptide 
levels correlated with weight and surface area in the normal subjects. 
Correlation was increased when fasting C-peptide levels were plotted against 
body weight. A postive correlation would have been expected in view of the 
evidence obtained from investigating insulin levels and obesity.
Peripheral fasting insulin and C-peptide levels correlated very closely, although 
three subjects had to be excluded from the data. High C-peptide levels and low 
insulin values were observed in these three subjects. Substantial amounts of 
insulin are removed from the blood in its initial transit through the liver, while 
the hepatic extraction of C-peptide is very low or negligible (Kuhl et al. 1978), 
the major site for the degradation of C-peptide being the kidney (Katz and 
Rubenstein, 1973). It has been reported (Katz and Rubenstein, 1973) that in 
animals, insulin, C-peptide and proinsulin are ail metabolised by the kidney to 
some extent and elevated fasting C-peptide levels have been reported in patients 
with renal insufficiency ( Kuzuya e t a l.1 9 7 6 ') . Defective degradation and 
removal of C-peptide from the body by the kidneys could, therefore, explain the 
high levels of one of these volunteers whose creatinine clearance was found to be 
low. However, the other volunteers were not assessed. Other workers (Horwitz 
et al. 1975) have observed that insulin and C-peptide levels correlate well in the 
fasting and fed states. This close correlation has enabled C-peptide
concentration to be used as an indicator of B cell secretion in peripheral blood in 
situations where it is difficult to measure insulin itself.
The intravenous glucose tolerance study has confirmed that impairment of 
glucose tolerance occurs in the latter part of the day (Roberts, 1964, 1967, 
Bowen and ReeveSL967, Jarrett and Keen, 1969, 1970, Abrams, 1968). In this study 
the k values were reduced in all subjects after the second infusion. The values 
obtained were within normally accepted criteria for diagnosis of diabetes 
mellitus based on glucose disposal rates in the early part of the day. Thus 
normal volunteers reacted as mild diabetics after the evening glucose infusion. 
Other workers (Carroll and Nestel, 1973) have also reported that after a glucose 
tolerance test the k values are reduced in the evening.
In the intravenous glucose tolerance study, the effect of glucose infusions in the 
morning and late evening on B cell activity was investigated. There was no 
significant difference in the integrated insulin responses after the two test meals 
but the C-peptide response was significantly increased after the second test. 
Carroll and Nestel (1973) reported significantly higher insulin levels when 
comparing evening and morning glucose tolerance tests. These insulin levels 
remained significantly higher up to 50 minutes after the start of the infusion. 
Blood samples were taken at two minute intervals up to 10 minutes into their 
study. The short half life of insulin (Samols and Marks, 1966) and the long half 
life of C-peptide could, therefore, explain the difference in the insulin and C- 
peptide results in the glucose infusion study since the time intervals between 
sampling in the study were considerably longer than that reported by Carroll and 
Nestel (1973).
The molar concentration of C-peptide is substantially greater than insulin in 
fasting healthy subjects (Melani e t al .19709Block e t al.'1972)The molar ratio  
of C-peptide to insulin at time of peak secretion was nearly equimolar in the 
peripheral circulation. Portal concentrations of insulin and C-peptide after 
stimulation by eating reach a value which closely approximates to equimolar 
secretion (Horwitz et al. 1975).
The six meal study was designed to determine B cell activity and plasma glucose 
levels following a test meal at six different times in a 24 hour period. This study 
has several advantages over previous reported work (Ahmed et al. 1976, 
Malherbe et al. 1969, Hansen and Johansen 1970, Molnar et al. 1968, 1972, 
S§hlierf and Raetzer, 1972). The meals were identical on all six occasions and 
they were randomly given to each group of subjects at different times. In 
addition, the subjects fasted for ten to twelve hours prior to the meal and C- 
peptide levels as well as insulin concentrations were measured after each meal.
In this study plasma glucose responses were considerably altered depending on 
the time of the day the meal was ingested. Both the peak size and the shape of 
the postprandial response of plasma glucose were affected.
The mean integrated plasma glucose response to food showed a diurnal change.
A delayed postprandial return of plasma glucose to basal levels was observed 
from the afternoon onwards. Other workers (Ahmed et al. 1976, Carroll and 
Nestel, 1973) have also observed this delayed return to fasting values in the 
afternoon.
Absorption of nutrients from the alimentary canal was altered during the day. 
The postprandial peak response of glucose was earlier in the morning compared 
with the early and late evening. The response of gastrointestinal hormone GIP 
has been reported to be dependent upon absorption of nutrients from the gut 
since in certain diseases with reduced nutrient absorption, for example, 
untreated coeliac disease or in cases of gross malabsorption there is a reduction 
in GIP response to oral stimuli (Creutzfeldt et al. 1976, Besterman et al. 1979). 
The integrated GIP response was only significantly increased in this study at 
1400 h. The failure to observe any changes in this response at other times may 
be.due to only small changes in the rate of absorption after each meal.
The similar B cell activity and increased glucose response during the six meal 
study suggests a progressive state of insulin insensitivity. There are a number of 
degrees of insulin resistance one being insulin insensitivity. Insulin resistance
may be defined as a state where a normal concentration of insulin produces a 
less than normal biological response. Gibson and Jarrett (1972) and Schultz et al. 
(1980) have reported a diumal rhythm in insulin sensitivity. Normal subjects 
require more insulin to maintain normoglycaemia between 0200-0600 h (Schultz 
et al 1980). Beck-Nielsen et al. (1978) reported that in isolated monocytes taken 
from fasted young healthy subjects, insulin binding was low in the late afternoon 
but increased during the evening reaching a maximum about 0800 h. The 
decrease in insulin binding to isolated monocytes (Beck-Nielsen et al. 1978) and 
insulin insensitivity (Gibson and Jarrett, 1972) during the afternoon can be 
interpreted as evidence that the known diurnal change in insulin insensitivity 
might be due in part to changes in insulin binding. Insulin action at the level of 
the target tissue consists of a complex sequence of events the details of which 
are still incompletely understood. Thus a defect at any point along the cascade 
of events involved in the insulin action sequence could result in an insulin 
resistant state (Olefsky, 1976b).
The impairment of the glucose response to a meal in the evening, therefore, was 
probably partly due to an alteration in the alimentary tract absorption of 
nutrients and partly to a change in insulin sensitivity causing an impairment of 
glucose utilization by the tissues.
The studies have shown that there are several advantages to measuring C- 
peptide levels. Fasting C-peptide levels are well above the detection lim it of 
the radioimmunoassay. Because of its slow metabolic clearance, plasma C- 
peptide levels remain elevated when insulin levels have returned to basal values. 
Blood samples can, therefore, be taken less frequently without effecting the 
shape of the response curve. Circulating levels of C-peptide reflect B cell 
secretory activity and because neither insulin nor insulin antibodies interfere 
with the radioimmunoassay its measurement can be of use in studying B cell 
function in a variety of physiological and pathological circumstances.
CHAPTER IV
CLINICAL SIGNIFICANCE OF 
IMMUNOREACTIVE C-PEPTIDE MEASUREMENTS
I l l
4:1 Introduction
The development of immunoassays for the measurement of serum 
immunoreactive C-peptide has been of great value in the investigation and 
diagnosis of certain clinical problems. Serum C-peptide levels correlate well 
with those of insulin, as the two peptides are secreted from the pancreas in 
equimolar amounts. In the peripheral circulation the relationship of C-peptide to 
insulin is approximately seven to one due to their different metabolic clearance 
rates. Substantial amounts of insulin are removed in the initial transit through 
the liver whilst the hepatic extraction of C-peptide is very low (Samols and 
Marks, 1966, S to ll et al. 1970). C-peptide levels are a reliable measure of B 
cell secretory activity after stimulation of these cells and can, therefore, be 
used as an indicator of endogenous insulin in the presence of exogenous insulin. 
The human C-peptide radioimmunoassay because of its species specificity, is 
unaffected by non-human C-peptide components which may be present in 
exogenous insulin.
4:1:1 Hyperglycaemic states
In the hyperglycaemic state, C-peptide estimations are clinically useful in the 
evaluation of pancreatic status after pancreatectomy, pancreatic tumour 
removal and in assessing residual B cell activity in diabetics. After an operation 
for removal of the pancreas due to nesidioblastosis or insulinoma, monitoring of 
C-peptide levels can indicate the presence of any residual pancreatic tissue. 
Removal of the tumour and long term monitoring of the C-peptide levels w ill 
indicate whether the tumour has been completely removed and the recurrance of 
the tumour or the presence of functional metastases. Serum insulin levels 
cannot always be assessed in these situations since insulin may have to be 
administered to control blood glucose levels.
One of the earliest uses of the C-peptide radioimmunoassay has been in 
monitoring B cell function in insulin dependent diabetics. The C-peptide 
radioimmunoassay, unlike the insulin radioimmunoassay,being unaffected by
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exogenous insulin. The presence of circulating insulin antibodies in insulin 
dependent diabetic interferes with the measurement of insulin levels using the 
insulin radioimmunoassay (Moxmess et al. 1971). Heding (1978) showed that in 
insulin treated diabetics proinsulin was bound to circulating insulin antibodies. 
This binding slows the removal of proinsulin from the circulation and thus 
increases its concentration in serum. The C-peptide and insulin 
radioimmunoassay would both give artificially high results when assessing this 
serum. The high results obtained would be a reflection of the crossreactivity of 
both the antisera with proinsulin. Kuzuya et al. (1977a) have used polyethylene 
glycol to precipitate the antibody bound insulin and proinsulin, thus leaving the 
C-peptide measurement as a direct reflection of endogenous B cell activity.
4:1:2 Hypoglffiaemic states
Human C-peptide measurements have been found to be most useful in the 
evaluation of hypoglycaemic states. There are three major hypoglycaemic 
situations where C-peptide measurements are of special value. Firstly, patients 
may become hypoglycaemic due to surreptitious injections of insulin. Before the 
development of the C-peptide assay these patients were diagnosed by detecting 
the presence of insulin antibodies. This interpretation may have been incorrect 
in some cases, since it has been reported (Foiling et al. 1972, Hirata et al. 1972, 
1974) that some subjects, that have spontaneous hypoglycaemia, have insulin 
auto antibodies. Secondly C-peptide levels are useful in the detection of an 
insulinoma in a diabetic in whom insulin measurements are affected by the 
presence of circulating insulin antibodies. The incidence of insulinoma of the 
pancreas in patients with diabetes mellitus appears to be about twice that of the 
general population. Thirdly C-peptide measurement is used in the diagnosis of 
insulinomas in non-diabetic patients.
There are three different types of carcinoma of the pancreas, namely 
adenocarcinoma arising from ductal or acinar cell, cystadenocarcinoma and 
carcinoma arising from the islet cell.
1 1 3
Pancreatic islets are composed of a number of distinct cell types each 
synthesising and secreting a specific hormone. Neoplasms may arise from any of 
these distinct cell types and may contain one or more different secretory cell 
types. The most common islet cell tumour are those which secrete gastrin 
(Zollinger-Ellison syndrome). The incidence of malignancy of these tumours has 
been reported as between 50-70 per cent. The second, most common type of 
tumour, is the insulinoma, which is usually benign. The incidence of this type of 
tumour is extremely rare, Kavlie and White (1972) reported an incidence of 1 
case per million persons. It has been reported that 5-10% of these insulinomas
have been found to be malignant (iVan Heirden e t a l . 1979 Hsein-Ch-in e t a l. 
1980). other islet cell tumours such as the glucagonoma (Montenegro et al. 
1980) the somatostatinoma (Ganda et al, 1977) and the vasoactive intestinal 
polypeptide tumours are extremely rare.
(a) Insulinomas
Insulinoma, the insulin secreting neoplasm of the beta cell was the first islet cell
tumour to be recognised. The tumours are found evenly distributed throughout
the pancreas as solitary or multiple, spherical to ovoid shaped nodules ranging in
size from a few millimetres to several centimetres. Tumours in the body and
tail account for two-thirds of the insulinomas removed at operation. On the
surface of the pancreas the tumours are brown, dark blue or blue-black in
appearance due to their vascularity. Ectopic insulinomas are extremely rare.
Creutzfeldt et al. (1973, 1976b,1977) have classified insulinomas by electron
microscropy and histochemical studies into four types. The majority of
insulinomas are type I comprised almost entirely of cells containing typical B
granules. Type II tumours have some cells which contain B cell granules. The 
have
types II and IV ^artyp ica l granules and carcinomas with virtually agranular' 
appearance respectively.
(i) Presenting symptoms of insulinoma patients
The presenting symptom of insulinoma is usually but not always hypoglycaemia.
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The clinical manifestations are, however, frequently bizarre and may go 
undiagnosed for a number of years. The major symptoms are due to the effect of 
low blood sugar levels on the central nervous functions. The lack of the brains 
major energy supply, glucose causes it to utilize ketone bodies. A number of 
hours are required, in man, for this change to be effected and therefore the brain 
is not protected against acute hypoglycaemia. This results in symptoms which 
are frequently mistaken for a primary nervous disorder. The symptoms which 
are only transient include dizziness, coma, seizure, abrupt behavioural changes 
and diplopia.
The second group of symptoms encountered in patients with insulinomas are 
associated with the adrenaline discharge that occurs in the face of 
hypoglycaemia. When exogenous insulin is given to healthy volunteers the 
symptoms resulting include profuse sweating, nervousness, tremulousness, 
palpitation, hunger, and pallor all of which are relieved after glucose 
administration. However, these symptoms are relatively uncommon in patients 
with insulinomas, the reason for this being that the glucose levels decrease 
gradually in these individuals thus avoiding any counterregulatory response. 
Hypoglycaemic coma occurs in a small percentage of these patients for a short 
duration. Between these hypoglycaemic attacks patients are usually normal.
(ii) Localisation
As pancreatic islet cell tumours are often small lesions that become manifest, 
not by their tumour mass, but by the hormones they secrete, their localisation 
can be difficult.
The non-invasive methods in use for the detection of a tumour are computed 
tomography and sonography. Invasive techniques include angiography and 
arteriography. Angiography involves the use of a radioopaque dye which is 
injected into a branch of the coeliac artery. This method is capable of detecting 
tumours of 1.5 cm in diameter, precisely localising where the tumour is situated
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and may also detect the presence of metastases in the liver. This technique has 
several drawbacks in that it is complex, expensive and time consuming. Coeliac 
and superior mesenteric arteriography was a major advance in the localisation of 
islet cell tumours. The arteriograph method has a success rate of some 40-70 per 
cent in localisation of tumours. This technique together with measuring the 
hormone levels can localise various cell tumours (Ingemanssen et al. 1975, 1976, 
Lunderquist et al. 1978).
(iii) Dynamic function tests
The diagnosis of insulinoma requires the demonstration of a serum insulin 
concentration which is inappropriately high for the existing level of blood 
glucose. In patients suspected of having B cell tumours, two methods of 
detection are available. The first depends on the development in these patients 
of hypoglycaemia. A prolonged fast for up to 72 hours is sometimes used in 
order to provoke a hypoglycaemic attack. Blood samples if  obtained when the 
patient is undergoing a hypoglycaemic attack are extremely important. The 
measurement of serum insulin, C-peptide and glucose can establish an initial 
diagnosis. Further tests can then be carried out in order to confirm this 
diagnosis. If an insulinoma is suspected in a patient and it is not possible to 
provoke fasting hypoglycaemia, a variety of tests can be used in order to obtain 
a diagnosis. The most useful of these is the insulin suppression test. In normal 
subjects, insulin secretion is inhibited in the presences of hypoglycaemia, but 
patients with B cell tumours do not show this inhibition. The infusion of insulin 
and the monitoring of plasma glucose and C-peptide levels demonstrates whether 
or not the patient's endogenous insulin is being suppressed. If this test gives an 
inconclusive result, a number of other insulin provocation tests can be carried 
out. However, in general provocation tests are less reliable in the diagnosis of 
all tumours (Marks J98T)
Patients with islet cell tumours have a decreased storage capacity for insulin, 
resulting in uncontrolled release (Floyd et al. 1964). This results in increased
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insulin and proinsulin levels. Proinsulin levels have been found to vary widely 
between patients with islet cell tumours (Rubenstein et al. 1974). The fasting 
plasma proinsulin concentration varied between 0.23-17.48 ng/ml. The cross- 
reactivity of proinsulin in both insulin and C-peptide radioimmunoassays varies 
considerably depending on the antisera. Care must, therefore, be taken when 
assessing samples from an insulinoma patient to know the degree of cross- 
reactivity of the antisera with proinsulin.
The work described in this chapter attempts to evalute with specific examples 
the usefulness of human C-peptide estimations in the diagnosis of various 
diseases.
4:2 Materials and Methods 
4:2:1 Plasma glucose
Plasma glucose levels were measured using hexokinase enzyme and an automatic 
glucose analysis.
4:2:2 Insulin Radioimmunoassay
Plasma immunoreactive insulin levels were measured in duplicate by the method 
described in Chapter HI. The detection lim it of the assay was 2.5 m U /L itre and 
the interassay coefficient of variation was 15% at 6.5 mU/Litre and 7.4% at 46 
m U/Li tres.
4:2:3 C-peptide Radioimmunoassay
Plasma immunoreactive C-peptide levels were measured in duplicate by the 
method described in Chapter II . The assay has a sensitivity of 10 pg/tube (0.1 
pg/Litre). The interassay coefficient of variation was 24.5% at 0.44 pg/Litre  
and 9% at 37 pg/Litre.
4:3 Clinical Studies
4:3:1 Factitious hypoglycaemia
Four cases of factitious hypoglycaemia are described.
Patient (A) The first was a woman, 23 years, who was a nurse. This patient was 
investigated because of a history of unexplained fits. She displayed biochemical
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hypoglycaemia on fasting associated with neuroglycopenic symptoms. Samples 
were taken during fasting and throughout the day and plasma immunoreactive 
insulin, C-peptide and glucose levels were measured (Figure 4:1). The 
demonstration of low plasma C-peptide with high circulating insulin and 
hypoglycaemia after 16 hours of fasting confirmed the diagnosis of insulin 
induced hypoglycaemia. For comparison, plasma glucose, immunoreactive C- 
peptide and insulin levels measured in ten healthy, non-obese, volunteers after a 
12 hour fast are also shown in Figure 4:1.
Patient (B) The second was a 35 year old man, who was admitted into hospital in 
a deeply unconscious state. He was reported to have been well all day and went 
to bed rather early claiming he was tired. Unable to rouse him, his wife called 
for an ambulance. On examination patient (B) was found to be deeply 
unconscious and unrouseable. Investigation revealed that his plasma glucose was 
1.5 mmol/Litre. He was immediately put on a glucose drip and regained 
consciousness within a few hours. Extensive tests were carried out including 
prolonged fasting with heavy exercise in order to provoke a hypoglycaemic 
attack. Hypoglycaemia in no instance could be established.
He was then discharged from hospital only to be re-admitted complaining of 
vomiting, intermittent diplopia, feeling weak and drowsy, having slurred speech 
and bouts of sweating. He was discharged again from hospital.
He was readmitted into hospital in a coma when his plasma glucose level was 
found to be 0.27mmol/Litre. Thirty-six hours after the start of glucose infusion 
he regained consciousness. A further 72 h fast was instituted and blood samples 
were taken for glucose estimation, none of which fell below 3.6 m m ol/Litre. A 
sample for immunoreactive C-peptide and insulin estimation was obtained from 
this patient when in the second coma. Immunoreactive C-peptide level was 
undetectable with insulin estimation of 109 m U/Litre. These results together 
with the low plasma glucose levels are diagnostic of insulin induced 
hypoglycaemia.
Plasma immunoreactive C-peptide, in s u lin  and glucose leve ls in a 
pa tien t (p a tien t A # — • ) w ith fa c t it io u s  hypoglycaemia undergoing 
a 16 hour fa s t.
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It was subsequently discovered that the patient obtained insulin from his brother- 
in-law who was a diabetic.
Patient (C) This patient was a 19 year old woman, whose insulin requirements 
had steadily increased until she was taking a total of 120 units daily when she 
was admitted into hospital. She was changed to a monocomponent insulin and 
her requirement fell to 3 units of Actrapid per day. This large decrease in 
insulin requirement when changing to monocomponent insulin is unusual. She was 
admitted into hospital for investigation. On two occasions she had 
hypoglycaemic attacks with plasma glucose levels of 2 and 1.5 mmol/Litre. The 
immunoreactive insulin levels were greater than 200mU/Litre with undetectable 
immunoreactive C-peptide levels on both occasions. No insulin had been given to 
the patient for twelve days. These results suggest that the patient was causing 
these hypoglycaemic attacks by insulin administration. However, no evidence of 
such administration could be obtained from the patient.
She was admitted into hospital on a subsequent occasion in a hypoglycaemic 
coma and at that time an ampoule of insulin was found hidden in one of her 
stockings.
Patient (D) A 24 year old man was investigated. He had a history of blackouts 
which usually occurred before meals when he was sitting down. These blackouts 
only lasted a few seconds but when regaining consciousness, he fe lt cold and 
sweaty. There was no family history of diabetes and no previous illnesses. His 
general health was good although he did complain of increased thirst. On 
admission into hospital he had several faints in the ward bulplasmcf glucose 
estimation on a blood sample taken during one of these attacks was found to be
6.4 mmol/Litre. He was discharged from hospital without medication.
The patient was reported to be injecting himself with insulin and also taking 
dextrose tablets, lots of lucozade and behaving in an odd manner. He stated in a 
letter to his doctor that he had been prescribed insulin at the diabetic clinic. At 
no time had anyone in the clinic prescribed insulin for him. The patient was seen
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at the diabetic clinic again and it was emphasised that he should not continue to 
inject himself with insulin as he was not a diabetic.
On the next occasion at the clinic a plasma glucose estimation of 6 mmol/Litre 
was recorded, the patient collapsed 30 minutes after this sample was taken. A 
blood sample was taken for plasma glucose, immunoreactive C-peptide and 
insulin estimation. The plasma glucose level was 2 mmol/Litre with an 
immunoreactive insulin level of greater than 200 m U/Litre and 1.1 yg/Litre  
immunoreactive C-peptide level. These results suggest that the patient was still 
continuing to self-administer insulin.
4:3:2 Insulinomas
There are generally three distinct stages in the diagnosis of an insulinoma:
(i) Investigation of the patient’s clinical history
(ii) Confirmation of the suspected diagnosis by clinical investigation.
(iii) Localization of the tumour (Marks ,1981). .
The following case studies demonstrate the usefullness of C-peptide 
measurement in insulinoma diagnosis.
Patient (E) A 32 year old woman was admitted into hospital for investigation. 
Eighteen months previously she began to lose consciousness for short periods, 
this being associated with dieting. The unconsciousness could be prevented by 
drinking sweet coffee. The patient had no allergies and was not receiving any 
medication. She appeared normal except for a six to seven stone increase in 
weight since the birth of her child. On admission to hospital a series of tests 
were carried out to investigate her condition. Blood samples were taken 
throughout the tests and assessed for plasma glucose, immunoreactive insulin and 
C-peptide levels.
(1) Insulin Stress test (0.15 U/kg body weight)
Plasma glucose levels were low (1.0 mmol/Litre) at the start of the insulin stress 
test (Fig. 4:2). The plasma glucose levels altered only slightly throughout the 
study. Immunoreactive C-peptide levels fell from a basal level of 1.9 yg /L itre
■x ± S D  in normal subjects
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to 0.9 yg/Litre 100 minutes from the start of the test. In ten normal, non-obese. 
volunteers the mean basal level of immunoreactive C-peptide was 1.85 -  0.6 
yg/Litre (x + SD). which fell to below 0.9 yg/Litre after 60 minutes and 0.63 -  0.34 
yg/Litre after ninety minutes. The mean plasma glucose level in the normal 
non-obese volunteers reached 1.37 -  0.5 ’mmol/L after 30 minutes and returned 
to 75 per cent of the basal level 120 minutes after the insulin injection.
(2) Calcium infusion test (10 mg Ca*/kg infused 0-10 minutes)
The data from the calcium infusion test (Patient E) is shown in Figure 4:3. The 
plasma glucose level fell from the basal value of 1.95 mmol/Litre to 1.1 
m m ol/Litre 45 minutes from the start of the infusion. The basal immunoreactive 
insulin level was 9 m U/Litre but rose to 21 m U/Litre 45 minutes after the start 
of the infusion. Rises in immunoreactive C-peptide levels were also recorded.
(3) Oral glucose tolerance test (100 g Hycal)
The data from the oral glucose tolerance test is shown in Figure 4:4. Basal 
plasma glucose level in the patient was 1.15 mm ol/Litre. After the glucose load 
plasma glucose levels reached a maximum of 5.3 mmol/Litre and remained 
elevated up to 210 minutes after the oral glucose. Levels returned to basal 300 
minutes after the start of the test. Basal immunoreactive C-peptide level was 
1.95 yg/L and fasting values were not reached by the end of the study.
The plasma glucose and immunoreactive insulin levels after a 100 g oral glucose 
tolerance in normal non-obese volunteers are shown in Fig. 4:5. The mean 
f  asting plasma insulin levels was 6.64 — 1.15 m U /L itre  (x -  SEM). The plasma 
insulin levels did not return to fasting values until 300 minutes. Glucose levels 
returned to fasting values only 120 minutes after the start of the test.
(4) Diazoxide infusion test (300 mg I.V. 0-30min)
A diazoxide infusion test was carried out in this patient. This test was carried 
out to investigate whether the patient could be controlled by diazoxide if  the 
tumour could not be removed. The results showed that immunoreactive insulin 
levels fell from a basal level of 15 m U/Litre to <1 m U/Litre after 30 minutes
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Figure 4:3
A Calcium Infusion Test carried  out in a pa tien t (pa tien t E) 
suspected o f having an Insulinoma" ’
o Glucose
*  C-Peptide
•  Insulin
1 0 mg C^Vkg infused 0-110 '
40T4
4-
O
20 2
2
An Oral Glucose Tolerance te s t followed by glucagon stim u la tion  
in a pa tien t (p a tie n t E) suspected o f having an insulinoma
o Glucose 
•  Insulin 
■ C- Pept ide 
lOGgCHO
0 100 200  300
Ti me (min)
Figure 4:5 P: Oral Glucose Tolerance tests in  normal non-obese volunteers
o Glucose 
•  Insulin
±SEM
i2o 180 -  
Time (min)
2 A 060
* 6 0 \  
E
0)
30 =
(Fig. 4.6).Immunoreactive C-peptide levels fell while plasma glucose rose during 
the infusion. The data from these tests indicated that the patient had a B cell 
tumour. She underwent surgery and a 2 cm tumour in the tail of the pancreas 
was removed. Patient (F) this patient was a 43 year old man, who had an 
eighteen month history of episodes of feeling drunk and unsteady. These attacks 
were usually precipitated by physical exertion or anxiety but were not related to 
meal-times or alcohol. These attacks occurred about four times a week. Each 
episode began with numbness of the lips and tongue, followed by blurred vision 
and was relieved by taking sweets. No sweating, palpitation, loss of 
consciousness or fits had occurred in the last six months. He used to drink 
heavily until three months prior to hospital admission when he found that 
abstinence decreased the frequency of these attacks. A prolonged fast was 
carried out with the measurement of B cell hormones and plasma glucose levels. 
(Fig. 4:7) Plasma glucose levels fell from a basal level of 4.4 mmol/Litre to 1.3 
mmol/Litre after 24 hours. Immunoreactive plasma insulin levels, initially was 
23 m U/Litre fell to 4 m U/Litre before rising to 13 m U/Litre after 22 hours. 
Immunoreactive plasma C-peptide levels fell to a level of 1.7 pg/Litre after 34 
hours of fasting. In view of this data the patient was diagnosed as having an islet 
cell tumour.
An angiogram revealed a 2 cm vascular mass at the junction of the body and the 
head of the pancreas. The tumour was removed and the patient recovered.
Patient (G) A 76 year old woman was admitted into hospital after 
hypoglycaemic attacks which occurred two or three times per week. These 
attacks seem to be prece ded by headaches and could be prevented by sitting 
down. The patient underwent a full physical examination and was found to have 
lost three stones in weight in one year although she had a good appetite. When a 
random blood sample was taken the plasma glucose level was 1.3 m m ol/Litre  
with immunoreactive insulin and C-peptide levels of 19 m U/Litre and 3.9 
pg/Litre respectively. A prolonged fast was initiated with two-hourly blood
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sampling (Fig. 4:8). The plasma glucose level fell to below 2 mmol/Litre after 
two hours and remained low throughout the study. Immunoreactive plasma 
insulin and C-peptide levels remained elevated throughout the study. This data 
indicated the presence of a B cell tumour. An EMI scan was carried out but no 
tumour was visible. Plasma glucose levels were found to be low and she was 
prescribed diazoxide and chlorothiazide. Her plasma glucose levels stabilized 
and she was discharged from hospital. Three months later she was readmitted 
because of hypoglycaemic episodes at home which resulted in loss of 
consciousness. The patient underwent surgery and a small nodule was removed 
from the tail of the pancreas. A fter the operation problems arose due to 
variable blood pressure and elevated plasma glucose levels. The patient died two 
days later and a post mortem report stated that the cause of death was 
intraduodenal blood loss following partial pancreatectomy.
Patient (H) The patient was a 43 year old male who complained of episodes of 
suddenly feeling intoxicated while driving. These attacks had recently been 
accompanied by impairment of consciousness, hallucination, odd behaviour and 
poor recollection of events. These attacks could be alleviated by food. A blood 
sample taken during one of these attacks revealed a plasma glucose level of 1.6 
mmol/Litre. Plasma immunoreactive insulin and C-peptide levels were 22 
m U/Litre and 2.8 yg/Litre respectively. These results indicated that this patient 
had a B cell tumour. A coeliac angiogram showed a tumour in the left lobe of 
the liver. A tumour was subsequently removed from the tail of the pancreas and 
a haemangioma removed from the liver. The tumour from the pancreas was 
histologically examined confirming the diagnosis of an islet cell tumour.
Patient (J) This patient was a 79 year old man who had been having attacks of 
spontaneous hypoglycaemia for the last two to three years. He had previously 
been aggressive and had lost consciousness in the morning prior to admission into 
hospital. A blood sample was taken and the plasma glucose level was found to be
1.5 mmol/Litre. He was immediately given glucose and after a few hours
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regained consciousness. Fasting plasma glucose levels were monitored for the 
next three days and found to be above 2.5 m m ol/Litre. He was discharged from 
hospital and was given no medication.
He was readmitted into hospital after another attack. A blood sample was 
taken, plasma glucose level was 1.8 mmol/Litre with immunoreactive C-peptide 
and insulin levels of 1.6 yg/Litre and 22 m U/Litre respectively. This data 
indicated that the patient hypoglycaemia was due to a B cell tumour. Due to the 
age of the patient it was decided to control the hypoglycaemia with diazoxide. 
The patient remained stabilised with fasting plasma glucose levels of 3.5 
mmol/Litre.
Patient (K) A 74 year old man with a history of hypoglycaemic attacks over a 
two-year period was admitted into hospital. During these attacks the patient 
felt intoxicated, confused and suffered dizzy spells. He had lost consciousness 
several times during these attacks. The patient was in good health apart from 
angina two years previously. In hospital he had an unsteady gait and slurred 
speech. His plasma glucose level was 1.6 mm ol/Litre on a random blood sample. 
He was, therefore, kept in hospital for further investigations.
(1) Prolonged oral glucose tolerance test (75 g Hycal)
The basal plasmcglucose levels was 3.2 mmol/Litre and was not regained until 300 
minutes after glucose ingestion (Figure 4.9). Basal immunoreactive insulin and 
C-peptide levels were 6 m U/Litre and 3.5 yg/Litre respectively. 
Immunoreactive insulin levels did not return to basal levels until 300 minutes had 
elapsed. Immunoreactive C-peptide levels were elevated throughout the test.
(2) Diazoxide infusion test (300 ng/h)
A diazoxide infusion test was carried out on this patient. The results showed
that immunoreactive insulin levels fell from a basal level 8 m U/Litre to 2.5
m U/Litre in 30 minutes (Fig. 4:10). Immunoreactive C-peptide levels fell while 
plasma glucose levels rose from 0.9 mmol/Litre to 3.6 mmol/Litre by the end of 
the infusion.
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The data from this test indicated that the patient had a B ceil tumour that could 
be controlled by diazoxide. In view of his age he was given diazoxide and 
chlorothiazide and discharged from hospital.
He was soon readmitted during a hypoglycaemic attack with a plasma glucose 
level of 2 mmol/Litre. He was maintained on a high carbohydrate diet and given 
dextrose tablets. He underwent surgery and a tumour was removed from the tail 
of the pancreas. The patient, however, died 5 days later in cardiac failure due to 
ischaemic heart disease. Histological examination of the tumour showed that it 
was mainly composed of B cells.
Patient (L) This patient, a 69 year old woman, had a two year history of episodes 
of feeling unwell. During these episodes the patient became confused and had 
impairment of consciousness, she was unable to recollect events and walked as if 
intoxicated. The patient had lost consciousness completely on two occasions. 
These attacks became more frequent occurring every one to three weeks. The 
patient had not tried eating to relieve the symptoms. She had also been 
suffering from frequent headaches, recurrent attacks of diarrhoea with resulting 
weight loss. The patient was investigated in hospital.
(1) Prolonged oral glucose tolerance test (75 g Hycal)
A prolonged oral glucose tolerance test was carried out (Figure 4:11). The basal 
plasma glucose levels was 2.5 mmol/Litre and was regained after 150 minutes. 
Basal immunoreactive insulin and C-peptide levels were 2.2 m U/Litre and 4 
yg/Litre respectively. Peak immunoreactive insulin and C-peptide levels 
occurred 90 minutes after the oral glucose load.
(2) Insulin stress test (0.15 U/kg insulin)
The basal immunoreactive C-peptide level prior to the insulin stress test was 4.5 
yg/Litre (Fig. 4:12) and fell to 1.7 yg/L itre 120 minutes after the start of the 
test with a fall in plasma glucose level to 1.6 mmol/Litre. Immunoreactive C- 
peptide did not fall below 1.6 yg/Litre during the test.
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(3) Prolonged fast followed by exercise
Immunoreactive C-peptide and insulin levels were initially high and remained so 
throughout the fasting and exercise period (Fig. 4:13) The plasma glucose level 
after two hours was 2.5 mmol/Litre and continued to fall to 2.1 mmol/Litre after 
6 hours.
This data indicated that the patient had a B cell tumour which was subsequently 
removed from the head of the pancreas.
4:3:3 Renal Failure
The patient was a 34 year old male with chronic renal failure presumably from 
childhood glomerulonephritis. This renal failure became clinically apparent at 
the beginning of 1978 when regular haemodialysis was commenced.
The patient presented with symptoms of hunger, sweating and dizziness. These 
symptoms were relieved by eating, especially carbohydrates. These attacks 
occurred when the patient was undergoing dialysis when hypertension also 
occurred. The patient's drug regimen consisted of triazolan, diazepam and 
alucaps. He was suspected of having a B cell tumour and an insulin stress test 
was performed.
(1) Insulin stress test (0.1 U/kg body weight)
Blood samples were taken at half-hourly intervals over a three-hour period 
following administration of 0.1 U/kg body weight of insulin (Fig. 4:14). The 
plasma glucose level fell to 1.5 mmol/Litre after 30 minutes and a level of 3.6 
mmol/Litre was reached 120 minutes after the insulin injection. In ten normal 
volunteers mean plasma glucose levels fell to 1.4 -  0.5 mmol/Litre ( x -  SD) and 
rose to a level of 2.9 — 1.04 mmol/Litre after 120 minutes. The basal C-peptide 
level in this patient was 8.7 yg/Litre considerably higher than in the normal 
volunteers (1.64 -  0.6 yg/Litre). The patients levels fell throughout the test to 
4.9 yg/Litre.
It was concluded that in patients with renal failure who are suspected of having 
an insulinoma, monitoring C-peptide levels has a limited value.
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4:3:4 Drug Interference
The patient, a 67 year old woman was admitted unconscious into hospital with a 
plasma glucose level of 1.4 mmol/Litre. An intravenous dextrose infusion was 
immediately started and the patient regained consciousness within thirty  
minutes.
The patient had previously been undergoing treatment for tuberculosis of the 
spine which had developed 3 years earlier. At the time of admission she was 
receiving rifinah which contains rifampicin and isoniazid.
A 48 hour fast was initiated after which a blood sample was taken. Plasma 
glucose level was 1.4 mmol/Litre and immunoreactive C-peptide and insulin 
levels were undetectable and <1 m U/Litre respectively. These results indicated 
that although the plasma glucose level was low, the plasma insulin and C-peptide 
levels were depressed making the diagnosis of an insulinoma unlikely. It was 
concluded that her hypoglycaemic episodes were probably caused by isoniazid 
medication which has been reported to depress circulating glucose levels (Marks 
1981a)
4:3:5 Comparison of fasting insulin, C-peptide and glucose levels in factitious 
hypoglycaemia, insulinoma patients and normal subjects
Fasting immunoreactive C-peptide, insulin and glucose levels were measured in 
14 insulinoma patients, 1 child with nesidioblastosis, 6 factitious hypoglycaemic 
patients and 28 normal subjects. Figure 4:15 shows the comparison of plasma 
immunoreactive C-peptide levels versus plasma glucose levels in these subjects. 
A significant correlation was observed in normal subjects (p < 0.05) but not, 
however, between glucose and insulin levels. The molar ratio of insulin/C- 
peptide levels is shown in Figure 4:16. Similar ratios were observed in 
insulinoma patients and normal subjects except the malignant insulinoma patient 
who had an elevated ratio. The ratio was considerably elevated in patients with 
factitious hypoglycaemia.
4:15 Comparison o f fas t ing  plasma immunoreactive C-peptide
and plasma glucose levels in fasted normal subjects and patients
■ Insulinoma patients
□ Factitious hypoglycaemic patients 
a Nor mal subjects
°Nesidioblastosis after pancreatomy
Corr 0*45 
Intercept 0-53 
Slope 0-236 
N=27
2*5
ir T
Glucose mmol/l
M
ol
ar
 
ra
tio
■ Disseminated insulinoma 
□ Nesidioblastosis after pancreatectomy
8«
4-
o.
CH
Insulinomas Factitious hypoglycaemia Normal
subjects
4:4 Discussion
The symptoms of hypoglycaemia can occur in a wide variety of diseases. They 
can be categorized into fasting or stimulated (reactive) hypoglycaemia. In 
reactive hypoglycaemia a pathologically low glucose concentration occurs in 
response to food whilst in order to precipitate fasting hypoglycaemia, starvation 
for a period of a few hours or longer is necessary. Patients with fasting 
hypoglycaemia may also exhibit a stimulated component, whereas patients with 
reactive hypoglycaemia never.have symptoms when food is withdrawn. There 
are two causes of hypoglycaemia in the fasted state. Either the liver is not 
producing enough glucose to meet ordinary demands or peripheral glucose 
utilization becomes so great that maximal hepatic production is insufficient to 
match glucose egress from the plasma compartment.
Fasting hypoglycaemia is usually investigated with the recognition and 
biochemical demonstration of hypoglycaemia and then the diagnosis of the cause 
of the symptoms. A doctor very rarely observes a patient when undergoing such 
an attack and the initial diagnosis is usually made on the patient's clinical 
history. Care must be taken to obtain details of hypoglycaemic attacks from 
relations since the patients are often incorrect regarding the nature, severity 
and duration of symptoms because of amnesia. A number of provocative tests 
are carried out in order to substantiate the initial diagnosis or to reduce its 
likelihood. The order in which these tests are carried out are based on the 
previous history of the patient.
(1) Factitious hypoglycaemia
One of the commonest causes of hypoglycaemia in practice is therapeutically 
administrated antidiabetic agents, insulin and the sulphonylureas (Goodman, 
1953, Marble, 1959). Factitious hypoglycaemia due to surreptitious injection of 
insulin (Ibbertson and Doak, 1961, Couropmitree et al. 1975, Safrit and Young, 
1978) and sulphonylureas (Walfish et al. 1975, Jordan et al. 1977) is uncommon 
but is an important cause of spontaneous hypoglycaemia. This syndrome is 
almost as uncommon as insulinomas (Jordan et al. 1977) and the purpose is
usually attention seeking. One of the patients (patient D) reported in this 
chapter suffered from delusions about his diabetic status and similar cases have 
been reported in the literature (Odei 1968). Since the advent of the C-peptide 
measurement the diagnosis of such patients is relatively simple but the 
management of such a syndrome involves psychiatric and social readjustment. 
This syndrome is commonly associated with women between the ages of twenty 
and forty who know the side effect of insulin. The few men discussed with this 
syndrome have been diabetics, tramps and down and outs (Creutzfeldt et al. 
1969, Jordan et al. 1977) although one of the men (patient D) reported in this 
chapter did not fall into any of these categories. In the four cases reported all 
subjects had high insulin levels with inappropriately low or undetectable C- 
peptide levels in the presence of hypoglycaemia. Similar results have been 
reported in the literature (Service et al. 1974, Couropmitree et al. 1975). 
Ibbertson and Doak (1961) reported that such patients have a delayed insulin 
response to intravenous glucose, glucagon and tolbutamide due to surreptitious 
self-administration of insulin.
Factitious hypoglycaemia can also be caused by surreptitous administration of 
sulphonylureas or other oral anti-diabetic agents. In this situation C-peptide 
measurement is not as helpful in diagnosis as hypoglycaemia occurs associated 
with elevated levels of both insulin and C-peptide. Provocation tests, in these 
patients, such as intravenous infusion of glucose, glucagon and L-leucine usually 
result in an excessive and rapid rise in plasma insulin levels (Jordan et al. 1977, 
Alberti et al. 1972, Walfish et al. 1975). Harrop et al. (1982) have reported a 
patient with factitious hypoglycaemia due to chronic glibenclamide ingestion 
whose C-peptide level failed to be suppressed after an insulin stress test. The 
response to insulin was similar in this patient compared with a patient with an 
islet cell tumour. It is, therefore, essential, in order to confirm a diagnosis, to 
take a blood sample from such patients to monitor for any antidiabetic agents.
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(2) Drug induced hypoglycaemia
A number of other drugs apart from therapeutic agents used in diabetes, have 
the ability to cause hypoglycaemia in patients. Care must, therefore, be taken 
to record a clinical history noting all drugs the patient has been prescribed.
Another hypoglycaemic agent besides those used for therapeutic effect is 
alcohol. Salicylates have a hypoglycaemic effect which is increased when taken 
with sulphonylureas (Setzer, 1972). Care must therefore be taken to note the 
drug combination that patients are prescribed. Other drugs which are known to 
cause hypoglycaemia under various conditions include paracetamol (Ruvalcada et 
al. 1966) propranolol (Skinner& Misbin ,1975)and barbiturates
(Hunter and Greenberg, 1954). A patient with drug induced hypoglycaemia has 
been reported in this chapter. The patient had been prescribed rifinah which 
contains isoniazid. Isoniazid has been reported by Marks „ (1981a) to
cause spontaneous hypoglycaemia in patients. Rifinah was therefore withdrawn 
from this patient.
(3) Insulinomas
Hypoglycaemia caused by an insulin secreting tumour is rare but following its 
natural course is a pernicious clinical entity. The diagnosis of an insulinoma is 
suspected on the basis of previous clinical history and results from biochemical 
tests. The commonest problem in differential diagnosis experienced by clinicians 
unfamiliar with spontaneous hypoglycaemia is the difference between insulinoma 
patients - andj ' ' patients with reactive hypoglycaemia (Marks 
, 1^81.) Tumours of the islets of Langerhans produce hypoglycaemia as
their major clinical manifestation because of their ability to secrete insulin 
inappropriately rather than in large amounts.
The neuroglycopenic symptoms experienced by the insulinoma patients cover a
wide range of deranged central nervous functions, ranging from impairment or
loss of co-ordination of various autonomic, sensory or motor activities to
changes in behaviour patterns, personality and intellectual qualities. Many 
workers (Marks ^1965, > Laurent et al. 1971, Gressner et al. 1973, Marks
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and Samols, 1974) have reported similar symptoms in patients with islet cell 
tumours. These symptoms in the patients can be alleviated in some cases by 
eating frequently and can be aggravated by abstinence from food. Weight gain 
was associated with the occurrence of the symptoms in patient E, reported in 
this chapter, who had previously associated her attacks with lack of food. These 
symptoms may go unrecognised for periods of greater than five years (Marks > 
1981. )# it has been reported by Stefanini et al. (1974) that only one-third of
r
1067 patients were diagnosed in the first year of onset of their symptoms. 
Neuroglycopenic symptoms in a patient may be due to an insulin producing 
tumour and therefore the first aim is to demonstrate an association of the 
patient's symptoms with fasting hypoglycaemia. The demonstration of 
hypoglycaemia due to fasting and of relief of symptoms by glucose remains the 
keystone of the diagnosis of an insulinoma as first proposed by Wipple (1944). 
Hypoglycaemia may only be slight or insufficient to cause neuroglycopenic 
symptoms after an overnight fast in some subjects due to frequent occurrence of 
low plasma glucose levels. A prolonged fast of up to 72 hours or more, 
accompanied by moderate exercise may be necessary to precipitate 
neuroglycopenic symptoms and is usually carried out in patients suspected of 
having an islet cell tumour. Johansen (1979) reported that patients with fasting 
hypoglycaemia usually developed neuroglycopenic symptoms as well as chemical 
hypoglycaemia during the first twelve to thirty six hours of the prolonged fast. 
Hypoglycaemia due to an insulin producing tumour is distinguished from other 
diseases causing hypoglycaemia by the inappropriately high plasma insulin and C- 
peptide levels. Insulinomas secrete insulin in short spurts and frequent 
measurement of insulin levels are required to demonstrate inappropriately high 
levels in peripheral blood. C-peptide with its long half-life  and larger pool size 
is less likely to show such marked changes in plasma concentration over a short 
period and is probably the B cell product of choice to measure in cases of 
suspected insulinomas. The prolonged fast has now been superceded, in most
v.
cases, by the insulin stress test. The prolonged fast has the disadvantages of 
being tedious and expensive although in some cases as in patient G it may be the 
only test that is available.
In the absence of fasting hypoglycaemia, if a patient is suspected of having an 
insulinoma a suppression test such as the insulin stress test can be advocated in 
which plasma glucose and immunoreactive C-peptide levels are monitored. 
(Turner and Johnston, 1973, Turner and Heding, 1977, Service e t a l . 1977. )• 
The insulin stress test is simple to carry out and can be accomplished without 
hospitalization of the patient. In the normal subject insulin produces marked 
suppression in C-peptide levels together with decreased plasma glucose level, C- 
peptide levels remaining low for approximately sixty minutes. Patients E and L 
underwent insulin stress tests and impaired suppression of immunoreactive C- 
peptide was observed compared with normal subjects confirming the diagnosis of 
islet cell tumours in these patients. This impairment of suppression is due to the 
lack of feedback inhibition of insulin on the B cells of the tumour. The 
regulation of insulin secretion is normally mediated by stimulatory and inhibitory 
signals depending on changes of glucose concentration and modulating effects of 
various hormonal and non-hormonal factors. In insulinomas the secretion is 
inappropriate to the stimulus and the ensuing hypoglycaemia fails to turn off 
further insulin secretion.
Measurement of immunoreactive C-peptide and insulin levels prior to the tests 
are important since some insulinomas are histogically undifferentiated and 
secrete proinsulin rather than C-peptide and insulin (Melani et al. 1970, Lazanus 
et al. 1972, Creutzfeldt et al. 1973, Rubenstein et al. 1974). Gutman et al.
(1973) reported a patient with a malignant tumour which consisted of 89% 
proinsulin. Turner and Heding (1977) reported that following an insulin 
suppression test, monitoring C-peptide levels is sufficient to diagnose most 
insulinomas but that a proinsulin assay is necessary to detect most 
undifferentiated adenomas. Raised plasma proinsulin levels after an overnight
fast have been reported by a number of workers (Turner and Heding 1977, 
Service et al. 1977) in patients with insulin producing tumours. A low C-peptide 
level, therefore, does not exclude the possibility of an insulinoma because of the 
low crossreactivity of human proinsulin in most C-peptide assays. However, 
cross 'reactivity of proinsulin in the C-peptide assays has been observed to vary 
(Cargill et al. 1980). The commonest cause of false positive C-peptide 
suppression tests is the failure to achieve hypoglycaemia of a sufficient degree 
and duration to permit the plasma C-peptide levels to fall (Marks,* 1981)* ,
There are two other suppression tests which are sometimes used to diagnose an 
islet cell tumour. The diazoxide test has been found to be useful (Le Quesne et 
al. 1979, Marks , J981.), ’ \  in assessing, prior to removal of an insulinoma,
whether the patient can be controlled by diazoxide, so that if  the surgeon is 
unable to resect the tumour he may not have to resort to a blind subtotal 
pancreatectomy. In both patients (patients E and K) reported in this chapter the 
infusion of diazoxide produced a decline in insulin levels with a corresponding 
fall in C-peptide values and a rise in plasma glucose levels. Both patients could 
therefore be controlled by diazoxide if the tumours were not found during 
surgery. Diazoxide is a hyperglycaemic thiazide which inhibits insulin release 
from the B cells of the pancreatic islets by incompletely inhibiting insulin 
synthesis and/or storage. (Creutzfeldt et al. 1969). Creutzfeldt et al. (1969) 
have shown that as a result of diazoxide the granules containing the insulin in the 
B cell undergo intracellular digestion.
The infusion of somatostatin as a diagnostic suppression test has been 
investigated in a few insulinoma patients (Christensen et al. 1975, Kerner et al.
1980) but results have proved unpredictable.
Provocation or stimulation tests of insulin secretion are less reliable in the 
diagnosis of islet cell tumours than suppression tests and prolonged fasts. 
Provocative agents include tolbutamide, leucine, glucagon, arginine and glucose.
They are used, nowadays only to investigate difficult cases in which they may 
provide additional information. A minority of malignant tumours do not respond 
to the provocation tests. The benign and better differentiated the tumour the 
more likely it is to respond favourably to suppression by diazoxide and 
somatostatin (Marks ,1981.)
The calcium infusion test detects inappropriate insulin release due to a defect in 
the secretory mechanism control in patients with islet cell tumours. Calcium 
infusion has been known for some years to stimulate the release of gastrin, 
calcitonin and at times 5 hydroxy tryptamine in patients with certain types of 
endocrine tumours (Passaro et al. 1972). An infusion of calcium gluconate causes 
insulin release and a fall in blood glucose concentration in patients with insulin 
secreting tumours (Kaplan et al. 1972, Frerichgand Creutzfeldt 1976, 1980) but 
no changes were observed in healthy volunteers (Gaeke et al. 1975). This has led  
to its use as a test for insulinomas either alone (Ohneda et al. 1975) or with 
intravenous glucose (Frerichs and Creutzfeldt 1976, 1980 -)• Frerictfe and 
Creutzfeldt (1976) reported that calcium given intravenously with glucose 
augmented the insulinaemic response to hyperglycaemia and was positive in 
approximately 65 per cent of insulinoma cases. However, this test does not 
produce consistent results and its value in the diagnosis of insulin-secreting 
tumours of the pancreas remains in question. In the series of patients described
in this chapter this test was usedLin a §ingl£,case. Patient E demonstrated
\
elevated insulin and C-peptide levels and a fall in plasma glucose level due to 
the calcium infusion. Due to the positive result in this test together with the 
results from other tests it was possible to diagnose that the patient had an islet 
cell tumour.
The oral glucose tolerance test is indispensible for the differentiation of the 
common functional reactive (post absorptive) hypoglycaemia, but is of no use in 
the diagnosis or differential diagnosis of fasting hypoglycaemia (Marks ,
1981). Misinterpretation of results from extended oral glucose tolerance tests
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has lead to an epidemic of "non-hypoglycaemia" which is prevalent in the 
U.S.A. (Yager and Young, 1974). Reactive hypoglycaemia occurring during an 
extended oral glucose test is not at all unusual in conditions characterised by 
fasting hypoglycaemia in the case of an insulinoma patient. In the two cases 
reported in this chapter plasma glucose levels of below 2 mmol/Litre oc curred 
during the oral glucose test. Neither the shape, magnitude nor duration of the 
initial hyperglycaemic phase provide help in determining the aetiology of the 
reactive hypoglycaemia. Insulinoma cells are generally relatively insensitive to 
a glucose stimulus, the sensitivity decreasing with the degree of functional 
dedifferentiation.
Glucagon is a potent stimulator of insulin release but also one of the most 
powerful glycogenolytic agents known and it can be used to test insulin secretion 
and glycogen reserves (Marks, 1960, Marks and Samols, 1968, Kumar et al. 1974).
The glucagon provocation test can be carried out in two ways; either after an 
overnight fast or in an attempt to terminate a spontaneous hypoglycaemic 
attack. The interpretation of results is different after the two tests. In the case 
reporte'd in this chapter, reactive hypoglycaemia in the patient was immediately 
terminated by intravenous glucagon. The glucagon caused an immediate rise in
plasma glucose and insulin levels. Kumar e t a l . (1974).  have reported a s im ila r  
exaggerated rise in plasma insulin levels within 5-10 minutes in 70 per cent of 
the insulinoma patient^ after which time insulin levels fell very rapidly. A fter an 
overnight fast insulinoma patients given glucagon, experience symptomatic 
rebound hypoglycaemia after an initial exaggerated rise in plasma insulin levels. 
Exaggerated insulinaemic responses to glucagon are shown in a number of other 
conditions, such as obesity, acromegaly and Cushing's syndrome, but none of 
these conditions can be clinically confused with insulinomas. Fajans i^nd F1oyd(1975) 
reported that 58% of patients with proven islet cell disease had abnormal 
glucagon responses.
The remaining provocation tests such as the L-leucine and tolbutamide test are 
very rarely used due to the significant percentage of false negatives reported 
(Wolfsdorf and Senior 1979, Fajans and Floyd,1975.)
The major site of removal of C-peptide from the body is the kidneys (Katz and 
Rubenstein, 1973, Horwitz et al. 1977). Patients with hypoglycaemia with 
chronic renal failure cannot be investigated by the measurement of C-peptide 
levels. Care must be taken to investigate the clinical history of the patient in 
order to exclude tests which would be of no practical use. In the case reported, 
in this chapter, the insulin suppression test resulted in abnormally high C-peptide 
levels yet plasma glucose levels were within the normal range. Metabolism and 
removal of C-peptide . was presumably impaired during this test due to the 
patients poor renal function. Other tests which allow the measurement of insulin 
should be used to investigate such a patient and establish a diagnosis.
Removal of the insulinoma by surgery is the first and obvious choice of 
treatment for most patients. In some cases, either because of the inability to 
localise the tumour or the age of the patient, medical treatment is preferred. A 
number of workers (Marks, 1971, Marks and Samols, 1974, Le Quesne et al. 1979) 
have recommended that patients undergo a diazoxide test, in order, to determine 
whether hypoglycaemia can be controlled with this treatment. Failure to find 
the tumour at operation should not, therefore, result in blind distal 
pancreatectomy but closure of the abdomen when the patient can then be 
controlled with diazoxide. Mengoli and Le Quesne (1967) and Stefanini et al.
(1974) showed that the majority of occult tumours are found in the head of the 
pancreas. Diazoxide, is a potent hyperglycaemic agent especially when given in 
combination with a diuretic benzothiadiazine such as chlorothiazide (Marks and 
Samols 1968a, Brunetti et al. 1968;. Chlorothiazide is also given to abolish the 
discomfort due to electrolyte and water retention. Diazoxide is not cytotoxic or 
teratogenic nor does it produce permanent or irreversible damage to the B cell.
Other hyperglycaemics have been tried without success and have adverse side 
effects. They include propranolol (Scandellari et al. 1976, 1978) and phenytoin 
(Ginsberg-Fellner, 1980). Cytotoxic drugs have been used in the treatment of 
malignant tumours of the pancreas and these include streptozotocin (B o rd e r  and 
Carter 1974), adriamycin (Eastman et al. 1977) and 5 flourouracil (Kraybill et al. 
1976).
In normal subjects a significant correlation was observed between fasting C- 
peptide and plasma glucose levels, no correlation could be obtained, however, 
between fasting insulin and plasma glucose levels although increasing the number 
of normal subjects may enable correlation of fasting insulin and plasma glucose 
levels. Plotting fasting C-peptide level against plasma glucose values from 
insulinoma patients clearly demonstrated a difference between these patients 
and normal subjects.
In conclusion, this series of patients has emphasised that the clinical history of 
the patient is extremely important in the diagnosis of most insulinomas. 
Insulinomas in a majority of cases in this series were easily detected by either 
prolonged fasting or insulin stress tests. Some patients, however, require further 
investigation in order to demonstrate the existence of tumours. The most useful 
test which is carried out in patients is the insulin stress test with the 
measurement of glucose and C-peptide levels.
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CHAPTER V
A POSSIBLE PHYSIOLOGICAL ROLE FOR C-PEPTIDE
15 3
5:1 Introduction
A high degree of species specificity exists in the primary structure of C-peptide. 
Considerable variation in both the amino acid sequence and the chain length is 
observed between species (Figure 5:1). This variation in the primary structure of 
C-peptide is much greater than that which has been observed in insulin structure. 
In addition, in some species, for example the rat, two different proinsulins are 
synthesised and two insulins and C-peptides are released equimolarly. The two rat 
C-peptides only differ in the amino acids at positions 8 and 17. The two rat 
proinsulins maintain the same net charge at neutral pH. The negative charge due 
to the glutamic acid at position 17 in rat C-peptide I is off-set by the positive 
charge at lysine B29 in the corresponding rat insulin. Neutral amino acid residues 
appear at position 17 and B29 of rat C-peptide II and rat insulin II respectively.
The large divergence in primary structure is more apparent in species which are 
not closely related to each other. Rat C-peptide I and II and human C-peptide have 
thirty-one amino acids each, twenty-one of which are common to all three 
peptides. The appearance of thirty-one amino acid residues in the C-peptides from 
three divergent mammalian orders namely, the primate, the rodent and the 
perissodactyl, and the clear homology of the terminal regions among all the 
C-peptides strongly suggests that the primative mammalian C-peptide contained at 
least 31 amino acids.
The large degree of variation in the primary structure of C-peptide between 
species has necessitated the development of species specific radioimmunoassays. 
Most naturally occurring peptides and their biosynthetically related peptides are 
difficult to obtain and therefore synthetic peptides are used increasingly as the 
starting material for developing radioimmunoassays. Unfortunately the purity of 
these chemically synthesised compounds is variable. C-peptide can be synthesised 
using the azide fragment condensation method (Yanaihara et al. 1974, 1978b) or
more recently the solid phase method (Igano et al. 1981). The condensation method 
used to synthesise rat C-peptide I and II involves the stepwise fragment
Figure 5:1
Species va r ia tion  of amino acid sequence of C-peptides
Human Rat I Rat I I Dog Porcine Bovine Monk
1 . Glu Glu Glu Asp Glu Glu Glu
2. Ala Val Val Val Ala Val Ala
3. Glu Glu Glu Glu Glu Glu Glu
4. Asp Asp Asp - Asn Gly Asp
5. Leu Pro Pro - Pro Pro Pro
6.
j Gin Gin Gin - Gin Gin Gin
7. Val Val Val - Ala Val Val
8. Gly Pro Ala - Gly Gly Gly
9. Gin. Gin Gin - Ala Ala
10. Val Leu Leu - Val Leu Val
1 1 . Glu Glu Glu - Glu Glu Glu
12. Leu Leu Leu Leu Leu Leu Leu
13. Gly Gly Gly Ala Gly Ala Gly
14. Gly Gly Gly Gly Gly Gly Gly
15. Gly Gly Gly Ala Gly Gly Gly
16. Pro Pro Pro Pro Leu Pro Pro
17. Gly Glu Gly Gly Gly Gly Glv
18. Ala Ala Ala Glu - Gly Ala
19. Gly Gly Gly Gly Gly Gly Gly
20. Ser Asp Asp Gly - - Ser
21. Leu Leu Leu Leu Leu - Leu
22. Gin Gin Gin Gin Gin - Gin
23. Pro Thr Thr Pro Ala - Pro
24. [.eu Leu Leu Leu Leu - Leu
25. 41a Ala Ala Ala Ala Ala Ala
26. Leu Leu Leu Leu Leu Leu Leu
27. Glu Glu Glu Glu Glu Glu Glu
28. Glu Val Val Gly Gly Gly Gly
29. Ser Ala Ala Ala Pro Pro Ser
30. Leu Arg Arg Leu Pro Pro Leu
31. |Gln Gin Gin Gin Gin Gin Gin
□ amino acids iden tica l in these species with human
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condensation from the C terminal 20-31 sequence. The products are then purified
I
by gel filtration or ion exchange chromatography.
Antisera against synthetic rat C-peptide I and II have been produced both in rabbit 
and guinea pigs (Yanaihara et al. 1978a). The conjugate used for the immunisation 
was either produced by coupling rat C-peptide II to human serum albumin or 
adsorbing rat C-peptide I and II onto polyvinyl pyrrolidone which binds non 
specifically to the peptides. Using these conjugates Yanaihara et al. (1978a) 
produced three antisera. Each antiserum could detect either rat C-peptide I and II 
or both depending on the standard and tracer used in the radioimmunoassay. The 
antiserum produced in the rabbit could detect both C-peptides equally. The 
C-peptide levels described in this chapter were obtained using this rabbit 
antiserum. Yanaihara et al. (1978a) stated that the major antigenic site of this 
antiserum was located in the 20 to 31 amino acid region of the C-peptide which is 
identical in both rat C-peptides.
The major route for proinsulin conversion to C-peptide and insulin involves trypsin- 
like and carboxypeptidase B like enzyme activity. (Clark and Steiner, 1969, 
Kemmler et al. 1971). A minor route in rodents has been described by Tager et al. 
(1973) resulting in the production of peptide A, an Nh^ terminal twenty two 
residue peptide from rat C-peptide I. This peptide is formed initially by 
chymotryptic-like cleavage of rat proinsulin I between residues 22 and 23 of the 
connecting region. This region is then enzymatically cleaved as before, producing 
two peptides, one with twenty two amino acids and one with seven. (Fig. 3:2) 
Yanaihara et al. (1980) described a similar fragment cleaved from rat proinsulin II. 
This fragment has been extracted from rat plasma by gel filtration on Sephadex 
G-50. The biological importance of either of these peptides after stimulation of 
the B cell has not yet been studied. However, Yanaihara et al. (1981), using a 
guinea pig rat C-peptide antiserum, which crossreacted 100% with rat C-peptide 
All (obtained from rat proinsulin II) demonstrated that a considerable proportion of 
the rat C-peptide is released in the form of rat C-peptide IIA in glucose perfused
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Figure 5:2
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rat islets. Immunohistochemical staining with antisera raised against rat C-peptide 
I and II have demonstrated that these peptides are stored in the same B cell 
although the amino acid sequence of the peptides are different (Yanaihara et al. 
' ]980).
There is some evidence for the direct autoregulation of insulin (Iversen and Miles, 
1971, Turner and Johnstone, 1973, Loreti et al. 1974) in whole pancreas, pieces of 
pancreatic tissue and isolated islets using exogenous insulin in a variety of animals 
including man. However, other workers have failed to demonstrate any 
autoregulation (Malaisse et al. 1967, Sando et al. 1970) This failure could be 
attributed to the failure to use species specific insulin. However, since C-peptide 
is secreted in equimolar amounts with insulin it is possible that the autoregulation 
of insulin is due to other B cell products such as C-peptide and proinsulin, in 
addition to insulin. The evidence for a possible physiological role for C-peptide in 
insulin regulation is also conflicting.
Toyota et al. (1975) investigated the effect of synthetic rat C-peptide I in the
perfused isolated rat pancreas on insulin secretion in the presence of 16.6 mM
glucose. They demonstrated that C-peptide inhibited glucose induced insulin
secretion in the rat pancreas and suggested that C-peptide may have a possible
regulatory role in insulin secretion. They postulated that a defective pancreas
where C-peptide may accumulate in the B cell may lead to diabetes because the
excess C-peptide inhibits insulin release. Wojcikowski et al. (1977) demonstrated
using isolated perfused rat pancreas that synthetic human, rat I and ra t II
C-peptides inhibited glucose stimulated insulin release to varying degrees. The
largest degree of inhibition was demonstrated when human C-peptide was present.
Both early and second phases of glucose stimulated insulin secretion were inhibited.
Stimulation of isolated pancreas with arginine in the presence of human C-peptide
attenuated both phases of glucagon secretion. Physiological C-peptide
concentrations in the extracellular space of the islet cell are estimated to be 
-6 -5approximately 10” to 10” molar at maximum. This calculation is based on insulin
measurement as no rat C-peptide assay was available at the time of the study. In
their experiments Wojcikowski et al. (1977) used a C-peptide concentration of 
-810” M which caused a significant effect. Although the degree of inhibition of 
glucose stimulated insulin secretion was greatest with human C-peptide, rat 
C-peptide II gave an appreciable degree of inhibition. Inhibition of insulin 
secretion was only slight with rat C-peptide I suggesting that the difference in 
effectiveness is not due to species heterogeneity but possibly due to small 
variations in the tertiary structure. Wojcikowski et al. (1977) suggested that 
C-peptide may be added to the list of participants involved in the interplay of islet 
cell hormones. However, Dunbar et al. (1976) working with isolated hamster islets 
demonstrated inhibition of glucose stimulated insulin release with proinsulin and 
insulin but not C-peptide. Inhibition of insulin secretion was almost total with 
proinsulin. In this study an undescribed C-peptide was used and, therefore, because 
of the large variation in C-peptide between species the data must be regarded with 
some scepticism. Further studies in isolated rat islets by Yasuda et al. (1976) did 
not demonstrate any inhibitory effect on insulin secretion of rat C-peptide II and 
human C-peptide although rat C-peptide I did have an inhibitory effect. The 
results produced from these two studies, may have been due to some disturbance of 
islet function by collagenase treatment. Studies in isolated rat pancreas by Kaneko 
et al. (1978) did not demonstrate any inhibition of glucose stimulated insulin 
release by rat C-peptide II. However, the infusion of C-peptide was at a lower 
concentration than that used in the studies of Wojcikowski et al. (1977).
The close relationship between the gastrointestinal hormones and insulin release 
has long been known. McIntyre et al. (1964) demonstrated that intrajejunal glucose 
resulted in a greater insulin response than intravenous glucose. One of the major 
gut peptides that contributes towards this increased insulin response is GIP. GIP 
release has been shown to be inhibited by a number of substances released from the 
pancreas. A number of workers have investigated the response of GIP to oral fat 
after intravenous injection of insulin or infusion of glucose and all have found that
GIP secretion is inhibited (Brown et al. 1 9 7 5 ,Crockett et aj# 1 9 7 5 , Ross and Dupre 
1978, Ebert et al. 1979). Other islet hormones, namely,
glucagon (Ebert et al. 1977), somatostatin (Pederson et al. 1975) and C-peptide 
(Dryburgh et al. 1980) have all been found to inhibit GIP release. Investigations 
into whether C-peptide may be involved in the negative feedback control of GIP 
has been studied in this department by Dryburgh et al. (1980). Using the rat 
intestinal perfusion model they were able to demonstrate that exogenous rat C- 
peptide II inhibited fat stimulated GIP release at doses which were only three times 
those encountered in the normal fed rat. Plasma glucose levels were significantly 
depressed in the group of animals receiving C-peptide alone. This may have been 
due to depression of glucagon levels by C-peptide which has already been 
demonstrated by Wojcikowski et al. (1977).
Care must be taken when using synthetic substances, as a substitute for the 
naturally occurring compounds. In the process of chemical synthesis small peptide 
fragments are often produced as a side reaction and if not removed can 
contaminate the synthetic material. The purity of these compounds is, therefore, 
extremely important and sufficient care has to be taken to ensure that the 
synthetic compounds used are homologous. Nevertheless, naturally extracted 
substances are not necessarily pure and may also be contaminated. Purification is, 
therefore, a very important process in obtaining compounds for use in vivo and in 
vitro studies. The development of biosynthetic compounds and the use of high 
pressure liquid chromatography has made it possible to obtain compounds which can 
be used in the knowledge that purity is maximal but the purification procedures 
necessary are tedious, time-consuming and also require a relatively large amount 
of starting material, which is not always possible.
In this chapter various investigations have been carried out in order to elucidate 
whether endogenous C-peptide inhibits fat stimulated GIP release in the rat. The 
stimulation of endogenous C-peptide enables any responses due to contamination of 
the exogenous C-peptide to be eliminated. In these studies, GIP secretion was
stimulated using either an in situ intestinal perfusion of fat or by dosing the rats 
orally in the conscious state. C-peptide was stimulated by intravenous injection of 
tolbutamide in either the jugular or tail vein and the biological effects of insulin 
were masked by the simultaneous injection of insulin antiserum. Due to the species 
variation in the primary structure of C-peptide a specific radioimmunoassay was 
set up and validated.
5:2 The immunoreactive rat C-peptide radioimmunoassay
Immunoreactive rat C-peptide was measured by a modification of a method 
described by Yanaihara (1979 Personal communication). The antiserum, standard 
and tyrosylated rat C-peptide I were all kindly donated by Professor N.Yanaihara. 
5:2:1 Materials and Methods
(a) Antiserum
The antiserum (batch no. R.901 12.15.76) was raised in a rabbit against rat C- 
peptide II which was adsorbed on to polyvinylpyrrolidine.
(b) Iodination methods
(i) Lactoperoxidase method. This was a modification of the Thorell and Johansson 
(1971) method. All reactions were carried out in a plastic autoanalyser cup at 
ambient temperature. The reactants were mixed with a small magnetic flea. 
Iodination procedure was as follows:-the reagents being added in the following 
order.
(1) 5 yg tyrosylated rat C-peptide I dissolved in 50 y l of 0.04M sodium acetate 
buffer pH 5.6.
(2) 50 y l 0.4M sodium acetate buffer pH 5.6.
l ? s
(3) 18.5 MBq (0.5mCi) in a 5yl aliquot of Na I.
(4) 10 y l 0.003% solution hydrogen peroxide (100 vols) dissolved in 0.04M sodium 
acetate buffer pH5.6
(5) 10 yl containing 500 ng of lactoperoxidase 0.04M sodium acetate buffer pH 5.6 
After 15 seconds.
(6) 240 yg sodium metabisulphite dissolved in 200 yl of 0.04M sodium acetate 
pH5.6.
The reactants were then loaded onto the purification column. The reaction time
was increased to 10 minutes in the course of developing the assay to investigate
125whether any increased incorporation of I into the rat C-peptide occurred.
(ii) Chloramine T method
The tyrosylated rat C-peptide I was iodinated using a modification of the Hunter 
and Greenwood (1962) chloramine T method. Rat C-peptide I was weighed out and 
dissolved in a small quantity of dilute acetic acid. The tyrosylated rat C-peptide I 
was then diluted in 0.05M phosphate buffer pH 7.4 to a concentration of 100 yg/ml. 
This solution was, then, aliquoted into plastic autoanalyzer cups containing 5 yg of 
tyrosylated rat C-peptide I and stored at -20°C until required. Iodination was as 
follows:- the reagents being added in the following order.
(1) 5 yg tyrosylated rat C-peptide I dissolved in 50 yl of 0.05M sodium phosphate 
buffer pH 7.4
(2) 50 y l of 0.05 M sodium phosphate buffer pH 7.4
(3) 18.5 MBq (0.5mCi) in a 5yl aliquot of N a '^ I .
(4) 20 yg chloramine T dissolved in lOyl of 0.05M sodium phosphate buffer pH7.4
(5) 25yg sodium metabisulphite dissolved in 200 yl of 0.05M sodium phosphate 
buffer pH7.4
After 10 seconds
(6) 500 yg potassium iodide dissolved in 50 yl of 0.05M sodium phosphate buffer 
pH7.4
The reactants were mixed throughout this process with a small magnetic flea. 
They were then loaded on to the purification column. Similar iodinations using 
different time intervals were carried out in the course of assay development.
(c) Purification of iodinated rat C-peptide I
A 30 x 1.1 cm column of Sephadex GIS- was equilibrated with 0.05 M sodium 
phosphate buffer pH7.4 containing 0.1% BSA. The iodination mixture was applied 
to the column and the iodinated C-peptide was eluted from the column with 0.05 M
sodium phosphate buffer pH7.4 containing 0.1% HSA. The unreacted iodide peak 
was eluted after the protein peak. The purified tracer was aliquoted and stored at 
-20°C.
(d) Standard
(i) Preparation of standard
Synthetic rat C-peptide I was used to produce the standard for the assay. The 
standard was weighed out on a Kahn microbalance and dissolved in a small quantity 
of 6 M acetic acid. This solution was made up to the concentration required 
aliquoted in 20 ng aliquots into freeze drying vials and lyophilized. The vials were 
stored at -20°C.
(ii) Investigation of standard purity using high pressure liquid chromatography 
High pressure liquid chromatography was used to investigate the purity of the rat 
C-peptide I standard. Chromatography was carried out at constant pressure using a 
Varian high pressure liquid chromatography machine equipped with a variable 
wavelength spectrophotometer.
Organic solvents used were HPLC grade. Buffers and salt solutions were made up 
with Analar or Aristar reagents using double glass distilled water.
Compounds for chromatography were freshly dissolved with 0.05 M sodium 
phosphate buffer pH7.4. The HPLC column used 250 x 5mm I.D . packed with 
Hypersil-ODS and operated at ambient temperature. Buffer A was 0.1M sodium 
phosphate buffer pH 2.5/. gO ^acetonitrile  ancj buffer B was 0.1M sodium 
phosphate buffer pH2.5/ 60%acetonitri1q a  linear gradient was supplied from 20- 
50v/v acetonitrile with a flow rate of 1 ml/min. The variable wavelength detector 
was set at 230 nm and the chart speed was 60 cm/hr.
(e) Assay procedure
(i) Rat C-peptide assay
The diluent buffer used in the assay was 0.05M sodium phosphate buffer pH7.4 
containing lg  BSA per litre.
Standard curves were constructed using rat C-peptide I in the range
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0.5-20 yg /L itre diluted in buffer.
To a series of polystyrene LP3 tubes were added either 50 yl of standard or 50 yl
of plasma sample plus 100 yl antiserum at a final dilution 1:2400 diluted in assay
buffer. 50 y l of rat C-peptide free plasma was also added to the standard curve
tubes. Standard and samples were set up in duplicate. A set of tubes were set up
without antiserum to measure non-specific binding of the samples and standard
125curve. The counts in these tubes were subtracted from the total I rat C-peptide
bound when calculating the amount of immunologically active rat C-peptide in
unknown samples. All tubes were mixed on a Vortex mixer and incubated at 4°C
for 24 hours. Tracer was diluted to give approximately 6000 cpm/100 yl (8000
dpm/100 yl). Tubes were then mixed on a Vortex mixer and incubated for a further
24 hours at 4°C . Separation of bound from free ^ ^ 1  tyr C-peptide was carried out
by double antibody precipitation. The antirabbit y globulin (Batch no.
H P /D /66-IC ) was used at a final dilution of 1:100. Double antibody precipitation
time was reduced by the addition of polyethylene glycol 6000 at a final
concentration of 2%, was added to the tubes. They were mixed on a Vortex mixer
and incubated at 4°C for 2 hours. The tubes were then spun in a refrigerated
centrifuge for 25 minutes at 2000 g and the supernatent was aspirated. The protein
125precipitate which contained the antibody bound I rat C-peptide was counted in 
an automatic gamma counter. The amount of immunologically active rat C- 
peptide in unknowns and standards was determined by subtracting the number of 
counts in the non-specific tube. The corrected values were then used in the 
construction of a standard curve and in calculating results. The protocol of the rat 
C-peptide assay is shown in Table 5:1.
(ii) Preparation of rat C-peptide free plasma
Fasted blood was obtained by cardiac puncture from anaesthetised rats. The 
plasma was treated with agarose charcoal according to the method of Stockhill 
(1979).
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Table 5:1
Protocol fo r  Rat C-peptide radioimmunoassay
Tube Buffer! A/S 1 CSS Std. Label NRS Dab 4%^PEG
Total
Non-specific binding (NSB) 
Maximum Binding (MB)
Zero Binding (Zero)
Top Standard
100
150
50
150
100
•1*
50
50
50
50 50
100 100 500
24 h a t 4 C 24 h 1 2 h a t 4WC
at 4 C
(iii) Validation of rat C-peptide assay
(1) Recoveries
2.5. 5. 10, 20 ng of rat C-peptide I were each added to 1 ml of plasma obtained 
from fasted Wistar rats.
(2) Parallelism of standard curves with circulating endogenous rat C-peptide
A plasma sample which had a high endogenous rat C-peptide level was serially 
diluted with rat C-peptide free plasma.
5:2:2 Results
(a) Iodination methods
The lactoperoxidase iodinations produced tracers which bound a maximum of only 
10% of the tracer to the antibody in conditions of antibody excess. The most 
successful tracer was produced when tyrosylated rat C-peptide I was iodinated for 
15 seconds with chloramine T. Forty per cent of this tracer was bound in conditions 
of antibody excess.
(b) Purification of tracers
The elution profiles on G15 columns of the lactoperoxidase iodinated products are 
shown in Figures 5:3 and 5:4.
The elution profiles on G15 columns of the chloramine T iodination are shown in 
Figures 5:5 and 5:6. Antiserum dilution curves using these tracers are shown in 
Figure 5:7. These tracers were aliquoted into small containers and stored at - 
20°C.
(c) Standard
The purity of the rat C-peptide I standard was investigated using high pressure 
liquid chromatography. This synthetic compound contained four peaks which are 
eluted from the column fairly close to each other (Figure 5:8).
(d) Assay conditions
The effect of increasing the preincubation time and varying the period the tracer 
was present in the tube is shown in Figure 5:9. A 24 hour preincubation period and 
24 hours in contact with the tracer before separation using double antibody 
technique were chosen for all future work.
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Figure 5:8
High pressure l iq u id  chromatogram o f ra t C-peptide I 
(syn the tic-)
Buffer A 0.1 M Sodium phosphate b u ffe r pH2.5 /A c e to n itr ite  
Buffer B 0.1 M Sodium phosphate bu ffe r pH2.5 /  A c e to n itr ite
Flow ra te  1 ml min"^
Chart Speed 60 cm hr” ^
Wavelennth 230 nm
20%
60%
(i) Standard curve
Under the conditions described for the rat C-peptide radioimmunoassay increasing
125quantities of rat C-peptide I displaced I tyrosylated rat C-peptide I in the range 
0.5 to 20 pg/1 (Fig. 5:10). The non-specific binding varied with the age of the 
tracer but was always less than 10% of the total.
(ii) Sensitivity
The lim it of sensitivity of the assay defined as two standard deviations from the 
zero standard (Fieldman & Rodbard, 1971) was 65 pg.
(e) Validation of rat C-peptide radioimmunoassay
(i) Precision
The intra assay coefficient of variation at a mean plasma level of 2.3 pg/1 was 11.5 
(n = 6) and at 9.6 pg/1 was 10.0% (n = 6).
The interassay coefficient of variation of four serum samples was calculated (Table 
5:2).
(ii) Recoveries
The mean recovery of exogenous rat C-peptide when added to fasted rat plasma 
was 93%.
(iii) Parallelism
Plasma samples containing a high concentration of endogenous rat C-peptide 
serially diluted in charcoal extracted plasma were superimposable upon the ra t C- 
peptide standard curve (Figure 5:9).
5:2:3 Discussion
The large species variation in the primary sequence of C-peptide has made it  
impossible to use the one assay for detection of C-peptide levels in most animals. 
The production of a specific antiserum which can detect both rat C-peptide I and II 
has been described by Yanaihara et al. (1978a). This antiserum cross reacts equally 
with both C-peptides. The cross reactivity of this antiserum with rat C-peptide A I 
and All is less than 0.001%. Yanaihara et al. (1981) have suggested that the 
concentration of these products may be higher than originally expected of a minor
Table 5:2
I t ite r  assay precis ion o f plasma samples containing a
range o f leve ls  o f endogenous 
Rat C-peptide
Mean Rat C-peptide value (p g /L itre ) No.of observations SD % Coeff o f 
V aria tion
2.05 9. 0.125 6.1
4.05 9 0.28 7
9.5 9 0.58 6.1
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Figure 5:9
Optim isation o f assay condition
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Figure 5:10
S uperim possib ility  o f s e r ia lly  d ilu ted  
plasma samples d ilu ted  in ra t C-peptide 
free serum upon a synthetic  ra t 
C-pentide standard s im ila r ly  d ilu te d
A Sample 1 
a Sample 2
°  Rat C-peptide standards in charcoal-extracted serum
Rat C-neptide (y g /L itre )
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pathway but it is unlikely that C-peptide Al and All interfere in the assay to any 
significant extent.
The difficulty of extracting naturally occurring rat C-peptide I and II has lead to  
synthesis of these peptides by the condensation technique. These synthetic 
peptides have been used to develop antisera, produce standards and tracers for 
radioimmunoassays. The high pressure liquid chromatogram of rat C-peptide I 
standard demonstrated its lack of purity, as 4 distinct components. Further studies 
will have to be completed with rat plasma and assessment of the immunogenicity 
of the high pressure liquid chromatography fractions using the antiserum to 
determine which peak is the rat C-peptide I. The levels of rat C-peptide measured 
in the rat plasma must, therefore, not be regarded as absolute values.
The problems encountered in obtaining a high specific activity tracer may have 
been due to impurities in the preparation of tyrosylated rat C-peptide I. A high 
pressure liquid chromatogram was not run and, therefore, the purity of the 
tyrosylated peptide could not be assessed. In conditions of antibody excess the 
maximum binding of the tracer varied between 30 -40% of total counts added.
5:3 Endogenous C-peptide induced inhibition of fat stimulated GIP release.
Study 1.
5:3:1 Materials and Methods
Thirty male Wistar rats weighing between 250 and 290 g fed on normal laboratory 
diet were used in this investigation. The rats were fasted in metabolic cages for 24 
hours prior to the investigation. The animals were anaesthetised with intra- 
peritoneal (I.P.) pentobarbitone (100 mg/kg body weight). The abdomen was opened 
along the midline and a polyethylene catheter (internal diameter 4mm) inserted 
into the upper intestine through a small incision in the region of the duodenal bulb. 
An incision was made in the terminal ileum and the contents of the gut flushed out 
with saline at 37°C. A second polyethylene catheter was then placed in the lower 
incision to allow free drainage of gut perfusates. The upper polyethylene catheter 
was attached to a peristaltic pump allowing perfusion of the gut with either 10%
bath. The gut perfusion was carried out for 30 minutes, 10 minutes after the start 
of perfusion an injection was given into the tail vein. Blood was collected 
immediately after the perfusion period from the vena cava. A 100 yl aliquot of 
whole blood was deproteinised with sodium tungstate and stored at 4°C  until assay. 
The remainder was placed in lithium heparin tubes which were immediately spun 
and the plasma was aliquoted and stored at -20°C. Animals were sacrificed 
immediately after blood sampling.
5:3:2 Experimental protocol
(1) Gut perfusion with 10% Intralipid at 37°C at a rate of 2 ml/min for 30 min. 
1 ml intravenous (I.V.) saline (0.154 mol/1) was given as a bolus into the tail vein 
(n = 11).
(2) Gut perfusion with saline (0.154 mol/1) at 37°C at a rate of 2 ml/min for 30 
min. 1 ml I.V. saline (0.154 mol/1) was given as a bolus into the tail vein (n = 6).
(3) Gut perfusion with 10% Intralipid at 37°C at a rate of 2 ml/min for 30 min. 
1 ml of glucose (0.5 gm/kg - 0.5 ml) and tolbutamide (83 mg/ml -0.5 ml) was given 
as a bolus into the tail vein (n = 6).
(4) Gut perfusion with 10% Intralipid at 37°C at a rate of 2 ml/min for 30 min. 
1 ml of glucose (0.5 gm/kg - 0.25 ml), tolbutamide (83 mg/ml - 0.5 ml) and insulin 
antibodies (0.25 ml - Batch no. M F/G P/5-IA ) (n = 6).
5:3:3 Analyses
(i) Glucose analysis
Blood glucose was determined in duplicate by a glucose oxidase method (Trinder, 
1969).
(ii) Immunoreactive GIP (IR - GIP) radioimmunoassay
Immunoreactive GIP was measured by a double antibody radioimmunoassay (Morgan 
et al. 1978). A porcine standard was used, parallelism was demonstrated between 
the standard curve and a serially diluted sample of rat plasma containing high 
levels of endogenous GIP. The assay sensitivity was 110 ng/Litre (2 standard
deviations from zero) and the interassay coefficient of variation was 4.1% at 2677 
ng/Litre at 22.5% at 138 ng/Litre.
(iii) Immunoreactive rat C-peptide (IR - RCP) radioimmunoassay 
Immunoreactive rat C-peptide was measured according to the method described 
earlier in this chapter.
5:3:4 Preparation of globulin fraction of insulin antiserum
Insulin antiserum (batch no. M F/G P/5-IA ) was placed in glass beakers containing a 
small magnetic bar. The serum was allowed to mix slowly on magnetic stirrers. 
Saturated ammonium sulphate at room temperature was placed in a microburrette. 
The ammonium sulphate was then added dropwise until half the original volume of 
the serum had been added. The mixture was then centrifuged at 2500 rpm for 10 
minutes and the supernatant discarded. The precipitate was then resuspended in 
distilled water and dialysised against distilled water for 48 h. The dialysate was 
then aliquoted into freeze drying vials and lyophilised. The vials were then stored 
at -  20°C until required. The binding capacity of the insulin antiserum was 
calculated from a Scatchard plot.
5:3:5 Results
The IR-GIP, IR-RCP and blood glucose levels are shown in Tabe 5:3 and Figure 
5:11.
Immunoreactive GIP (IR-GIP) levels were significantly increased (p < 0.02) in the 
group perfused with Intralipid compared with the control group (saline perfusion). 
No significant difference was observed in the IR-GIP levels between any of the 
groups perfused with 10% Intralipid (Groups 1, 3 and 4). However, when data from 
groups 3 and 4 were combined (those animals which had high circulating C-peptide 
levels) a significant inhibition (p < 0.05) of IR-GIP levels was observed in these 
animals compared with rats only Intralipid perfused (Group 1).
The immunoreactive rat C-peptide (IR-RCP) levels were significantly increased in 
group 4, one of the groups of rats which had had B cells stimulated, compared with 
saline injected rats (Group 1) (p < 0.05). The addition of insulin antiserum to the
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Table 5:3
Endogenous C-peptide induced in h ib it io n  o f IR-GIP 
release: Study 1
x ± SEM
Groups IR-GIP (n g /L itre ) IR-RCP (y g /L itre ) Glucose (m m ol/Litre)
Group 1 
Gut perfusion
in t r a l ip id / IV  356 ± 44 
saline ri = 11
Group 2 
Gut perfusion
sa lin e / IV 179 ± 22 
sa line  n = 6
15.1 ± 2.02 4.8 ± 0.27
16.65± 2.2 4.4 ± 0 .5 3
Group 3
Gut perfusion 263 + 
in t r a l ip id / IV  
glucose + tolbutamide 
n = 6
28.8 ± 7.1 4.9 ± 0.29
Group 4 
Gut perfusion
in t r a l ip id  IV 253 ± 28 
glucose + tolbutamide 
+ in s u lin  antibodies 
n -  6
55.2± 15.1 5.3 ± 0.82
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cocktail of glucose and tolbutamide resulted in an increase in the circulating 
C-peptide levels compared with rats receiving only the cocktail. Mean C-peptide 
levels in group 3, the group receiving only tolbutamide and glucose, were elevated 
compared to their saline control, but the elevation failed to achieve statistical 
significance. Glucose levels in all groups showed no statistical difference.
The binding capacity of the insulin antiserum injected into the rats was calculated 
from a Scatchard plot (Fig 3:12). The antiserum had a binding capacity 
15.9 x 10 m ol/Litre and equilibrium constant 21.43 x 1 0 ^  L/mol. The serum 
from each rat was screened for the presence of antibodies in the group given 
insulin antibodies. All rat sera showed insulin antibodies present at the end of the 
study and the residual insulin binding was calculated to be 3.6 ng insulin per rat. 
5:3:6 Discussion
The plasma GIP levels reported in this study were only significantly depressed in 
the presence of high circulating C-peptide levels when data from both B cell 
stimulated groups were combined. Increasing the number of animals in each group 
may have been sufficient to obtain significance in each group.
The low circulating levels of antibodies at the end of the study and the similar 
glucose levels in all groups of rats indicated that only a small proportion of the 
antibodies injected were passing into the circulation. A probably explanation is 
that the high concentration of antibodies used caused the collapse of the vein and 
the antibodies remained in the interstitial tissues.
The level of C-peptide present after stimulation with glucose and tolbutamide 
without insulin antibodies was not significantly elevated. The doses of glucose and 
tolbutamide may have been insufficient but more likely the route of administration 
prevented the entire dose reaching the circulation. Since the tail vein as an 
intravenous route was unsuitable for the purpose of the study an alternative route 
the jugular vein was investigated.
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Study 2
5:4:1 Materials and Methods
Forty male Wistar rats weighing between 250 and 290 g fed on normal laboratory 
diet were used in this investigation. The rats were fasted in metabolic cages for 24 
hours prior to the investigation. The procedure followed was exactly the same as 
Study I except that the substances were injected into the animals via the jugular 
vein. A small polyethylene cannula attached to a 26 gauge needle was placed into 
the external jugular and kept patent with saline (0.154 mol/Litre). The I.V. cannula 
was connected to a syringe and injected 10 minutes after the start of the gut 
perfusion.
5:4:2 Experimental Protocol
(1) Gut perfusion with saline (0.154 m ol/Litre) at a rate of 2 ml/min for 30 
minutes. 1 ml I.V. saline (0.75 ml) and normal guinea pig serum (0.25 ml)
(2) Gut perfusion with 10% Intralipid at 37°C at a rate of 2 ml/min for 30 minutes. 
1 ml I.V. saline (0.154 m ol/Litre - 0.75 ml) and normal guinea pig serum (0.25 ml).
(3) Gut perfusion with 10% Intralipid at 37°C at a rate of 2 ml/min for 30 minutes. 
1 ml I.V. glucose (0.5 gm/kg - 0.25 ml), tolbutamide (8.3 mg/kg -  0.5 ml) and normal 
guinea pig serum (0.25 ml).
(4) Gut perfusion with 10% Intralipid at 37°C at a rate of 2 ml/min for 30 minutes. 
1 ml I.V. glucose (0.5 gm/kg - 0.25 ml), tolbutamide (83 mg/kg -0.5 ml) and insulin 
antibodies (0.25 ml Batch no. M F/GP/6-VA).
5:4:3 Analyses 
See Study 1.
5:4:4 Preparation of globulin fraction of insulin antiserum and normal guinea pig 
serum
The procedure followed was exactly the same as in Study 1 except that another 
batch of insulin antiserum was used (Batch no. M F/GP/6-VA).
5:4:5 Results
The IR-GIP, IR-RCP and glucose levels are shown in Table 5:4 and Figure 5:13. 
Immunoreactive GIP (IR-GIP) levels were significantly increased in the group 
perfused with Intralipid (Group 2) compared with the saline perfused group (Group 
1) (p < 0.005). There was a significant inhibition (p < 0.005) of IR-GIP levels in 
groups 3 and 4 given glucose and tolbutamide with or without insulin antibodies 
compared with control rats (Group 2). No significant difference was noticed 
between the rats receiving normal guinea pig IgG and insulin antibodies.
No significant difference was observed in immunoreactive rat C-peptide (IR-RCP) 
levels in Intralipid and saline gut perfused group (Group 1 and 2). A significant 
increase in IR rat C-peptide levels was noticed in the two groups (Groups 3 and 4) 
given glucose and tolbutamide with and without insulin antibodies compared with 
the control group (Group 2) (p<0.0025 p< 0.05) respectively. Immunoreactive rat C- 
peptide levels were not statistically different between Group 3 and 4.
Blood glucose levels were similar in Group 1 and 2. A significant difference (p < 
0.005) was observed in the group of rats given the insulin antibodies (Group 4) 
compared with rats given normal guinea pig serum (Group 3).
The binding capacity of the insulin antiserum injected into the rats was calculated 
from a Scatchard plot (Figure 5:14). The antiserum had a binding capacity 1.82 x 
1 0 moles/Litre and an equilibrium constant of 7.8 x 10^L /m ol. The antiserum 
was made up in half its original volume on resuspending the lyophilised material, 
therefore, each animal received 500 pi of the original antiserum. All rat sera in 
Group 4 showed insulin antibodies present at the end of the study and the residual 
binding capacity was calculated to be 0.6 yg insulin per rat.
5:4:6 Discussion
In this study fasting plasma GIP levels were elevated compared with the previous 
investigation. A significant depression of plasma GIP levels was observed in those 
rats with high circulating C-peptide levels either with or without insulin antibodies 
compared with the rats given intravenous saline. Immunoreactive C-peptide levels
Table: 5:4
Endogenous C-peptide induced in h ib it io n  o f GIP 
release: Study 2
x ± SEM
Groups IR-GIP (n g /L itre ) IR-RCP (y g /L itre ) G1ucose(mmol/Litre)
Group 1
Gut perfusion
saline IV 305 ± 28
saline + NGPS
5.98 ± 1.29 7.66 ± 0.37
Group 2
Gut perfusion
in t r a l ip id  IV 680 ± 18.8
saline
5.6 ± 1.1 8.6 ± 0.43
Group 3 
Gut perfusion 
in t r a l ip id  IV
glucose, 458 ± 15.9 
tolbutamide ] 
and NGPS ji
12.3 ± 1.2 19.9 ± 0.69
Group 4 |j
Gut perfusion j 
in t r a l i  pi d
IV glucose, 4go ± 32Q
tolbutamide
and in s u lin
antibodies
10.4 ± 2.0 24.00 ± 0.44
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were elevated compared with the control group in both groups receiving the B cell 
stimuli. Blood glucose levels were significantly elevated in the group given 
insulin antibodies indicating that circulating insulin was being removed by the 
antibodies thus reducing the rate of removal of glucose.
The gut perfusion technique used in the two studies was first described by Doluisio 
et al. (1969). English et al. (1975) used this technique to study the effect of three 
polyene macrolides on cholesterol absorption from the gut. This method of gut 
perfusion has been used by several workers to investigate the release of GIP in 
response to various nutrients in the rat. Watt et al. (1978) perfused the intestines 
of rats with glucose, a highly significant response was produced in GIP levels in 
portal blood after 15 minutes which plateaued by 30-45 minutes. The perfusion 
with a fat emulsion, 10% Intralipid, produced a slower rise in portal GIP levels 
which were significantly higher after thirty minutes but had increased further by 
45 minutes (Dryburgh et al. 1980).
The experiments employing the gut perfusion technique used a perfusion rate of 
120 ml/min, as this was the flow rate used in previous experiments. This is far in 
excess of the physiological flow rate and it is quite probable that the intestinal 
absorption rate of fat is diminished. Studies have shown that GIP release is 
dependent on the absorption of nutrients. Investigations using non-dietary fibres 
and selective carbohydrates inducing GIP release have demonstrated not only the 
importance of nutrients specific molecular structure but also the rate of nutrient 
absorption. In certain diseases which are characterised by malabsorption a 
diminished GIP response is observed, lending further weight to the suggestion that 
absorption of nutrients is required for GIP release (C reutzfe ld te ta l 1976,Besterman 
e t a l .1979.)
This study provides evidence that endogenous C-peptide does inhibit fat stimulated 
GIP release. The circulating GIP levels after perfusion with Intralipid were 
significantly raised but were only 2-3 fold higher than basal levels, in contrast to a 
4-5 fold elevation that is expected after an oral fat load in humans. The gut
perfusion technique is clearly unphysiological and therefore a change in 
experimental protocol is desirable. Oral fat dosing as an alternative to gut 
perfusion was chosen as being closest to physiological conditions. In order to 
maximise the GIP response to fat the rats were pretreated on a high fat diet as it 
had been reported (Deschodt-Lanckman et al. 1971) that a high fat diet increases 
pancreatic lipase activity in rats, increasing the rate of absorption of a fat load 
and hence should increase the GIP response.
5:5 Endogenous C-peptide induced inhibition of fat stimulated GIP release in fat 
p re treated rats.
5:5:1 Materials and Methods
Thirty male Wistar rats weighing between 250 and 290 g were fasted for 24 hours 
prior to the study. They were given 3 ml of triolein for 4 days prior to the study as 
well as being allowed free access to standard laboratory food. The animals were 
anaesthetised two hours after oral dosing. A small polyethylene cannula attached 
to a 26 gauge needle was then placed into the external jugular and kept patent with 
saline (0.154 mol/1). Blood was collected by cardiac puncture then put into lithium  
heparin tubes and immediately spun in a refrigerated centrifuge. Plasma for 
hormone and glucose estimation was aliquoted and stored at -20°C. The animals 
were sacrificed immediately after blood sampling.
5:5:2 Experimental Protocol
(1) Control group given 1 ml saline orally,
(2) 1 ml triolein orally 2 h prior to 1 ml I.V. saline (0.154 mol/Litre - 0.75 ml) and 
normal guinea pig serum(0.25 ml)„
(3) 1 ml triolein orally 2 h prior to 1 ml I.V. glucose (0.5 gm/kg - 0.25 ml), 
tolbutamide (83 mg/kg - 0.5 ml) and normal guinea pig serum (0.25 ml).
(4) 1 ml triolein orally 2 h prior to 1 ml I.V. glucose (0.5 gm/kg - 0.25 ml), 
tolbutamide (83 mg/kg - 0.5 ml) and insulin antibodies (0.25 ml - batch no. 
MF/GP/6-VA).
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5:5:3 Analyses see Study 1 except for glucose analysis
(a) Glucose analysis
Plasma glucose was measured by glucose oxidase method (Beckman glucose 
analyser) using the enzyme hexokinase.
5:5:4 Preparation of globulin fraction of insulin antiserum and normal guinea pig 
serum
The procedure followed was exactly the same as in Study 1 except that another 
batch of insulin antiserum was used (Batch no. MF/GP/6-VA)
5:5:5: Results
The IR-GIP, IR-RCP and plasma glucose levels are shown in Table 5:5 and Fig. 5:15 
The plasma immunoreactive GIP following oral triolein was significantly increased 
in all groups compared with the control rats (Group 1). However, no significant 
difference was observed in IR-GIP levels between any of the groups which had 
received oral triolein.
Immunoreactive plasma rat C-peptide (IR-RCP) levels were significantly higher 
(p < 0.0005) in the group given oral triolein (Group 2) than in the saline dosed group 
(Group 1). Significantly raised IR-RCP levels were observed in those groups 
receiving the B cell stimuli with or without insulin antibodies compared with the 
control group (Group 2) (p < 0.0005).
Plasma glucose levels were significantly raised in the group given insulin antibodies 
compared with those receiving normal guinea pig IgG (p < 0.0025). Both these 
groups had significantly elevated plasma glucose levels compared with controls 
(Group 2) (p < 0.0005).
The binding capacity of the antiserum injected into the rats was the same as in 
Study 2, as the same antiserum was used. The sera from the rats (Group 4) were 
screened for the presence of insulin antibodies. All rat sera showed insulin 
antibodies present at the end of the study and the residual insulin binding capacity 
was calculated to be 9.45 ng insulin per rat.
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Table 5:5
Endogenous C-peptide induced in h ib it io n  o f GIP release 
in  fa t  pretreated ra ts
mean ± SEM
Groups IR-GIP (n g /L itre ) IR-RCP (yg /L itre ) Glucose (m m ol/Litre)
Group 1
^o t r io le in  329 ± 21 
IV sa line
1.87 ± 0.24 3.4 ± 0.10
Group 2
T r io le in  687 ± 60 
IV sa line , NGPS
10.1 ± 1.56 3.2 ± 0.20
Group 3
T r io le in  683 ± 84 
IV Glucose, 
tolbutamide, NGPS
26 ± 0.57 8.8 ± 0.86
Group 4 
T r io le in
IV Glucose, 655 ± 59
tolbutamide,
and antibodies
23.7 ± 1 . 2 13.3 ± 0.45
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5:5:6 Discussion
Rats were maintained on a short term high fat diet in order to produce an 
increased GIP response to fat. Fat pretreatment did not result in a significant 
increase in GIP above those reported in Study 2 but the experimental design was a 
more physiological one.
No statistical difference was observed in GIP levels between any of the groups of 
animals receiving triolein. The previous studies had demonstrated inhibition of fat 
stimulated GIP release by both endogenous insulin and C-peptide. This suggests 
that the short term fat pretreatment may affect the control of GIP release. A 
defective feedback mechanism of insulin on fat stimulated GIP release in obese 
subjects has been demonstrated by Creutzfeldt et al. (1978). This defect can be 
explained by decreased number of receptors (Roth et al. 1975) on the GIP cell. The 
presence of C-peptide receptors has not been reported. It is possible to speculate 
that fat pretreatment causes a defect in the feedback mechanism on the GIP cell. 
The measurement of plasma C-peptide levels in each of the studies, reported in 
this chapter, showed a large variation in the basal values depending on the 
techniques used in the investigations. Comparison of C-peptide values in the two 
gut perfusion studies showed a two-fold difference in the basal values. In these 
studies the route of administration of intravenous substances was either via the ta il 
or jugular vein. It seems unlikely that changing the route of administration of the 
intravenously substances would alter the basal C-peptide levels. The gut perfusion 
technique necessitates a number of procedures involving handling of the gut which 
may affect basal C-peptide values. Measurement of rat C-peptide levels after oral 
triolein showed very low basal values indicating that the gut perfusion technique 
may have affected the C-peptide levels.
Previous studies in this department by Dryburgh et al. (1980) demonstrated that fat 
stimulated GIP release was inhibited by exogenous C-peptide. In this chapter 
investigations have been reported that indicate that endogenous C-peptide may 
indeed play a role in the control of GIP release. Several pathological conditions
which have exaggerated GIP responses with low circulating C-peptide levels due to 
defective secretion of the B cell have been reported, in untreated juvenile onset 
diabetics (Ebert and Creutzfeldt, 1978). mild chronic pancreatitis (Ebert et al. 
1976'$, Botha et al. 1978) and after duodenopancreatectomy (Creutzfeldt et al. 
1976 • ) These exaggerated GIP responses could, therefore, be explained by the low 
C-peptide levels being unable to regulate GIP secretion. Pretreatment of rats with 
oral fat appears to affect the inhibition of GIP release by both insulin and 
C-peptide. Further studies investigating whether short term high fat diets affect 
the inhibition of GIP release using exogenous insulin were carried out in both rats 
and man and are described in the following Chapter. The inhibition of fat 
stimulated GIP release by endogenous C-peptide should be studied in orally dosed 
rats maintained on normal laboratory food. Unfortunately, due to the short supply 
of insulin antiserum this could not, at present, be investigated.
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CHAPTER VI
THE EFFECT OF HIGH AND LOW FAT DIETARY REGIMENS 
ON THE ENTEROINSULAR AXIS RESPONSES TO FAT AND GLUCOSE
IN RAT AND MAN.
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6:1 Introduction
In the previous chapter inhibition of fat stimulated GIP release by endogenous 
insulin or C-peptide could not be demonstrated in fat pretreated rats. A more 
detailed investigation of the phenomenon was, therefore, carried out using 
exogenous insulin whose inhibitory properties on fat stimulated GIP have previously 
been documented.
As long ago as 1927 (Sweeney, 1927) dietary composition was shown to influence 
glucose tolerance in healthy individuals. Himsworth (1933, 1934) confirmed and 
extended this information to conclude that a high fat diet decreased glucose 
tolerance and that this decrease was due to changes in susceptibility to insulin. A 
number of workers (Zaragoza-Hermansr&Fdlder,T97Q5 Susini & Uvaul978,Lavau e t a l . 
1979) have demonstrated that short-term feeding of rats on a high fat diet in vivo and in 
vitro w ill induce an insulin resistant state.
Insulin resistance may occur due to an alteration at any one or all of three levels 
(1) prior to the interaction of insulin with the receptors (2) at the level of the 
receptor or (3) at steps distant to the insulin receptor interaction. Causes of 
insulin resistance at the prereceptor level include factors that reduce free insulin 
concentration, such as increased insulin degradation or insulin binding to proteins 
other than the receptor. At the level of the receptor, alteration in receptor 
affinity or concentration also result in a decrease in biological response to a given 
concentration of free hormone. Finally, any changes in the 'coupling function' 
between the concentration of hormone-receptor complexes and the final biological 
response would also result in tissue resistance to insulin action. Insulin resistance 
may be defined as a state where normal concentrations of hormone produce a less 
than normal biological response.
The initial step in the action of insulin on a tissue is to bind with a specific 
receptor on the membrane of the cell. Decreased cellular insulin receptors have 
been observed in a variety of tissues from obese animals (Kahn et al. 1973, 
Olefsky, 1976a) and man (Bar et al. 1976, Olefsky, 1976). A potential causal
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relationship between decreased insulin receptors and insulin resistance is obvious. 
However, the quantitative relationship between decreased insulin receptors and the 
biological effect of insulin is not straightforward because of the presence of 
"spare" receptors on insulin target tissues (Kono & Barham, 1971) The functional 
consequences of a moderate decrease in insulin receptors is a shift in the insulin 
biological function dose response curve, resulting in a decreased response to 
submaximal insulin concentrations but no change in the maximal response to the 
hormone (Kono&Barham,!971) Receptors are continually being synthesised and 
degraded (Kahn, 1976). A variety of factors regulate receptor concentrations. 
Plasma insulin levels appear to be a major factor and the effect is dependent on 
the duration of exposure to the hormone. Grundleger and Thenen (1982) 
demonstrated a decreased receptor number in soleus muscle of rat fed a high fat 
diet for a short time (10 days) but no change in receptor affinity. Other workers 
(Ip et al. 1976, Sun et al. 1977) observed a greater than 40 per cent decrease in 
insulin binding and receptor number, but no change in the affinity constant of 
either class of binding site in isolated fat cells or liver plasma membranes obtained 
from rats fed on a high fat, carbohydrate free diet. Other workers (Olefksy, 1976, 
Lavau et al. 1979, Grundleger and Thenen, 1982) have suggested that the decreased 
binding of insulin was not fully accounted for by decreased receptor number 
therefore additional defects distal to the insulin receptor complexes may exist. 
Glucose transport has been investigated in fat fed rats. Rats maintained on this 
diet transport glucose into muscles and adipocytes more slowly than rats 
maintained on a high carbohydrate diet (Lavau et al. 1979, Grundleger and Thenen, 
1982). Grundleger and Thenen (1982) showed that this impairment process of 
glucose metabolism was of far greater importance than the decrease in glucose 
transport. The glucose transport process, although depressed, may not be the rate 
limiting step.
Studies investigating the effect of a high fat diet on the intracellular metabolism 
of glucose in adipocytes and muscle cells have shown an impairment in insulin
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responsiveness. Increased fatty acid uptake and decreased conversion of glucose to 
fatty acids occurs in animals fed a high fat diet. The main function of adipose 
tissue is the synthesis and storage of lipids and mobilisation of this fuel storage for 
the provision of energy. In the adipocytes, obtained from fat fed rats, fatty acid 
synthesis is strongly inhibited and lactic acid production is increased together with 
glycerogenesis and glycogenesis (Susini &Lavau,197&) .In muscle tissue, a high fat 
diet, inhibits glycolysis whilst glycogen storage is only slightly depressed in both 
the basal and insulin stimulated states (Grundleger and Thenen 1982). Studies on 
enzymes such as hexokinase II (Marshall et al. 1976), pyruvate dehydrogenase 
(Griglio et al. 1969) and glucose 6 phosphate dehydrogenase (Lavau et al. 1979) 
have all shown decreased activity in tissues obtained from rats maintained on high 
fat diets. This would suggest that the unresponsiveness of the glucose metabolic 
pathway to insulin originates in the reduction in intracellular capacity to handle 
glucose entering the cell in response to the hormone. A modulation of insulin 
action via alterations of intracellular metabolism suggests a fine adjustment that 
allows a much more sensitive response than would be accomplished by the mere 
modification of the insulin receptor.
Reports in the literature show either no change (Lavau et al. 1979) a moderate 
decrease (Zarazoya-Hermans and Felder, 1970) or a rise (Grundleger and Thenen, 
1982) in basal plasma insulin levels in rats maintained on a high fat diet. The 
conflicting findings could, however, be due to variations in the age, the strain of 
rat, type of diet and time maintained on diet.
The relationship between the gastrointestinal hormone GIP and insulin release in 
response to oral glucose is well known. Several substances have been shown to 
inhibit GIP release namely insulin (Brown et al. 1975), somatostatin (Pederson et 
al. 1975), glucagon (Ebert et al. 1977) and C-peptide (Dryburgh et al. 1980). A 
number of factors are responsible for affecting GIP release. Absorption of
197
nutrients is necessary for GIP secretion, as has been demonstrated by studies using 
disaccharidase inhibitors (Ebert and Creutzfeldt, 1978) and non-nutrient dietary 
fibres (T4organ. e t al .1979,Jenkins e t a l . 1980)Changes in diet have been shown 
to effect GIP secretion. Reiser et al. (1980) placed volunteers on diets providing 
30% of total energy as either sucrose or wheat starch. They demonstrated that 
after oral sucrose a greater GIP response was observed in those subjects 
maintained on the sucrose diet, and concluded that induction of the intestinal 
enzyme sucrase on the high sucrose diet resulted in facilitation of GIP release 
because of the increased rate of absorption of sucrose.
Obesity is characterised by hyperinsulinaemia both in fasted and stimulated states 
and the resistance to both endogenous and exogenous insulin in obesity has been 
shown to be a progressive condition that comprises two main phases - an early 
phase without insulin resistance and a later phase in which insulin resistance 
becomes more apparent. The latter condition is associated with a decreased 
number of insulin receptors in all target tissues (Kahn et al. 1973). The decrease in 
receptors is related to the degree of hyperinsulinaemia and returns towards or to 
normal when the hyperinsulinaemia is corrected (Assimacopoulos-Jeannet and
JeahrenaudJ976).
Hyperinsulinaemia in obesity may be caused, at least in part, by an overactive
enteroinsular axis. An exaggerated GIP response after ingestion of a mixed meal
has been observed in obese subjects (Ebert et al. 1976) in whom exogenous insulin
fails to inhibit fat stimulated GIP release (Creutzfeldt et al. 1978). A fter 21 days
of starvation their GIP levels after a glucose load tend towards normal (Willms et
al. 1978). Similar results were obtained on diets providing only 800 calories per day
consumed for three weeks, thus the GIP response may be more dependent upon
previous diet than on body weight. Ebert et al. (1976) have shown that a diminished
GIP response was observed in obese individuals after only seven days on a reduced
energy intake. The mechanism causing hypersecretion of GIP release in obesity
may, therefore, be due to adaptation of the GIP cells to the incoming nutrient load 
and the ability of insulin to regulate GIP release.
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The ability of exogenous insulin to inhibit fat stimulated GIP secretion in both rats 
and humans maintained on low and high fat diets was investigated. In the human 
studies the experimental design was such that the high and low fat diets were not 
isocaloric and therefore body weight was carefully monitored. Investigations into 
GIP responses to oral fat and glucose were also carried out.
6:2 Materials and Methods
6:2:1 Investigations of the responses of the enteroinsular axis of rats pretreated on 
a high fat diet
Male Wistar rats weighing between 240-290 g were used in these investigations. 
The 180 rats were divided into two groups. The first group (fat-pretreated group) 
were given 3 ml triolein/day orally for 4 days prior to the experiments as well as 
being allowed free access to standard laboratory food. This provided 20% of total 
energy as fat. The second group (untreated low fat group) was fed on standard 
laboratory food which contained 3.5% energy as fat. Rats were weighed each day 
and fasted for 24 h prior to each experiment. Three experimental protocols were 
performed on fat-pretreated and untreated rats during which they were 
anaesthetised with intraperitoneal (IP) pentobarbitone (100 mg/kg body weight). 
Blood was collected by cardiac puncture into lithium heparin tubes and the samples 
were immediately centrifuged. Plasma for hormone and glucose estimation were 
divided and stored at -20°C.
6:2:2 Experimental Protocol
(a) Time course of responses to oral fat
Fat pretreated and untreated groups of rats were each divided into five sets (six 
rats/set). Set A from each group received no triolein. Animals in the other four 
sets (B - E) of each group received 1 ml triolein (8 kcal) orally. Blood was 
collected by cardiac puncture at 0 min (Set A) and at 30, 60, 120 and 180 min. after 
oral dosing (Sets B - E respectively).
(b) Effect of fat pretreatment on responses to oral fat with and without 
intraperitoneal insulin
Groups of fat pretreated and untreated rats were each divided into three sets (10 
rats/set) and given: Set A - 1 ml triolein orally 2 h before IP insulin (1 U/kg body 
weight); Set B - 1 ml triolein orally 2 h before IP saline (154 mmol/1); Set C - 1 ml 
saline (154 mmol/1) orally 2 h before IP saline. Blood was collected by cardiac 
puncture 20 min after the IP injection in all cases.
(c) Effect of fat-pretreatment on responses to oral glucose with and without 
intraperitoneal insulin
Groups of fat pretreated and untreated rats were each divided into three sets (10 
rats/set). Set A was given 3 ml 2.78 M glucose (5.8 kcal) orally 40 mins before IP 
saline (154 mmol/1); Set B: 3 ml saline (154 mmol/1) orally 40 min before IP saline 
(154 mmol/1) Set C: 3 ml 2.78M glucose (5.8 kcal) orally 40 min before IP insulin 
(I U/kg body weight). Blood samples were collected by cardiac puncture 20 min 
after IP injection in all cases.
6:2:3 Investigation of the response of the enteroinsular axis in man on a high fat 
and low fat diet
9 volunteers (6 male 3 female) aged between 23-31 years (28 -  1.87 x -  SEM) within 
20% of ideal body weight (Metropolitan life assurance tables) were investigated. 
Informed consent was obtained from all volunteers. There was considerable 
variation in the normal dietary fat intake of the volunteers ranging from 12-157 g 
fat per day (99 -  20.1 g). The percentage of energy derived from fat in their diets 
varied from 20-50% per day (38 -  2.5 g). The study was initially carried out in 5 
subjects. A further 4 subjects were investigated because one of the initia l group 
had to be excluded because of his excess fat intake. The first group (n = 5 3 males 
2 females) ate a low fat diet providing less than 30 g of fat per day (low fat) for 
nine days. After a further fifteen day period on their usual dietary regimen the 
volunteers ate a high fat diet for nine days. This was achieved by supplementation 
of their low fat diets with 250 ml of double cream and butter per day providing 
140 g fat. They were, therefore, consuming in excess of 140 g fat per day. Their
zuu
energy intake during this time was similar to their normal intake.
The second group of volunteers were maintained on a reversed dietary regimen i.e. 
high fat before low fat diet. This second group was carefully assessed beforehand 
to ensure only those whose fat intake was usually less than 130 g of fat per day 
took part. All volunteers were weighed throughout the studies. Three test meals 
were given to each volunteer. Blood was collected by means of an indwelling 
catheter inserted into the antecubital vein and kept patent with 0.12M sodium 
citrate. Blood samples were collected into lithium heparin and fluoride oxalate 
tubes. The samples were immediately centrifuged and aliquoted. Plasma was 
stored at -20°C  until assayed.
6:2:4 Experimental Protocol
(a) Effect of a high and low fat diet on responses to oral fat
200 ml of double cream (96 g fat) was given to the second group of volunteers (4) 
on day nine of the low and high fat dietary regimens after an overnight fast. Two 
volunteers from the first group were also given a fat load after being maintained 
on a high fat diet for a second time. Two basal blood samples were taken prior to 
ingestion of the cream. Blood samples were then taken after 30, 60, 90, 120, 150, 
180 and 210 minutes.
(b) Effect of a high and low fat diet on responses to oral fat with exogenous insulin 
Following an overnight fast on day seven of both the low and high fat diets all the 
volunteers were given oral fat followed by intravenous insulin.
Two basal blood samples were taken prior to ingestion of the cream (96 g fat) and 
blood samples were then taken 30, 50 and 60 min then insulin (0.2 U/kg body 
weight) was given intravenously to each volunteer. The first group had insulin 
injected via the blood sampling catheter while the second group had the insulin 
injected into the other arm. Blood samples were taken 90, 120, 150, 180 and 210 
min after the start of the test.
(c) Effect of a high and low fat diet on responses to oral glucose 
On day nine of the low and high fat diets the first group of volunteers (5) were 
given 75 g of liquid glucose orally (Hycal). A fter an overnight fast two basal blood 
samples were taken and then the Hycal made up to 250 ml with water was given to 
each volunteer. Blood samples were taken at 30. 60, 90, 120, 150, 180 and 210 min 
after the glucose load.
6:2:5 Chemical analyses
Plasma immunoreactive rat insulin was measured by a double antibody 
radioimmunoassay employing an antiserum raised against porcine insulin (batch no. 
MF/GP/10-VA), iodinated bovine insulin and a rat insulin standard ( lo t  no. RC 
791009). The sensitivity of the assay was 0.5 yg/Litre and the interassay 
coefficient of variation was 15.6% at 0.5 yg/Litre and 6.7% at 6.7 yg/L itre.
Plasma immunoreactive human insulin was measured by a double antibody 
radioimmunoassay employing an antiserum raised against porcine insulin (HP/G P/3- 
VA), iodinated bovine insulin and a human insulin standard (NI5BC 66/3004). The 
sensitivity of the assay was 2.5 m U/Litre and the interassay coefficient of 
variation was 15% at 6.5 m U/Litre and 7.4% at 46 m U/Litre.
Plasma immunoreactive human C-peptide was measured by the method described in 
Chapter II. The assay has a detection lim it of 10 pg/tube (10 ng/Litre). The 
interassay coefficient of variation was 24.5% at 0.44 yg/Litre and 9% at 
3.7yg/Litre.
Immunoreactive GIP was measured by a double antibody radioimmunoassay (Morgan 
et al. 1978). A porcine GIP standard was used but parallelism was demonstrated 
between the standard curve and serially diluted samples of both rat and human 
plasma containing high levels of endogenous GIP. The assay sensitivity was 
llOng/Litre and the interassay coefficient of variation was 4.1% at 2677 ng/Litre 
and 22.5% at 138 ng/Litre.
Rat plasma glucose was measured using a glucose oxidase method. Glucose 
estimation on human samples utilised the enzyme hexokinase in an automatic 
glucose analyser. Plasma triglyceride were measured in rat plasma by a fully 
enzymnatic U.V. kit and in human samples by an enzymatic colorimetric kit.
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6:2:6 Statistical analyses
Results were compared using Student's t test for unpaired, paired data and analysis 
of variance.
6:3 Results
6:3:1 Investigation of the responses of the enteroinsular axis of rats pretreated on 
a high fat diet
The untreated control rats were slightly, but significantly heavier than the fa t- 
pretreated rats, throughout the study. There was, however, no significant weight 
gain in either group of rats on completion of the fat-pretreatment (control rats 
297.0 -  4.14 before pretreatment versus 297.5 -  4.13 g after pretreatment p NS; 
fat pretreatment rats 280.2 -  4.96 g before pretreatment versus 279.0 -  10 g after 
pretreatment p NS; x — SD n = 60). There were no significant differences in fasting 
plasma glucose, insulin or GIP levels between the two groups on completion of the 
fat-pretreatment.
(a) Time course of response to oral fat
Mean GIP levels were consistently higher in animals in the fat-pretreated sets, but 
the differences did not reach statistical significance at any single time point 
(Figure 6:1). However, when the data was subjected to analysis of variance (two 
factor with replication) the two groups were found to be significantly different at 
the 5% level.
Plasma triglyceride concentrations (Figure 6:2) were significantly higher in the fat 
pretreated rats than in the controls at 120 and 180 min (p < 0.01) and were 
associated with marked lipaemia in the former but not the latter.
(b) Effect of fat pretreatment on response to oral fat with or without exogenous 
insulin
In the untreated control group of rats administration of IP insulin caused a 
significant inhibition of triolein stimulated GIP release ( Plasma GIP levels in 
animals given oral trolein + IP saline 853 — 93 ng/Litre in those given triolein + IP 
insulin 663 -  49 ng/Litre p < 0.025) not observed in the fat-pretreated rats which
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showed similar triolein-stimulated GIP levels whether they were given IP insulin or 
saline (1008 — 95 versus 1116 -  100 ng/Litre pNS). Plasma glucose levels in rats 
given IP insulin after oral fat fell significantly less in the pretreated than in the 
untreated controls (2.6 -  0.48 versus 1.57 -  0.15 mmol/Litre p < 0.05) although 
plasma insulin levels 20 min after insulin injection were similar in the two groups 
(4.1 -  1.7 versus 4.7 -  1-22 yg/Litre pNS , Fig 6 .3 )
(c) Effect of fat pretreatment on the response to oral glucose with and without 
intraperitoneal insulin
Following oral glucose, fat-pretreated rats had significantly higher levels of plasma 
glucose (10.2 -  0.39 versus 8.9 -  0.41 mmol/Litre p < 0.025) and insulin (6.2 + 1.2 
versus 2.5 + 0.59 yg/Litre p < 0.01) one hour after dosing than untreated controls 
(Figure 6:4). Plasma GIP levels showed a tendency, significant at the 10% level, to 
be higher in the fat-pretreated group compared with their untreated controls.
No significant difference was observed in plasma immunoreactive insulin and 
plasma glucose levels in pretreated rats given oral glucose intraperitoneal insulin 
compared with the untreated control group.
6:3:2 Investigation of the responses of the enteroinsular axis in man on high and 
low fat diets
No significant change was observed in the weight of the volunteers during the
entire study (Table 6:1). Basal triglyceride, insulin, C-peptide and GIP levels were
not significantly different on the two dietary regimens. Basal LSI levels were
elevated on the high fat compared with the low fat diet (29 -  2.9 versus 19 -  1.44 LSI
x + SEM p < 0.025.)D ietary energy intake records were maintained thoughout the 
study periods (T'able- 6:2)
(a) Effect of high and low fat diets on responses to oral fat
Figure 6:5 shows the plasma immunoreactive GIP concentrations which were not 
significantly different after fat loads on high and low fat diets.
Basal plasma glucose levels were similar throughout the fat loads on both diets.
Plasma C-peptide and insulin levels showed no significant rise after oral fat 
throughout the study. No significant difference was observed between insulin and 
C-peptide levels on the two diets.
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Effect of high and low fat diets on bodyweiqht in man 
Mean -  SD n = 9
Low fat diet: start (Day 1): 66.4 -  9.6 kg
end (Day 9) : 66.1 -  10.1 kg
High fat diet: start (Day 1) : 66.4 -  9.3 kg
end (Day 9) : 66.4 -  10.1 kg
D
A
IL
Y 
EN
ER
GY
 
AN
D 
FA
T 
IN
TA
K
E
209
>-<o
<h-
I—
<
CO
CM o ,__
LTV ‘
+
+  1 +  1
CNI
O .— L A
OO CM ■—
> - -— -
< CM ---- s ----s
O LO c o r—
\ CO CO CO
LLl CO CO
id +  1
< +  1 +  1
f - OO
z OO CO LO
— — LO CM
,— „ CM CM CO
> - r— - ---- -— CM
CD CD v— ■ - ----
CC u OO
LlJ CM CO CO
Z — CM 00 r - .
UJ
—) +  1 +  1 +
z V
< OO CO vO
UJ CM CO LO
2: LO CM LO
•  +->  4-> a>
(U - r -  
• r -  X J-a •a+J fO 
cO 4 -  
4 -
sz 
5  cr>
LO
CU
-Q n3
00 h-a UJ
LO ~
OO Q
+  1 00 .
CL _ l Ll Ll
c 3 < • •
CD O c 3 _ J 3
<u on — • cn •
2: CD 3 ln LO
E E S- S-
<u cu+j +j
+j +j 
s - s -  
o  o-C JC 
CO CO
Lt_ Ll. 
 i  •:n 
•  •
CO CO
210
to+Ja>
+j(O
<+-
c-s
T3
c .03
c
o
‘+-><0q-
fO
S-
o
o+->
tocu
to
sz
o
C l­
io(U
S-
CSj
(U
>•r—
+->
a(O
CD
i -
o
re
tore
t o
to
<us-
c r:
CO r-
Orco
o
“CM
,o
CD
O
O
O
CO
ooo
CM
— t—ooo
Ti
m
e(
m
in
)
211
(b) Effect of high and low fat diets on responses to oral fat with exogenous insulin 
All volunteers experienced a number of side effects approximately twenty minutes 
after insulin infusion. These lasted for varying lengths of time and included 
sleepiness, sweating, deterioration in vision and finally hunger. All volunteers 
stated that after the second insulin stress test these effects were less dramatic and 
persistent.
One volunteer from the initial group was excluded from the study since his normal 
dietary fat intake (157 g of fat per day) was very high.
After oral fat. plasma GIP secretion was inhibited by exogenous insulin on the low 
fat diet but not on the high fat diet in the remaining eight volunteers (Fig. 6:6) 
(AUC plasma GIP : 3979 -  547 pgml ^.hr (x — SEM) after fat + insulin versus 5490 — 
599 pgmF^.hr after fat alone on LFD, p < 0.01 5652 -  962 pgml'^.hr versus 4503 — 
654 pgml’ ^hr on HFD. p NS). The volunteer with the normal high fat intake showed 
no suppression of GIP release with IV insulin on the low fat diet.
Plasma glucose levels (Figure 6:7) were significantly lower on the low fat diet after 
the insulin compared with the high fat diet at all timepoints. Plasma glucose levels 
were plotted as a percentage fall of-glucose levels from basal values since basal 
levels were elevated on the high fat diet (Fig. 6:8) Normoglycaemia was achieved 
faster whilst on the high fat diet than on the low fat diet.
Plasma insulin levels were measured in four volunteers. No significant difference 
was observed in basal levels or in the disappearance rate of exogenous insulin.
Figure 6:9 shows the mean plasma C-peptide levels which were not significantly 
different on either diet.
Plasma triglyceride levels were significantly raised 180 min after oral fat on the 
high fat compared with the low fat diet (1.6 — 0.2 versus 1.14 -  0.12 m m ol/Litre  
p< 0.025) calculation of the area under the curves showed a significant increase in 
plasma triglyceride levels on the high fat compared with low fat diet (AUC  
triglycerides 1.27 -  0.09 mmol/Litre .hr (x -S E M ) on HFD than on LFD 6.38 -  
0.12 mmol/Litre .hr. p < 0.005) (Fig. 6:10)
212
CO4->
CD
+->
<d4-
co
•I—x:
-ae
<d
> ,J=!
-a
<l>
o4-
n34-
rdJ-
o
S-
a j+->4—rd
CD
>a)
CD
a>
>
•r~
+->O
rd<u
S-
o
£Z
ZJ
VO
co
a)
s_=3cn
O)c
Q.
0
o o o o
6 0 0 0
V V V V
a a a a
*  *  
*  *  *  
*  * *  *
o
LOO
o
CO
•o
r-
O
oo
CO
--T“
oo
o
CM
Ti
m
e(
m
in
) 
12
0
in  
+-> 
cu
+->
03q-
J Z
CTj
T3c
05
13inc
>>XJ
■oai
2:
o
o
q -
+->ra
q -
03
S-
o
S-aj
+->
q -
03
a>w
ou
Z3
rc5
£
in
03
in
m m cm incvio ooo
66  o o 
v v v v 
a a a . a
# ♦ # 
* * 5 
*  *  
♦
213
*
*
%
O
E 
E
LU 
( / )
cr. 8
c  3
a
io
cu
i -
3
a> ®
"D'D 
>  LU
.2>g <0 CO
I - J  +1 II 
•  o H Z
13
ZT
CM
6
c
3
0 )c
8
c
J ,
o
E
P
.o
CD
h O
r -in To" CM o
214
to
4->
<U
-P
rd
oo
T3
sz03
c
o
Z3
to
•c
to
o
o
c:
cu
>
rdS-
S-
<u
+->
<+-
rd
<u
to
o
o
zs
CD
rd
LL
tord
0)>
0)
(0
CO
(0
•Q
lE
in
^  CN lOr-o o
O O
X v a a
♦
*  *
CD
CDC
rd
-Co
a>cn
rd
+->
c
a>
o
S-
<ua.
oo
to
a>
s_
ZJ05
LU
C/)
8
_ l
a
a >  a >
B B  
-»-< ■*-<
CO (0 *5
x; > HI 
D)g cn 00
if  3  +*i ii
•  O I— I z
5 '
-Q
O )
X
N .
D
CN
O
$z
ohco
„o
<o
oa)
—r~o
12
P 
Tim
e 
(m
i n
)
Fi
gu
re
 
6:9
 
Pl
as
ma
 
im
m
un
or
ea
ct
ive
 
C
-p
ep
tid
e 
le
ve
ls
 
af
te
r 
or
al
 
fa
t 
fo
llo
w
ed
 
by 
in
tra
ve
no
us
 
in
su
lin
 
on 
lo
w
and
 
hig
h 
fa
t 
di
et
s"
!
215
a>
■a
$
i
O *  wII +
Z  I— I
o a) 
■5 S
O) |
i f  3
o
Lo<o
r—
CM
Ti
m
e(
m
in
) 
12
0 
18
0
mm
o 
l .
L
. h
r
216
Figure 6:10 Incremental p lasma tr ig ly c e r id e  leve ls on both
low and high fa t  d ie ts .
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(c) Effect of high and low fat diets on the response to oral glucose 
Plasma insulin levels were not significantly different after oral glucose on the two 
diets (Figure 6:11). Plasma C-peptide levels were significantly elevated 150 min 
after oral glucose on the low fat compared with the high fat diet (3.3 -0 .7  versus 
1.8 -  0.3 yg/Litre p < 0.025) (Fig. 6:12). Correlation of insulin and C-peptide levels 
between 60-210 min. after oral glucose was carried out. A significant correlation 
was obtained on the low fat diet (coeff. of corr. = 0.47 p < 0.05) but not the high 
fat diet (coeff of corr = 0.28 pNS).
The plasma glucose levels were statistically similar on both dietary regimens 
following oral glucose. (Fig. 6:13).
6:4 Discussion
The dietary intake of rats can be controlled within very narrow limits. Normal fat 
intake of rats maintained in laboratory conditions is approximately 3.5% of their 
diet, which is very low when compared with levels usually found in Western man's 
diet. Oral fat dosing of rats increases their fat intake to 21%, which, although 
abnormal for the rat is closer in composition to a typical Western diet.
Humans have a large degree of variation in their daily fat intakes. In most 
prosperous countries fat usually contributes 35% to 45% of the total energy intake 
while in poorer countries this figure is about 15% or even lower. In order to 
maintain human subjects on diets of varying fat content the majority of dietary fat 
can be withdrawn and replaced by one substance so that the fat intake can be 
carefully controlled. The amount of fat in the diet prior to the study appears to 
effect the GIP responses to an oral fat load in rats. However, human subjects 
showed no change in GIP response which may be explained by the large variation in 
their normal dietary fat intake.
Maintaining both rats and humans on either short-term high or low fat dietary 
regimens results in no change in weight. Grundleger and Thenen (1982) maintained 
rats on both high fat and high carbohydrate diets for ten weeks and observed no 
increase in body weight in either case. Lavau et al (1979) fed rats low or high fat
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diets and observed no difference in their weights after four weeks, although 
epididymal adipose tissue ancl ce^ size increased during the high fat diet.
On the high fat dietary regimen both rats and humans showed increased 
triglyceride levels following oral fat compared with a low fat diet. This increase 
was more marked in the rats than in the human subjects. Adaptation of the 
enzyme pancreatic lipase to dietary lipids has been reported in the rat (Deschodt- 
Lanckman et al. 1971). Unsaturated fatty acids stimulate lipase significantly more 
than saturated fatty acids. This increase in activity of pancreatic lipase has been 
reported in other animals (Behrman and Kare, 1969, Wills and Hinners, 1968). 
Dietary enzyme adaptation has been reported to take only 2 to 3 days, the enzyme 
levels being stabilised after 3 to 7 days. However, it has been suggested that 
changes, such as increased absorption of lipids, depends also on the adjustment of 
other digestive processes such as gastric emptying or intestinal motility.
GIP levels were elevated following oral fat in rats pretreated on a high fat diet 
compared with their unpretreated controls but no such increase occurred in the 
human subjects. A possible explanation for this difference is that the habitual fat 
intake of the human subjects was much greater than that of the rats and therefore 
the proportional increase in fat intake was not as great in the human subjects when 
placed on the high fat diet. The fat intake of the human volunteers was extremely 
variable ranging from 12 to 137 g per day considerable more variation than 
observed in the rats. At the end of the human study one volunteer was excluded 
who had a normal dietary fat intake of approximately 157 g per day while the 
other participants had an intake of less than 127 g of fat per day. These volunteers 
when on the high fat diet had a minimum fat intake of 135 g per day, resulting in a 
large increase in fat content compared with the low fat regimen and an increase of 
greater than 34% above their normal dietary intake.
There is some evidence that the rate of absorption is a factor in determining the 
magnitude of the GIP response. A reduction of nutrient absorption rate in certain 
diseases, such as untreated coeliac disease (Creutzfeldt et al. 1976o) and marked
malabsorption (Besterman et al. 1979) and the addition of the unabsorbable
carbohydrate guar gum to the meal (Morgan et al. 1979; Jenkins. 1980) have all 
been shown to depress GIP response to oral nutrients.
Exaggerated GIP responses to a mixed meal have been reported in obese subjects 
(Creutzfeldt et al. 1978). These could, however, be reduced by dietary restriction 
(Willms et al. .1978). Reiser et al. (1980) showed that maintenance on a high 
sucrose diet resulted in a greater GIP response to sucrose compared with subjects 
on high starch diets. Diet composition, therefore, appears to be more relevant 
than body weight in determining the magnitude of GIP response to oral nutrients. 
The data from the rat study support this concept but because human subjects 
habitually consume more fat than rats longer term dietary modification may be 
necessary in order to show any modification of GIP secretion in response to oral fat 
in man.
A number of workers (Brown et al. 1975,Crockett et al. 1976) have shown that 
intravenous infusions of insulin or glucose reduced the rise in fat stimulated GIP 
levels and. therefore, a negative feedback control of insulin on GIP release has 
been suggested. In the rat study the untreated group showed inhibition of fat 
stimulated GIP release by exogenous insulin but this was not observed in the fat 
pretreated group. In the human studies, the eight volunteers, who had a fat intake 
of less than 130 g per day, showed inhibition of GIP release to insulin on the low fat 
diet but no effect was apparent on the high fat regimen. One subject in the initial 
study had a habitual high fat intake and appeared insensitive to insulin on both 
dietary regimens. Creutzfeldt et al. (1978) have observed in obese subjects that 
there is also a defective insulin feedback mechanism. The experimental design of 
the human studies, was such that low and high fat diets were randomised. It was 
therefore, possible to show that the sensitivity of the GIP cells to insulin could be 
reversed after a short-term dietary change.
A degree of insulin insensitivity was observed in both rats and human on short term  
high fat diets. This was more marked in the rodent study. Other workers
(lavau e t al.1979, Grundleger and Thenen] 982)1-^0 investigated the effect of 
high fat diets in order to establish what causes the change in insulin sensitivity. 
Investigation into insulin receptor number in human monocytes (Pederson et al. 
1980) and rat soleus muscles (Grundleger and Thenen, 1982) have showed that they 
are altered by dietary changes. Grundleger and Thenen (1982) have demonstrated 
that although receptor number decreased on a high fat diet, post receptor changes 
were far more important in contributing to insulin sensitivity.
In obesity insulin resistance also occurs at the level of the target tissues. The B 
cells of obese animals oversecrete insulin and the hepatic clearance of insulin is 
decreased. The concentration of insulin in the portal vein is raised so that more 
insulin reaches peripheral tissues (Karakashi et al. 1976). Insulin and C-peptide 
levels showed a positive correlation at the 5% level on the low fat diet after oral 
glucuose. No such relationship could be reported on the high fat diet. More data is 
required from a large number of subjects before any definite conclusions can be 
drawn.
Exogenous insulin (0.2 U/kg bodyweight) in normal subjects generally results in mild 
to moderate neuroglycopenic symptoms commencing twenty to thirty minutes after 
the insulin injection and lasting ten to thirty minutes. In the human studies all 
subjects experienced such symptoms on both dietary regimens. The initial insulin 
stress test appeared to produce the most severe symptoms irrespective of the 
regimen and the after effects were prolonged for a considerable period. The 
plasma glucose levels although significantly elevated on the high fat diet after the 
insulin stress test had little  effect on the actual recovery time and severity of the 
symptoms experienced by the subjects. It would, therefore, appear that the 
reduced severity of the symptoms experienced after the second insulin stress test 
was due to the mental and physical awareness of the effects of insulin.
In conclusion, increased intake of a particular nutrient i.e. fat resulted in a state of 
mild insulin insensitivity in both man and rats and hypersecretion by GIP cells in 
rats. Pathological conditions characterised by hyperinsulinism such as obesity
(Creutzfeldt et al. 1978) and maturity onset diabetes (Brown et al. 1975) may be 
partly due to an overactive enteroinsular axis caused by previous dietary intake.
CHAPTER VII
FINAL DISCUSSION
7:1 Human C-peptide radioimmunoassay
An assay for the measurement of human C-peptide has been developed suitable for 
routine hospital laboratory use. Although there have been previous reports of C- 
peptide assay described in the literature, there have been problems concerning the 
standardisation of the assay which were still unresolved when this assay was 
developed.
A prerequisite for developing a radioimmunoassay is an adequate supply of C- 
peptide for use as immunogen and standard. Human C-peptide is required since 
there is a large species variation in the primary structure of this peptide. The 
rarity of natural human C-peptide has made it essential to synthesise the peptide in 
order to obtain sufficient quantities for radioimmunoassay development. Recently 
a biosynthetic human C-peptide has been produced which w ill hopefully be 
available in sufficient quantity to overcome this problem. Natural human C-. 
peptide contains thirty-one amino acids. However, some "so called" synthetic C- 
peptides contain extra amino acids and functional groups. Kaneko et al. (1974) 
reported the development of a human C-peptide assay using antisera raised against 
a 35 amino acid peptide, whose crossreactivity with natural human C-peptide was 
claimed to be similar to the synthetic peptide. Work described in Chapter II has 
demonstrated that many C-peptide standards are not pure or do not always run 
parallel to endogenous C-peptide depending on assay conditions. The lack of an 
international C-peptide standard has lead to the development of many different 
’in house' standards. It will not be until biosynthetic human C-peptide is available 
in sufficient quantity and purity, that the problem of standardisation w ill be finally 
resolved.
Normal mean overnight fasting C-peptide values vary widely between laboratories 
ranging between 1.1-2.45 yg/Litre (Block et al. 1972, Kaneko et al. 1974. Heding 
and Rasmussen. 1975, Beischer et al. 1976). This may be due, in part, to the lack 
of an international standard. However, there have been reports that circulating C- 
peptide is heterogenous and this may contribute to the large variation in fasting
values. Various closely related peptides with different immunogenic properties 
have been identified in serum (Kuzuya et al. 1977, Kakita et al. 1980). A number 
of workers have reported that different C-peptide antisera gave different values 
with the same plasma sample (Heding, 1975, Kuzuya et al. 1978). Serum samples 
have been shown to contain small and large molecular weight substances whose 
chemical identity is unknown and which crossreact in the C-peptide assay (Kuzuya 
e t aVI 977,1978, Kakita et al. 1980).
The production of a human C-peptide antiserum raised against the peptide coupled 
to ovalbumin by gluteraldehyde at the N terminal glutamic acid residue has been 
described in Chapter II. This is the first report of an antiserum raised against C- 
peptide using this conjugation method, and has theoretical advantages over the 
carbodiimide method of conjugation used by other workers (Melani et al. 1970, 
Beischer et al. 1976) which has been discussed previously. The C-peptide antiserum 
was raised in a primitive breed of sheep (Soay) since attempts in rabbits proved 
unsuccessful. The Soay was chosen since these animals have previously proved 
successful in producing antiserum to non immunogenic compounds and a better 
immune response should occur theoretically in primitive breeds of animals. Human 
C-peptide antiserum has been raised by other workers in goats, guinea-pigs and 
rabbits (Melani et al. 1970. Kaneko et al. 1974. Heding, 1975, Beischer et al 1976). 
Due to the low immunogenicity of C-peptide high titre antiserum was not obtained 
from the sheep. Sufficient antiserum was, however, obtained due to the large 
volume of blood which could be obtained from the animal.
C-peptide and insulin are released in equimolar amounts from the pancreas. 
However, the measurement of C-peptide, as well as insulin, can provide additional 
information on B cell function and in certain situations, outlined below, it has 
advantages over insulin measurements.
The difference in the half lives between insulin and C-peptide makes them suitable 
for investigating different aspects of B cell function. The half-life of C-peptide 
has been reported to be longer than that of insulin. Published data concerning the
half-life of C-peptide have reported values anywhere between 11-33 minutes 
(Horwitz et al. 1973. Munemura et al. 1974, Kutuza and Maksuda 1976, Faber et al.
.Ij976» Krause 1977). This large disagreement in the calculated half-life of C- 
peptide is due, in part, to experimental design and degree of crossreactivity of 
proinsulin in the C-peptide assay. The slower metabolism of C-peptide compared 
with insulin makes it impractical to measure it when short, rapid, changes in B cell 
secretion are being studied. Insulin is, therefore, a better indicator of rapid 
changes in B cell secretion because of its shorter half-life . However, when looking 
at an overall effect it is possible to measure C-peptide levels at less frequent 
intervals than insulin and still obtain a reliable estimation of the integrated B cell 
response.
Another method of obtaining an estimation of integrated B cell function is to 
measure urinary C-peptide levels. The C-peptide radioimmunoassay can be easily 
modified to measure levels in urine. Several workers have reported C-peptide 
levels in urine (Kuzuya et al. 1976, Horwitz et al. 1977, Meistas et al. 1981). The 
urinary clearance of C-peptide is approximately 5% compared to 0.2% for insulin. 
This makes it possible to measure urine C-peptide levels in clinical situations 
where insufficient or no serum can be obtained, for example, in infants.
Differences in the basal circulating concentrations of C-peptide and insulin have 
meant that there are advantages in measuring C-peptide rather than insulin in 
basal conditions and when the B cell is suppressed. Mean fasting plasma C-peptide 
level in normal subjects, measured in the assay described in Chapter II, was 1.38 -
0.61 yg/L itre. The assay was developed to be extremely sensitive having a lim it of 
detection calculated to be 10 pg (Feldman and Rodbard, 1971) corresponding to a 
concentration in unextracted plasma of 0.1 yg/Litre which is well below normal 
fasting levels. However, fasting plasma insulin levels in normal subjects are 
approximately 10-fold lower between 0.12 - 0.2 yg /L itre (3-5 m l/L itre ) which is 
near, and sometimes, below the detection lim it of most insulin assays. The 
measurement of fasting C-peptide levels would, therefore, be expected to give 
more reliable results.
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The C-peptide primary sequence is contained within the 
proinsulin molecule and therefore antisera prepared against human C-peptide 
crossreact with human proinsulin. The C-peptide antiserum described in Chapter II 
has a crossreactivity of 10 per cent with proinsulin. This is lower than the 
proinsulin crossreactivities previously reported for other human C-peptide assays 
which are generally between 15-66 % (Melani et al. 1970, Kaneko et al. 1974, 
Caygill et al. 1980). It is important to know the degree of crossreactivity in the 
assay but whether a high or low crossreactivity is advantageous depends on the 
clinical situation. Most insulin antisera, however, generally crossreact to a very 
much larger degree with human proinsulin than does the C-peptide antiserum 
described in Chapter II. In addition, assessment of some insulin antisera has shown 
that the crossreactivity with proinsulin is variable, dependant upon the relative 
concentration of proinsulin and insulin.
The addition of a tyrosine residue to the N terminal end of the C-peptide molecule 
made it possible to produce an iodinated peptide. Difficulties were, however, 
encountered in producing a tracer of sufficiently high specific activity for use in an 
assay without causing damage to the peptide. Eventually a lactoperoxidase method 
was used in which the reaction was stopped after only fifteen seconds. Other 
workers have reported no such difficulties in producing an iodinated C-peptide 
either using lactoperoxidase or chloramine T methods (Kaneko et al. 1974, Beischer 
et al. 1976) which, once again, suggests that the nature of the synthetic peptide 
must be important.
7:2 B cell function in normal human subjects : the relevance of immunoreactive 
C-peptide measurements.
The large variation in reported fasting C-peptide values makes it essential to 
establish our own reference plasma C-peptide levels using the assay described in 
Chapter II, in response to a variety of stimuli. The measurement of C-peptide 
levels in normal subjects has led to several observations.
The correlation between fasting plasma C-peptide levels and body weight was
calculated in normal non-obese volunteers since Krause (1977) had reported the 
dependence of basal plasma C-peptide levels on body weight. This might have been 
expected since insulin and body weight have previously been observed to be 
correlated (Bagdade et al. 1967).
Blood samples were obtained hourly from ten normal non-obese subjects for 24 
hours after a test meal. Calculation of mean fasting plasma C-peptide levels from 
10 hours after the meal gave a mean value of 1.7 -  0.2 yg/Litre. Previously 
reported mean fasting plasma C-peptide levels were 2.53 — 3.8 yg/L itre over a 24 
hour period but this data was obtained from six normal pregnant women allowed 
three meals during the study (Lewis et al. 1976).
Ingestion of a mixed meal at 1000 h produced an increase in C-peptide levels 
approximately 4-fold above basal values. Ingestion of the same meal at 0200 h 
produced a significantly greater integrated C-peptide and insulin response. 
However, as the sampling time points in this study were hourly it is d ifficult to 
draw any firm conclusions and the six meal study was, therefore, carried out.
The "six meal" study clearly showed that peak plasma insulin levels varied 
depending on the hour at which the meal was eaten. Meals were eaten on six 
separate occasions at different times in a 24 hour period. Variation in the time of 
the meal also affected the time at which peak post prandial plasma insulin and 
C-peptide levels were obtained. Plasma insulin levels reached a maximum 
approximately thirty minutes after the test meals consumed at 1 0 0 0  h and 0 2 0 0  h. 
However, maximum levels occurred 90-120 minutes after the other meals. This 
variation was also reflected in the C-peptide data. Insulin secretion is dependent 
not only upon the circulating glucose levels but also upon insulinotropic gut 
hormones which are secreted when carbohydrates are taken orally. This component 
of insulin secretion has been termed by Linger and Eisentraut (1969) "the 
enteroinsular axis" . A potential major component of the enteroinsular axis is the 
gastrointestinal hormone, GIP. In order to ascertain to what extent the changes in 
B cell response were due to changes in the enteroinsular axis when meals were
eaten at different times of the day volunteers were given i.v. glucose loads at 
1000 h and 0200 h on different occasions. Differences in B cell response to 
intravenous glucose at different times were very small. The two intravenous 
glucose loads gave similar peak and integrated plasma insulin responses. However, 
the integrated C-peptide response was slightly but significantly greater in response 
to the test carried out at 0200 h. These results demonstrate that the longer half- 
life of C-peptide has made it possible to detect small difference in the B cell 
response to glucose loads which is not possible by monitoring insulin levels and 
sampling at the same time points.
Since differences in maximum insulin levels were observed when nutrients were 
given orally at different times of the day it is suggested that changes in the 
enteroinsular axis might be partly responsible. However, the height of peak plasma 
GIP levels following a meal did not depend on the time at which the meal was 
eaten. The nature of the component of the enteroinsular axis which might be 
causing these differences in insulin secretion observed, therefore, remains 
unknown.
Integrated C-peptide and insulin responses in the first six hours after each meal 
were compared. It was unexpected to find that they did not show any significant 
correlation. A similar lack of correlation was found in response to intravenous 
glucose.
Insulin and C-peptide are mainly metabolised by different organs in the body. A 
large proportion of secreted insulin is extracted during its initial transit through 
the liver (Samols and Ryder, 1961) while C-peptide is not extracted to any 
significant degree (Stoll et al. 1970), the kidney being the major organ responsible 
for its degradation and removal.
It was possible to correlate peripheral insulin and C-peptide in seventeen non-obese 
volunteers in the fasting state. However, no such correlation was observed after 
intravenous glucose or a test meal. The extent of correlation of insulin and 
C-peptide is related to hepatic insulin clearance on the one hand and the removal
of C-peptide by the kidneys on the other. In chronic renal failure patients both 
insulin and C-peptide levels have been reported to be elevated. Jaspan et al. (1977) 
reported that such patients had no correlation between plasma insulin and 
C-peptide levels. A reduction in hepatic insulin clearance has been observed in 
subjects with mild glucose intolerance. Malmquist et al. (1981) studied normal and 
mildly glucose intolerant males and demonstrated that insulin C-peptide ratios 
were elevated in the latter. The volunteers in the present study were neither obese 
or glucose intolerant and had normal hepatic and renal function. The reason for 
the failure to correlate stimulated insulin and C-peptide levels is not clear, 
although this might be possible if the number of volunteers in the study and the 
frequency of sampling were to be increased.
7:3 The diagnostic use of C-peptide estimations.
Human C-peptide plasma levels have been estimated in a wide variety of clinical 
conditions (Horwitz et al. 1978, Molar et al. 1978). The C-peptide assay described 
in Chapter II has been used to assess plasma C-peptide levels in certain specific 
clinical conditions. Its main use has been in the diagnosis of patients with insulin 
producing tumours. The major clinical manifestation in these patients is 
hypoglycaemia due to inappropriate secretion of insulin. The definitive diagnosis 
of an insulinoma takes place in three stages
(a) The suspicion and demonstration of recurrent hypoglycaemic attack followed 
by
(b) biochemical analyses to determine the cause of the hypoglycaemia and 
finally, if hyperinsulinism (or more correctly inappropriate insulin secretion) is 
demonstrated.
(c) localisation of the tumour (Marks, 1981)
A wide variety of tests have been used in the assessment of insulinoma patients. 
The most common is the prolonged or overnight fast with the measurement of 
plasma glucose, insulin and C-peptide levels. The demonstration of inappropriately 
high C-peptide and insulin with low glucose values distinguishes insulinoma patients
from all other patients with hypoglycaemia. However, the prolonged fast requires 
hospitalisation and close observation and so may be impractical both for the 
hospital and the patient. Insulin stress tests have therefore been advocated if 
hypoglycaemia cannot readily be induced or if prolonged fasting is not possible.
The development of the C-peptide radioimmunoassay enables B cell secretory 
function to be assessed during insulin induced hypoglycaemia. Impairment of B cell 
suppression during this test has been clearly demonstrated in two patients 
described in Chapter IV compared to normal non-obese subjects. The major 
advantage of this test is that it is suppressive rather than a provocative test, it is 
of short duration and it can be carried out on outpatients. However, when 
performing an insulin stress test, care must be taken to ensure that hypoglycaemia 
is induced in order to evaluate the C-peptide results and that the patient has 
adequate renal function. Failure to meet these criteria would produce results 
which would be meaningless.
Insulinoma patients have similar or slightly raised fasting insulin C-peptide ratios 
compared with normal subjects. One patient in our series with a disseminated 
malignant insulinoma had an elevated ratio suggesting that chronic insulin 
overproduction or possibly the presence of liver metastases had affected hepatic 
insulin clearance.
Monitoring fasting C-peptide andplasma glucose levels in normal subjects and 
insulinoma patients clearly demonstrated the difference between the two group as 
shown in Chapter IV. However, these results represent only a small series of 
patients and the possibility cannot be excluded that a larger series of subjects will 
contain some whose fasting C-peptide and glucose values fall in an area where they 
are difficult to assess.
A number of other mainly provocative tests have been used, in the past, to 
investigate patients suspected of having insulinomas. Nowadays th e ir use is  confined 
only to a few cases where diagnosis is inconclusive, in which they may provide 
additional useful information.
The value of C-peptide levels in the detection of factitious hypoglycaemia due to 
exogenous insulin has been clearly demonstrated when undetectable or low 
C-peptide levels are found in conjunction with high circulating insulin values. 
Although the frequency of these cases is uncommon C-peptide estimation is 
valuable in demonstrating unequivocally the administration of insulin.
7:4 The physiological role of C-peptide.
Circulating C-peptide was considered to be biologically inert. Its physiological 
function was assumed to be confined to aiding the biosynthesis of insulin by holding 
the amino acid sequence of the insulin precursor in the correct three dimensional 
structure to facilitate alignment of the A and B chains of insulin. However, studies 
using synthetic C-peptide have suggested that it may have several other biological 
roles.
C-peptide may be involved in islet cell hormone release (Toyota et al. 1976, 
Wojcikowski et al. 1977). However, as discussed in Chapter V the evidence is 
conflicting, with other workers demonstrating that this peptide has no effect in the 
isolated islet or pancreas (Yasuda et al. 1976, Kaneko et al. 1978). The 
concentration of C-peptide used and isolation procedures varied and these factors, 
were probably responsible for the different results obtained.
The close relationship between the gastrointestinal hormones, GIP and insulin 
release has long been known. GIP has been shown to be inhibited by a number of 
substances released from the pancreas including insulin (Brown et al. 1975) and 
somatostatin (Pederson et al. 1975). Previous work in this department has 
suggested a possible role for C-peptide as an inhibitor of fat stimulated GIP 
release. Dryburgh et al. (1980) demonstrated that exogenous rat C-peptide 
inhibited fat stimulated GIP release in the rat. However, the purity of the 
exogenous C-peptide (synthetic rat C-peptide II) was not assessed and the 
concentration of this peptide in the rats was approximately three times higher than 
circulating levels in normal fed rats.
Studies were, therefore, carried out to ascertain whether endogenous C-peptide 
produced the same effect. In the course of the work it became clear that the 
experimental design was very important. GIP was initially stimulated in the rats 
by perfusion of the intestines with a fat emulsion. Fat stimulated GIP release was 
inhibited in the presence of high circulating endogenous C-peptide levels when 
insulin bioactivity was blocked by means of insulin antiserum. However, the gut 
perfusion technique resulted in an unphysiologically fast transit time for the 
emulsion through the gut with the result that fat absorption was probably impaired. 
GIP release is dependent upon absorption of nutrients and using the gut perfusion 
technique fat stimulated plasma GIP levels were low. only approximately twice 
basal levels. In addition, problems were encountered in the route of intravenous 
administration of tolbutamide and insulin antiserum to ensure reproducible high 
circulating C-peptide levels. Care also needed to be taken to avoid unnecessary 
handling of the gut and pancreas to prevent falsely elevated C-peptide levels. 
Further studies were, therefore, carried out orally dosing rats with fat to eliminate 
the problems of the gut perfusion technique. In order to attain a maximum GIP 
response to an oral fat load rats were pretreated with oral fat for four days prior 
to the experiment as this had previously been shown to increase the GIP response 
(Kwasowski, 1983). It was an unexpected finding that in these fat-pretreated rats 
fat stimulated GIP levels were not reduced in the presence of high circulating 
endogenous C-peptide. Obese subjects with abnormal glucose tolerance have been 
reported to have a defective feedback mechanism of insulin on GIP release 
(Creutzfeldt et al. 1978). It is, therefore, possible to suggest that the inhibition of 
C-peptide on GIP release was effected by fat pretreatment in the rats. At this 
point, however, the supply of insulin antibodies necessary in these experiments was 
exhausted. In view of the results obtained from the fat pretreated rats, it was 
decided to investigate this aspect further. Studies were, therefore, carried out to 
investigate the effect of insulin, a known inhibitor of GIP release, in fat pretreated 
rats.
The work carried out. so far, indicates that endogenous C-peptide is, in fact, an
inhibitor of fat stimulated GIP release, further investigation is required in rats 
maintained on normal laboratory diets, subject to adequate supplies of insulin 
antiserum being available. The recent availability of biosynthetic human 
C-peptide will enable investigation in man to be carried out and should resolve the 
question of the relative importance of C-peptide and insulin in the feedback 
inhibition of GIP.
7:5 The effect of high fat diets on the enteroinsular axis in man and rats.
The lack of inhibition of fat stimulated GIP secretion in the presence of high 
circulating C-peptide levels in fat pretreated rats could be explained by a 
defective feedback inhibition mechanism. Studies were, therefore, carried out in 
similarly treated rats given insulin, a known inhibitor of fat stimulated GIP release 
(Brown et al. 1975). No inhibition of GIP release by exogenous insulin was observed 
in rats maintained on short term high fat diets. However, insulin induced inhibition 
was demonstrated in rats maintained on a low fat dietary regimen. This study 
could, therefore, explain the lack of C-peptide inhibition of GIP release in fat 
pretreated rats described previously.
A mild state of insulin insensitivity was also observed in the fat pretreated rats 
after exogenous insulin. Other workers (Lavau e t al . ’1979, Grundleger and Thenen, 
1980;) have observed similar changes in insulin sensitivity in rats maintained on 
short-term high fat diets.
Further studies were carried out to investigate whether this lack of GIP inhibition 
by exogenous insulin observed in rats could be induced on a high fat dietary 
regimen in man. Previous workers (Brown et al. 1975) have shown that exogenous 
insulin inhibits fat stimulated GIP release in volunteers consuming a 'normal' diet 
although the fat intake of the subjects was not stated. Studies were initially  
carried out in five volunteers maintained on nine day low fat and high fat diets. 
Volunteers were maintained on their 'normal' diets for 15 days between the low 
and high fat dietary regimens. One volunteer had to be excluded since inhibition of 
GIP release by exogenous insulin could not be demonstated on either dietary
regimen. This volunteer had a high 'normal' fat intake of 157 g of fat per day. To 
increase the numbers in the study, a further group of four volunteers was, 
therefore, chosen, whose 'normal' fat intake was below 130 g. This second group of 
volunteers were maintained on a reverse dietary regimen compared with the first 
group i.e. high fat followed by low fat diet.
Inhibition of fat stimulated GIP release by exogenous insulin was demonstrated in 
these subjects maintained on a low fat dietary regimen. However, as in rats, 
volunteers showed no such inhibition when on the high fat diet. Due to the 
experimental design of the human study it was possible to demonstrate the 
reversibility of insulin insensitivity on the GIP cells. When maintained on the high 
fat diet subjects showed no inhibition of GIP release by exogenous insulin but nine 
days on a low fat diet was sufficient to re-establish inhibition by insulin. 
Creutzfeldt et al. (1978) observed a defect in the insulin feedback mechanism on 
GIP release in obese subjects. Our findings suggest that these results might be 
explained by the previous dietary history of the subjects rather than their body 
weight. Insulin inhibition of GIP release was not, however, investigated in a 
subsequent study by Creutzfeldt's group (Willms et al. 1978) on the effect of 
dietary restriction and starvation on GIP release in obese subjects. Creutzfeldt et 
al. (1978) also reported an exaggerated GIP response in obese subjects given a 
mixed high energy meal. However, starvation or dietary restriction with minimal 
weight loss reduced the GIP response (Willms et al. 1978). In view of the results 
described in Chapter VI a possible explanation of this data could lie in changes in 
the feedback control of GIP by insulin and C-peptide which are secreted in 
response to a mixed meal. In addition short term high fat feeding in rats resulted 
in significantly elevated GIP release in response to fat calculated from time course 
data. This effect was not observed in the human experiments although exaggerated 
GIP secretion in obese subjects is well documented. The dietary fa t intake of a rat 
is normally very low unlike a typical western human diet and this may explain the 
differences observed between the two species. Both rat and human studies suggest
that previous diet is more relevant than body weight in determining the magnitude 
of the GIP response to oral nutrients.
Dietary adaptation to a high fat diet resulted in increased absorption of 
triglycerides and a degree of insulin insensitivity in both rats and man. GIP release 
in response to fat was elevated in the rat. The elevated GIP release in rats may be 
dependent on both increased absorption of fat and insulin insensitivity of GIP cells. 
However, in man, insensitivity of the GIP cells to exogenous insulin was present 
without an elevated GIP response to fat on the high fat diet. It would be 
interesting to ascertain whether a longer period of exposure to a high fat diet in 
man would lead to hypersecretion of GIP in response to oral fat alone.
The implication of these studies indicate that previous diet is important in 
determining the GIP release to a particular substance. An exaggerated GIP release 
to nutrients results in an overactive enteroinsular axis causing hyperinsulinaemia. 
7:6 Future work.
The measurement of human C-peptide levels has proved clinically useful in certain 
conditions for example insulinomas. However, proinsulin levels are often elevated 
in such patients. Immunoreactive insulin and C-peptide data are difficult to 
interpret due to varying degrees of crossreactivity of the antisera with proinsulin. 
The estimation of proinsulin levels would, therefore, be desirable to enable insulin 
and C-peptide results to be more accurately interpreted. Biosynthetic human 
proinsulin and C-peptide will shortly become available in larger quantities as a 
result of change in commercial processes for manufacturing human insulin for 
diabetics. It will, therefore, be possible to develop a direct radioimmunoassay for 
proinsulin suitable for routine hospital laboratories.
The availability of biosynthetic human C-peptide suitable for infusion into human 
volunteers will be very useful in the elucidation of the physiological role of C- 
peptide. Investigations into both the endocrine role of C-peptide and its possible 
paracrine role within the islets should prove rewarding.
Lack of time prevented the follow up in the human dietary studies of the single
volunteer with a habitually high fat consumption who demonstrated a defective 
feedback inhibition of GIP. It would be interesting to ascertain whether giving a 
long-term high fat diet to human volunteers has a more permanent effect upon the 
feedback inhibition of insulin upon GIP. These studies would extend our 
understanding of the role of diet in the activity of the enteroinsular axis and the 
secretion of insulin and may ultimately prove relevant in the investigation of 
various disease states, for example, coronary artery disease, where hyperinsulinism 
appears to be implicated.
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